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1   INTRODUCTION  
 
1.1  Leukotrienes 
 
1.1.1  Leukotrienes – a family of eisosanoids 
Eicosanoids (greek eicosi for “twenty”) constitue a group of lipid mediators that are 
oxygenated metabolites of one common precursor, the arachidonic acid (AA). This essential 
20-carbon polyunsaturated fatty acid is esterified at the sn-2 position of cellular membrane 
phospholipids and can be released by phospholipases via enzymatic deacylation for further 
conversion. A wide variety of cell types synthesize various eicosanoids by distinct enzymatic 
pathways, which are referred to by the name of its initial oxygenase enzyme. Thus, 
prostanoids are formed by the cyclooxygenase (COX) pathway, and the 5-lipoxygenase (5-
LO) pathway leads to production of leukotrienes (LTs). Furthermore, 12- and 15-
hydroxyeicosatetraenoic acids (12- and 15-HETE) and epoxyeicosatrienoic acids are formed 
by the 12-LO, 15-LO and cytochrome P450 oxygenation pathways, respectively [1]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Overview of eicosanoid biosynthesis. AA is released from membrane phospholipids by PLA2 enzymes 
and is further metabolized by different enzymes including COX, 5-LO, 12-LO, 15-LO and cytochrome P450 to 
produce various eicosanoids. Figure according to [1].  
 
 
Structural studies carried out in the laboratory of Dr. Bengt Samuelsson in the late 1970s led 
to the discovery and characterization of LTs as novel AA metabolites [2-4], which were 
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described to exert profound proinflammatory activities including smooth muscle contraction 
[5] or neutrophil chemotaxis [6]. These investigations finally resulted in the elucidation of the 
LT biosynthesis pathway catalyzed by 5-LO. The term “leukotrienes” indicates the presence 
of three conjugated double bonds within the 20-carbon structure of AA (“trienes”) and points 
out that these compounds are derived from leukocytes (greek leuko for “white”) [7-9]. 
 
1.1.2  The leukotriene biosynthesis pathway 
5-LO catalyzes the first two steps within the LT biosynthesis pathway. The first enzymatic 
step is catalyzed by the oxygenase activity of 5-LO and involves the abstraction of a hydrogen 
from C-7 of AA followed by the insertion of molecular oxygen at position C-5 to form 5-
hydroperoxyeicosatetraenoic acid (5-HpETE). A second enzymatic step is catalyzed by the 
LTA4 synthase activity of 5-LO and involves removal of a hydrogen from C-10, resulting in 
the formation of the conjugated triene C-5,6 epoxide leukotriene A4 (LTA4) by dehydration. 
The further metabolization of the unstable intermediate LTA4 is dependent on the cell type 
and the enzymes present (see Figure 2): it is either converted into LTB4 by LTA4 hydrolase or 
it can be conjugated with glutathione to form LTC4, which is catalyzed by LTC4 synthase and 
the LTC4 synthase isoenzymes microsomal glutathione S-transferase type 2 (MGST2) and 
type 3 (MGST3) [8-12]. LTC4 is exported from the cell by the ATP-dependent multidrug 
resistance proteins, including MRP1 and MRP2 [13]. Subsequently it is metabolized by the 
enzymatic removal of the gamma glutamyl portion of glutathione to yield LTD4, which is 
further converted to LTE4 by the cleavage of glycin [1, 8]. Also LTB4 is exported by a protein 
carrier, which has not yet been identified [1, 14]. 
Besides LT formation, the 5-LO pathway is also involved in the production of several other 
AA metabolites. The first intermediate of AA conversion by 5-LO, 5-HpETE, can 
alternatively be rapidly reduced to the corresponding alcohol 5-hydroxyeicosatetraenoic acid 
(5-HETE). Thereby, the ratio of LTA4 to 5-HETE production is dependent on intracellular 
conditions and, in experimental models, on the terms of the experimental assay. Cellular 
glutathione peroxidases, but also a pseudoperoxidase activity of 5-LO have been accounted 
for the reduction of 5-HpETE [11, 15, 16]. Further oxidation of 5-HETE by 5-
hydroxyeicosanoid dehydrogenase (5-HEDH) is stimulated by activation of the respiratory 
burst and by oxidative stress, and leads to the formation of 5-oxo-eicosatetraenoic acid (5-
oxo-ETE). 5-oxo-ETE in turn can also be further converted into several additional 
eicosanoids by both enzymatic and nonenzymatic pathways [1, 17, 18]. Lipoxins comprise 
another group of AA metabolites that are generated through the combined action of 5-LO and Introduction 
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15-LO, 12-LO or aspirin acetylated COX-2 (COX-2/ASA). These bioactive 
trihydroxytetraene derivatives of AA appear to function contrarily to LTs as stop signals for 
inflammatory responses [1, 19, 20]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: 5-Lipoxygenase reactions. 5-LO catalyzes the conversion of AA to 5-HpETE followed by the formation 
of the epoxide LTA4. Enzymatic hydrolysis of LTA4 by LTA4 hydrolase leads to LTB4, whereas LTC4 synthase 
catalyzes the conjugation with glutathione to generate LTC4 [16]. 
 
 
The output of cellular LT biosynthesis depends on the availability of free AA, which is 
controlled by the enzymatic phospholipid deacylation and reacylation process, and on the 
regulation of expression, intracellular compartimentalization and catalytic activity of each of 
the  proteins of the 5-LO pathway [1, 8]. 
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1.1.3  Phospholipases A2 – the release of arachidonic acid 
 
The phospholipase A2 family 
Enzymes of the phospholipase A2 (PLA2) superfamily catalyze the hydrolysis of the sn-2 ester 
bond in a variety of different glycerophospholipids present in cellular membranes. This 
results in the production of a free fatty acid such as arachidonic acid (AA), eicosapentaenoic 
acid (EPA) or docosahexaenoic acid (DHA) on the one hand, as well as a lysophospholipid, 
which both can serve as precursors for the generation of lipid signaling molecules that exert 
important biological functions [21, 22].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Phospholipase A2 reaction. PLA2s catalyze the hydrolysis of the sn-2 ester bond in membrane 
phospholipids. Figure according to [23]. 
 
Different PLA2 enzymes have been classified into 15 separate groups with subgroups 
according to their primary structures, molecular weight, disulfide bonding patterns, 
localization and properties such as Ca
2+ requirement. These groups are assigned to five main 
types of PLA2s, namely the secreted PLA2s (sPLA2s), cytosolic group IV PLA2s (cPLA2s), 
Ca
2+ independent group VI PLA2s (iPLA2s), platelet activating factor acetylhydrolases (PAF-
AHs) and finally a lysosomal PLA2 [21, 24]. 
The sPLA2 family comprises group I-III, groupV and group IX-XIV PLA2s, which are small 
secreted proteins that are characterized by their low molecular weight (14-17 kDa), the 
requirement of millimolar concentrations of Ca
2+ for catalysis, the presence of six conserved 
disulfide bonds with one or two variable additional disulfide bonds, and a His/Asp dyad in the Introduction 
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active site. Mammalian sPLA2s do not show a distinct preference for the release of certain 
fatty acids, but they generally seem to prefer anionic phospholipid substrates [21, 24-26]. 
Upon secretion, they may act in a paracrine as well as in an autocrine fashion to release fatty 
acids including AA, which can subsequently be converted into eicosanoids. However, recent 
studies suggested that certain sPLA2s also function intracellularly to release AA, before being 
secreted [24, 27-31]. 
The group IV PLA2s (cPLA2 family) is comprised of six enzymes, which are named group 
IVA to IVF PLA2s or alternatively described as cPLA2α, β, γ, δ and cPLA2ζ. They are large 
cytosolic proteins with variable sizes (61-114 kDa), which function through the action of a 
Ser/Asp dyad. The cPLA2 enzymes do not have the same disulfide bonding network as 
sPLA2s and require only micromolar concentrations of Ca
2+ for activity. One exception is 
group IVC PLA2, which acts in a Ca
2+-independent manner. The different cPLA2s show 
different specificity for fatty acids in the sn-2 position of glycerophospholipids. Group IVA 
PLA2 (cPLA2α) is specific for AA containing phospholipids and plays a major role in 
eicosanoid generation. Group IVB and C, in contrast, have very little specificity. Group IVD 
seems to favorably address linoleic acid (LA) containing membrane lipids, while group IVE 
and F hydrolyze both AA and LA [21, 32-36].  
The members of the iPLA2 family do not require Ca
2+ for catalytic activity and act through a 
catalytic serine in the active site. Moreover, fatty acid specificity has not been observed in any 
of the group VI PLA2 enzymes. The iPLA2s are presumed to play a major role in 
phospholipid remodeling [21, 37]. The PAF acetylhydrolase family also does not require Ca
2+ 
for catalysis and likewise contains an active site serine. PAF-AHs hydrolyze the acetyl group 
from the sn-2 position of platelet activating factor [21, 38]. Finally, the recently discovered 
lysosomal PLA2, also named 1-O-acylceramide synthase, was found to acylate the hydroxyl 
group in the C-1 position of ceramide using the acyl group from the sn-2 position of 
phospholipids as substrate [21, 39, 40]. 
Although different PLA2s, especially sPLA2s and iPLA2s have been shown to be involved in 
the release of AA, cPLA2α is widely recognized as the key enzyme for the initiation of 
eicosanoid metabolism. 
 
The structure of cytosolic phospholipase A2 alpha (cPLA2α) 
The crystal structure of cPLA2α, which was solved in 1999, revealed the presence of an N-
terminal C2 domain connected to a C-terminal catalytic domain by a short 5-amino acid 
flexible linker [41]. Introduction 
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The C-terminal region of cPLA2α contains two homologous catalytic domains A and B 
interspaced with an isoform-specific sequence. The lipase consensus sequence, GXSGS, is 
localized in the N-terminal region of domain A. The active site dyad is composed of Ser-228 
and Asp-549, which mediates the hydrolysis of phospholipid substrate. Furthermore, a 
conserved arginine (Arg-200) seems to play an important role by binding the charged 
headgroups present in membrane glycerophospholipids [21, 22, 41-44]. The Ser/Asp active 
site is located at the bottom of a narrow funnel lined by hydrophobic residues and covered by 
a lid (residues 413-457). It has been suggested that anionic residues on the cPLA2α catalytic 
domain play a role in displacing the lid by electrostatic repulsion with anionic lipids on the 
surface of cellular membranes. Removal of the lid exposes hydrophobic residues (Ile-339, 
Leu-400, Leu-552) proximal to the active site, which facilitates membrane penetration and 
allows the fatty acid chain of a phospholipid substrate to enter the active site [41, 45, 46]. The 
cPLA2α was shown to preferentially hydrolyze AA from the sn-2 position of membrane 
phospholipids, which seems to be due to the architecture of the active site funnel. In contrast 
to oleic acid (C18:1) and linoleic acid (C18:2), which are poorly released, cPLA2α also 
hydrolyzes α-linoleic acid (C18:3) and eicosapentaenoic acid (C20:5), which are found in 
rather low quantities in cellular membranes, though [37, 41]. The cPLA2α catalytic domain 
contains a phosphatidylinositol 4,5-biphosphate (PIP2) binding site located at a cluster of 
basic residues (Lys-485, -541, -543, -544), which may regulate membrane binding through 
association with anionic phospholipid [45, 47]. Furthermore, a tryptophane residue (Trp-464) 
within the catalytic domain seems to be involved in a calcium-independent mechanism of 
cPLA2α membrane association [48]. Finally, several serine residues are present in the 
catalytic domain, which can be phosphorylated by signal-activated protein kinases [37]. 
At its N-terminus, cPLA2α contains a Ca
2+ binding C2 domain, which is a conserved structure 
present in several lipid binding proteins such as protein kinase C (PKC) and promotes Ca
2+-
dependent interaction of proteins with membranes. C2 domains are composed of 
approximately 120 amino acids, which form an eight-stranded anti-parallel β sheet [21, 46, 
49, 50]. The cPLA2α C2 domain binds two Ca
2+ ions through a cluster of aspartic acid 
residues in the four calcium binding loops (CBLs) of the membrane binding surface. In the C2 
domains of several other proteins, Ca
2+ binding neutralizes the anionic residues and, due to 
the presence of basic amino acids in the membrane binding region, the potential switches to 
electropositive, which allows binding to anionic phospholipids in membranes. In the cPLA2α 
C2 domain, in contrast, Ca
2+ binding facilitates hydrophobic residues in CBL1 (Phe-35, Leu-
39) and CBL3 (Tyr-96, Val-97) to preferentially associate with charge-neutral Introduction 
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phosphatidylcholine (PC) and to penetrate into the membrane interface [51-59]. As another 
feature, finally, a specific site in the cPLA2α C2 domain (Arg-57, Lys-58, Arg-59) was 
identified to bind ceramide-1-phosphate (C1P) [60]. 
 
Regulation of cPLA2α expression 
The cPLA2α is ubiquitously and constitutively expressed in most cells and tissues, yet 
expression levels can be increased by certain pro-inflammatory cytokines and growth factors 
in several cell-types. Regulation of cPLA2α expression by cytokines can be mediated through 
transcriptional mechanisms as well as post-transcriptional effects on mRNA stability. 
Glucocorticoids, on the other hand, were shown to repress the expression of cPLA2α and 
production of eicosanoids. Interestingly, mature T and B lymphocytes are an exception in that 
they do not seem to contain detectable levels of cPLA2α [61-66].   
 
Regulation of cPLA2α enzymatic activity 
As the initial and rate-limiting step of eicosanoid biosynthesis, the cellular liberation of AA 
by cPLA2α is tightly regulated, mainly by Ca
2+ mediated membrane association, binding of 
secondary lipid messengers and by phosphorylation on serine residues. 
Ca
2+ binding is not required for catalysis itself, as it is the case for the enzymes of the sPLA2 
family, but an increase of the intracellular Ca
2+ level induces cPLA2α transolcation to and 
association with intracellular membrane surfaces, which is mediated through the C2 domain 
as described above. The PC binding specificity of cPLA2α thereby plays a role in regulating 
the subcellular targeting of cPLA2α to distinct intracellular membranes. In cells exposed to 
Ca
2+-mobilizing agents, cPLA2α translocates primarily to the nuclear envelope, endoplasmatic 
reticulum (ER) and the Golgi apparatus, and it has been suspected that this may be due to an 
enrichment of PC in these membranes. In detail, cPLA2α redistributes to Golgi in response to 
physiological short-duration elevations of the intracellular Ca
2+ exceeding 100-125 nM, and 
to Golgi, the ER and the nuclear envelope at an intracellular Ca
2+ concentration of greater 
than 210-280 nM. Sustained elevations of the intracellular Ca
2+ thereby stabilize cPLA2α 
membrane association resulting in the release of AA [37, 46, 67-73]. However, cPLA2α 
activation has been also reported without any change in the intracellular Ca
2+ level and 
cPLA2α displayed also Ca
2+-independent membrane binding, which may be regulated by 
hydrophobic binding of the catalytic domain, by anionic lipids and by phosphorylation [47, 
74-78].  Introduction 
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Anionic phospholipids, particularly phosphatidylinositol 4,5-biphosphate (PIP2) and 
phosphatidylinositol 3,4,5-triphosphate (PIP3) can promote cPLA2α binding to lipid vesicles 
and increase its activity in vitro in a Ca
2+-independent manner. Interestingly, even though the 
PIP2 binding site is located in the catalytic domain, PIP2 activation requires the presence of 
the C2 domain, indicating its decisive role in cPLA2α interfacial binding. It has been 
suggested that PIP2 binding may induce a conformational change that leads to optimized 
positioning of the catalytic domain on the membrane or that may cause the increase of the 
catalytic efficiency. Furthermore, it has been suggested that PIP2 facilitates cPLA2α 
translocation to perinuclear membranes at low intracellular Ca
2+ concentrations by serving as 
an anchor molecule [22, 45, 47, 76, 79-82]. As another lipid, ceramide-1-phosphate (C1P) can 
bind cPLA2α via the C2 domain and activates the enzyme in a Ca
2+-dependent manner. It was 
suggested that C1P may function to recruit cPLA2α to intracellular membranes and to 
decrease the dissociation constant from membrane surfaces [60, 83-85]. 
The catalytic domain of cPLA2α contains several serine residues that can be phosphorylated 
depending on the cell type and the agonist used for activation. In detail, Ser-505 is addressed 
by mitogen-activated protein kinases (MAPKs), namely ERK1/2 or p38 MAPK, Ser-515 
serves as a target of Ca
2+/calmodulin-dependent protein kinase II (CamKII) and Ser-727 is 
phosphorylated by MAPK-activated protein kinases such as MAPK-interacting kinase Mnk-1. 
Phosphorylation of cPLA2α on either Ser-505, Ser-515 or Ser-727 was found to increase 
enzymatic activity 2-3 fold in vitro [86-90]. On the other hand, it was suggested that 
phosphorylation may influence cPLA2α membrane binding affinity, rather than playing a role 
strictly in the regulation of catalytic activity. In this regard, Ser-505 and Ser-727 
phosphorylation of cPLA2α played a role in cellular AA release under conditions of transient 
Ca
2+ increases, but was less important with higher sustained elevation of the intracellular Ca
2+ 
concentration. Furthermore, there are studies revealing that phosphorylation on Ser-505 
increased the phospholipid binding affinity of cPLA2α particularly at low Ca
2+ concentrations. 
It was shown that Ser-505 phosphorylation promotes membrane penetration of hydrophobic 
residues of the cPLA2α catalytic domain, presumably by inducing a conformational change of 
the protein. These enhanced hydrophobic interactions facilitate sustained membrane 
interaction in response to transient Ca
2+ elevations. As phosphorylated cPLA2α (Ser-505) fails 
to release AA in the total absence of an increase of intracellular Ca
2+, it seems that 
phosphorylation per se is insufficient, but plays an augmentative role in cPLA2α mediated 
cellular AA release [37, 46, 77, 87, 91-93]. The treatment of cPLA2α expressing Sf9 insect 
cells with the protein phosphatase inhibitor okadaic acid results in phosphorylation of Ser-727 Introduction 
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and triggers AA release yet without an increase in the intracellular Ca
2+ level. Thus, Ser-727 
phosphorylation may facilitate a membrane association of cPLA2α in a Ca
2+-independent 
manner, but the functional relevance has not yet been elucidated [22, 93-95]. A role of 
CamKII in cPLA2α phosphorylation has been reported in norepinephrine and angiotensin II 
stimulated vascular smoothe muscle cells (VSMC) and in fetal bovine serum treated U-937 
myeloid leukemia cells. In VSMC, CamKII was required for cPLA2α activation and directly 
bound to the enzyme resulting in the phosphorylation of Ser-515 and an increase of the 
enzymatic activity. Moreover, Ser-515 phosphorylation was required for norepinephrine-
induced translocation of cPLA2α to the nuclear envelope in VSMC [88, 96-98]. Importantly, 
it should be taken in account that the three serine residues may also be interactive, as Mnk-1 
is activated by members of the MAPK familiy, and because ERK activation can occur 
downstream from CamKII [22, 99, 100]. Further phosphorylation sites have been reported at 
Ser-437 and Ser-454 in Sf9 cells, but further studies have yet to be carried out to clarify the 
impact of phosphorylation at these residues [95]. Taken together, phosphorylation events may 
function to regulate catalytic activity and membrane binding of cPLA2α. 
As another regulating factor, the specific subcellular localization of cPLA2α plays an 
important role in AA release and subsequent eicosanoid production. Besides Ca
2+-dependent 
translocation of the enzyme from the cytosol to the perinuclear region, cPLA2α has also been 
reported to localize inside the nucleus. In subconfluent endothelial cells, a truncated form of 
cPLA2α was found in the nucleoplasm, which translocated to the nuclear envelope from its 
intranuclear side in response to cellular stimulation. Although cPLA2α lacks classical nuclear 
localization signals, it has been observed that nuclear import can occur through association 
with binding proteins. In this regard, cPLA2α associates with the nuclear transcription factor 
B-Myb containing nuclear localization signals and directing the nuclear import of cPLA2α 
[101, 102]. During phagocytosis of opsonized zymosan by macrophages, cPLA2α was found 
to translocate to the forming phagosome and also to membrane ruffles at the plasma 
membrane [103]. Also in neutrophils, cPLA2α has been reported to translocate to the plasma 
membrane upon stimulation with N-formyl-leucyl-phenylalanine (fMLP), opsonized zymosan 
or phorbol-12-myristate-13-acetate (PMA). It is recruited to this site by the association with 
components of the NADPH oxidase system and releases AA, thereby assisting in the 
production of superoxide [104]. Finally, cPLA2α colocalizes with MAPKs at cytoplasmic 
AA-rich lipid bodies in human leukemic U937 cells [105]. 
Several interaction partners of cPLA2α have been identified, which may also play a role in the 
cellular regulation of cPLA2α. Vimentin, the major component of the intermediate filaments, Introduction 
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is enriched in the perinuclear region and binds to the C2 domain of cPLA2α in the presence of 
Ca
2+, which might possibly stabilize the binding of cPLA2α to the membrane. The cPLA2α –
interacting protein PLIP interacts with the N-terminal region of cPLA2α. In renal mesangial 
cells, cPLA2α colocalizes with PLIP in the nucleus, and overexpression of PLIP enhances 
cPLA2α-mediated PGE2 synthesis. The p11/calpactin light chain, a member of the S100 
protein family, interacts with the C-terminal region of cPLA2α and inhibits enzymatic activity 
in vitro. In this regard, the induction of p11 protein expression seems to account for the 
inhibitory effect of dexamethasone on the release of AA. Finally, also some annexins can 
function as negative regulators of cPLA2α. The C-terminal region of annexin I binds to the C2 
domain of cPLA2α inhibiting enzymatic activity by specific interaction, whereas annexin V 
inhibits cPLA2α activity mainly by substrate depletion [46, 106-111]. 
 
 
1.1.4  5-Lipoxygenase (5-LO) – key enzyme for leukotriene biosynthesis 
 
Structure of 5-LO 
The three-dimensional structures of several plant and animal lipoxygenases, including soy 
bean 15-LO, coral 8-LO and rabbit reticulocyte 15-LO, have been resolved successively in 
various studies. The structure of human 5-LO as one of six human lipoxygenases, in contrast, 
has not been determined up to now. However, computational models based on the crystal 
structure of rabbit reticulocyte 15-LO indicate that human 5-LO is composed of a C-terminal 
catalytic and an N-terminal regulatory domain with characteristics similar to that of cPLA2α 
[9, 12, 16, 112-116]. 
The catalytic C-terminal domain (residues 121-673) has a mainly helical structure and 
contains a non-heme iron in its active site, which plays a decisive role in 5-LO catalytic 
activity. The iron of the isolated, inactive enzyme was found to be in the ferrous state (Fe
2+), 
whereas the conversion into the active, ferric form (Fe
3+) requires the interaction with fatty 
acid hydroperoxides. Importantly, the iron cycles between the ferric (active) and the ferrous 
(inactive) form during 5-LO catalytic action [12, 117-120]. As it is a typical feature of 
mononuclear non-heme Fe
2+ enzymes, the iron of the 5-LO active site is coordinated by a 2-
His-1-carboxylate facial triad (His-372, His-550 and Ile-673), but also His-367 and Asn-554 
seem to function as additional ligands. The catalytic domain is subject to regulation by 
phosphorylation of several serine residues (Ser-271, Ser-663 and Ser-523) [11, 12, 16, 118, 
121-123]. Introduction 
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The smaller regulatory N-terminal domain (residues 1-114) shows some structural and 
functional similarities to the C2 domains, which are found in several proteins such as protein 
kinase C (PKC) or cytosolic phospholipase A2 (cPLA2) as described above. However, due to 
differences in the arrangement of β-strands in the N-terminal domain of 5-LO this region is 
referred to as C2-like domain. The 5-LO C2-like β sandwich contains typical ligand-binding 
loops, which have been found to bind various lipids (phosphatidylcholine [PC], glycerides or 
lipid membranes), Ca
2+ or Mg
2+ ions (two per 5-LO protein), and also coactosin-like protein 
(CLP), which is known as an F actin-binding protein. These factors positively regulate 5-LO 
catalysis by improving access to the substrate AA and oxidation of ferrous to the active ferric 
5-LO, or they may lead to stabilization of an active 5-LO structure [12, 16, 124-127].  
 
Regulation of 5-LO protein expression 
Most of the cells known to express 5-LO are of myeloid origin and the capability to express 
5-LO seems to be acquired during cell maturation. Thus, 5-LO can be mainly found in mature 
leukocytes including granulocytes, monocytes / macrophages, mast cells and dendritic cells, 
but also in B lymphocytes, whereas platelets, T lymphocytes and erythrocytes are 5-LO 
negative. It is believed that 5-LO expression is up-regulated during leukocyte differentiation 
in the bone marrow, but also when blood monocytes enter tissues, an increase of 5-LO 
expression occurrs in the course of differentiation into macrophages [9, 12, 16]. Accordingly, 
differentiation inducers such as dimethylsulfoxide (DMSO), retinoic acid, 1α,25-
dihydroxyvitamin D3 and transforming growth factor β (TGF β) have been shown to stimulate 
5-LO mRNA and protein expression in several studies [128-132]. Although the expression of 
5-LO is restricted to a certain subset of cells, the promoter of the 5-LO gene has been 
characterized to show similarity to typical house-keeping genes [133]. 5-LO transcription was 
found to be regulated by DNA methylation and histone deacetylation [134-137]. 5-LO up-
regulation during the cell differentiation process, however, does not seem to occur due to 
changes in DNA methylation. In fact, other mechanisms involving regulatory elements within 
the coding sequence of the 5-LO gene, and processes resulting in transcript elongation, seem 
to account for 5-LO expression in response to the differentiation inducers 1α,25-
dihydroxyvitamin D3 and TGF β [16, 138-140].  
 
Regulation of 5-LO catalytic activity in cell-free assays 
As aforementioned, the presence of hydroperoxides is an important parameter for 5-LO 
activity, as they regulate the redox state of the active-site iron. Various lipid hydroperoxides Introduction 
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such as 5-, 12- or 15-Hydroperoxyeicosatetraenoic acid (5-,12- or 15-HpETE) and 13-
Hydroperoxyoctadecadienoic acid (13-HpODE) have been reported to activate 5-LO in crude 
leukocyte homogenates, whereas hydrogen peroxide and several other organic peroxides were 
not effective [118, 120]. In this regard, addition of glutathione peroxidase-1 (GPx-1) to cell-
free 5-LO activity assays resulted in an inhibition of 5-LO product formation due to reduction 
of lipid hydroperoxides [127]. Although lipid hydroperoxides are needed to generate active 
ferric enzyme, they may, in the course of their formation during the 5-LO catalytic reaction, 
also be responsible for rapid inactivation of 5-LO. After initiation of 5-LO catalysis by 
conversion of 5-LO to its active state, the further reaction profile is characterized by a linear 
propagation phase with maximal conversion rates, and an irreversible turnover dependent 
inactivation, which is also referred to as suicide inactivation of 5-LO [11, 141].  
Secondly, Ca
2+ ions are key determinants of 5-LO enzymatic activity and activate 5-LO 
purified from human leukocytes [142]. In mutagenesis studies it was shown that Ca
2+ binds to 
the N-terminal C2-like domain of 5-LO via certain residues in the ligand-binding loop 2 (Asn-
43, Asp-44 and Glu-46), and that these residues are important for Ca
2+-stimulated 5-LO 
activity. In equilibrium dialysis studies a Kd of 6 µM was determined and a 2:1 stoichiometry 
of Ca
2+ binding to 5-LO was suggested [125, 143]. Furthermore, half-maximal activation of 
purified 5-LO was achieved with 1-2 µM Ca
2+, and 4-10 µM Ca
2+ were required for maximal 
activation of the enzyme [144, 145]. Interestingly, with a lower efficiency, Mg
2+ ions can 
substitute for Ca
2+ regarding in vitro activation of 5-LO, and bind to 5-LO via a similar site as 
Ca
2+ [146]. Several mechanisms of Ca
2+-induced 5-LO activiation have been suggested. Ca
2+ 
appears to reduce the requirement for activating lipid hydroperoxides and a Ca
2+-mediated 
increase of 5-LO affinity to AA was observed [147, 148]. Moreover, it was shown that Ca
2+ 
increases the hydrophobicity of 5-LO, and thus facilitates 5-LO binding to 
phosphatidylcholine (PC) vesicles and association with cellular membranes. In fact, activation 
of 5-LO by Ca
2+ requires the presence of PC or also CLP [126, 143, 145, 149-151].  
In this regard, phospholipids represent a third important factor for 5-LO activity. Enzymatic 
activation was shown to be up-regulated by membrane preparations that could be replaced by 
PC vesicles. Three tryptophane residues (Trp-13, Trp-75 and Trp-102) located within the Ca
2+ 
binding loops confer the selective binding of the C2-like domain of 5-LO to PC. Thereby, a 
higher affinity for zwitterionic PC than for anionic phosphatidylserine (PS) and 
phosphatidylglycerol (PG) vesicles was detected, and it was suggested that the PC selectivity 
accounts for the binding of 5-LO to the PC rich nuclear membrane [126, 152, 153].  Introduction 
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Various glycerides like 1-oleoyl-2-acetyl-sn-glycerol (OAG), 1-O-oleyl-rac-glycerol (OG), 
1,2-dioctanoyl-sn-glycerol (DOG) and 1-O-hexadecyl-2-acetyl-sn-glycerol (EAG) directly 
stimulate 5-LO catalysis in vitro and it was found that OAG directly binds to the 5-LO C2-
like domain via the three tryptophane residues, which constitue the PC binding pocket. Ca
2+ 
and phospholipids or membranes, however, prevent the stimulatory effect of OAG. Thus, it 
was suspected that uncharged glycerides bind to the C2-like domain in the absence of charge 
neutralization or changes in side chain orientations, which are considered important for Ca
2+-
induced 5-LO binding to PC. Similar to Ca
2+, OAG was also found to render 5-LO activity 
resistant against inhibition by GPx activity and seems to increase the affinity of 5-LO towards 
lipid hydroperoxides [16, 127].  
The coactosin-like protein (CLP), as another factor influencing 5-LO activity, was reported to 
bind and up-regulate 5-LO activity via the phospholipid binding site of the C2-like β 
sandwich. In vitro studies revealed, that CLP up-regulates Ca
2+ induced 5-LO activity in the 
absence of PC and also increases LT formation, when PC is present. It was suggested that 
CLP, similar to membranes, can function as a scaffold for 5-LO, stabilizes the enzyme and 
prevents inactivation of 5-LO in vitro [124, 154, 155]. 
Finally, ATP has been shown to bind and stimulate purified 5-LO, but the binding site has not 
yet been resolved. Interestingly, ATP hydrolysis is not required for the activating effect. It 
appears that 5-LO is stabilized in the presence of ATP. Thus, ATP affinity can be utilized for 
purification of 5-LO [16, 156-158]. 
 
Regulation of cellular 5-LO catalysis 
In the cellular context an even more complex picture arises. In addition to the previously 
mentioned parameters, several cellular factors and conditions have an influence on the 
regulation of LT biosynthesis. 
Because lipid hydroperoxides are crucial for the initial oxidation of the iron in the 5-LO 
active site, the cellular redox tone is decisive for cellular 5-LO product formation. Thus, 
formation of reactive oxygen species (ROS), inhibition of glutathione peroxidases (GPx) or 
depletion of glutathione can result in an up-regulation of LT formation, whereas the presence 
of highly active GPx enzymes suppress 5-LO activity by the reduction of peroxides. In 
monocytes and the monocytic cell-line Mono Mac 6 (MM6), GPx-1 is responsible for the 
rather strong suppression of cellular 5-LO activity in these cells, whereas GPx-4 is involved 
in 5-LO inhibition in the B lymphocytic cell line BL41-E95-A and immature HL-60 cells 
[159-162].  Introduction 
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Early studies revealed that stimulation of cells with Ca
2+ ionophores triggers a pronounced 
Ca
2+ influx into the cell and effectively activates cellular LT formation [2]. Also, other Ca
2+ 
mobilizing agents such as thapsigargin (TG) or the soluble agonists platelet activating factor 
(PAF), LTB4,  N-formyl-leucyl-phenylalanine (fMLP), the cytokine IL-8 or phogocytic 
particles such as zymosan, urate or phosphate crystals are used to induce cellular 5-LO 
activation and LT biosynthesis. Naturally occurring inflammatory stimuli like fMLP, C5a, 
PAF or LTB4 are rather poor activators of 5-LO metabolism, which appears to be due to the 
rather moderate Ca
2+ influx that can be achieved compared to ionophores [11, 12, 163]. 
However, in intact cells, lower Ca
2+ concentrations (200-300 nM) seem to be sufficient for 5-
LO activation than in cell free systems (1-10 µM), indicating that cellular events can 
relativize the Ca
2+ requirement [16, 164, 165]. Recent studies indicated that endogenous 
diacylglycerides (DAGs), formed upon cellular activation of LT synthesis with Ca
2+ 
ionophore or TG, might reduce the requirement for Ca
2+ and it was suggested that in the 
absence of DAGs, elevation on intracellular Ca
2+ is not sufficient to facilitate 5-LO 
metabolism [166]. On the other hand, cellular 5-LO activation might not necessarily involve 
Ca
2+ under certain conditions. Thus, addition of exogenous AA was sufficient for 5-LO 
product formation in Ca
2+ depleted human neutrophils or RBL-1 cells, and simultaneous 
induction of cell stress or osmotic shock further enhanced 5-LO activity in the absence of 
Ca
2+ [167, 168].   
Besides the intracellular Ca
2+ level, certain kinase pathways have an important inpact on 
cellular 5-LO product formation. Mitogen-activated protein kinase - regulated protein kinase 
2 (MAPKAPK2, MK2), a downstream kinase of p38 MAPK, as well as ERK1/2 were found 
to phosphorylate 5-LO in vitro at Ser-271 and Ser-663, respectively, and activation of these 
kinase pathways mediates cellular activation of 5-LO. Interestingly, the in vitro 5-LO 
phosphorylation efficiency of these kinases is havily dependent on the presence of unsaturated 
fatty acids [169-171]. As touched in the previous section, stimulation of MK2 by cell stress or 
osmotic shock can activate 5-LO without an increase in the intracellular Ca
2+ level in certain 
cell types, but can also support Ca
2+-induced activation in cells. It is yet debatable if 
phosphorylation by MAP kinases directly affects 5-LO enzymatic activity or rather regulates 
nuclear membrane association of 5-LO, modulates its interaction with other cellular 
components or lowers the requirement for Ca
2+ in the cellular context. Recent data suggest an 
effect of 5-LO phosphorylation on 5-LO subcellular localization [12, 16, 172, 173]. 
Furthermore, protein kinase A (PKA) can phosphorylate 5-LO at Ser-523, which directly 
inhibits 5-LO activity in vitro, as well as in the cell, which may be due to allosteric changes Introduction 
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that lead to decreased enzymatic activity. Moreover, phosphorylation of Ser-523 was shown 
to affect the cellular localization of 5-LO, resulting in the accumulation of the enzyme in the 
cytoplasm [174, 175]. PKA activation is stimulated by agents that rise intracellular cAMP 
(e.g. PGE2 or adenosine), which have been observed to down-regulate cellular LT 
biosynthesis and association of 5-LO with the nuclear envelope. Polyunsaturated fatty acids 
prevent cAMP-mediated inhibition of 5-LO product synthesis in activated neutrophils [16, 
176].  
In addition to increased intracellular Ca
2+ and 5-LO phosphorylation, a third determinant of 
cellular 5-LO catalysis was described very recently. The endogenous generation of 
diacylglycerides (DAGs) via the phospholipase D (PLD) / phosphatidic acid phosphatase 
(PA-P) pathway was shown to be critical for cellular 5-LO activation and its redistribution to 
the nuclear membrane in ionophore- and TG-stimulated neutrophils. Inhibition of PLD or PA-
P potently suppressed 5-LO product synthesis, which could be reversed by the addition of 
OAG, apparently substituting for endogenous DAGs. It was suggested that in agonist-
stimulated cells, DAGs are required for association of 5-LO with the nuclear membrane, and 
it seemed that in the absence of DAGs, elevation of intracellular Ca
2+ is not sufficient to 
enable cellular 5-LO metabolism. However, also DAGs alone seemingly are insufficient for 
5-LO product formation and nuclear membrane association. Possibly, DAGs may reduce the 
Ca
2+ requirement for the activation of 5-LO [166]. 
The subcellular localization of 5-LO is an important parameter for cellular LT biosynthesis, 
and therefore is clearly regulated. In resting cells, 5-LO occurs as a soluble enzyme. 
Dependent on the cell type, 5-LO is either found in the cytosol (e.g. in neutrophils, 
eosinophils or peritoneal macrophages) or it is localized within the nucleus associated with 
chromatin (e.g. in alveolar macrophages, Langerhans cells or rat basophilic leukemia cells) 
[12, 16]. Nuclear import sequences, which are rich in basic amino acids, are present both in 
the N-terminal and also in the C-terminal domain of 5-LO, and also nuclear export sequences 
have been identified. Elicitation of resting cells by glycogen, cytokines or by cell adhesion, 
was found to cause nuclear import of 5-LO, which occurs without activation of the enzyme. 
However, the capacity for LT generation seems to be higher, when 5-LO is located in the 
nucleus [173, 177-179]. Upon stimulation with various agonists, which lead to cellular LT 
formation, 5-LO translocates from the soluble compartment to the nuclear envelope. Thereby, 
cytoplasmic 5-LO associates with the endoplasmatic reticulum (ER) and the outer nuclear 
membrane, whereas intranuclear 5-LO was observed to translocate to the inner nuclear 
envelope [12, 16, 173].  Introduction 
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Finally, 5-LO interactions with other cellular proteins have to be considered as factors that 
can influence 5-LO catalysis in the cell. As mentioned previously, CLP binds and up-
regulates 5-LO activity in vitro. In resting cells, CLP is localized in the cytosol, but both CLP 
and 5-LO are found in the nuclear fraction of human neutrophils after stimulation with 
ionophore, and also in stimulated MM6 cells, the same pattern of subcellular redistribution 
was found for CLP as for 5-LO. It was suggested that the two proteins permanently form a 
complex, which may facilitate the formation of 5-HpETE and 5-HETE in the cytosol, when 
activated by Ca
2+ in the presence of AA from exogenous sources. Moreover, CLP and 5-LO 
as a complex may associate with the nuclear membrane in a coordinated fashion, which is a 
prerequisite for LTA4 formation and metabolization from endogenously AA in stimulated 
cells [16, 124, 155]. Another cellular interaction partner of 5-LO is the 5-LO activating 
protein (FLAP), which is a member of the MAPEG protein family (membrane-associated 
proteins in eicosanoid and glutathione metabolism) that also includes LTC4 synthase, mPGE 
synthase-1 and MGST-1, -2 and -3 [180, 181]. FLAP is located in the nuclear envelope as a 
permanently membrane-bound protein. A concomitant expression of FLAP and 5-LO has 
been detected in several blood cells [182-184]. In cell transfection experiments and in studies 
using FLAP-deficient macrophages from knock-out mice, the requirement of FLAP for 
cellular LT biosynthesis from endogenous AA clearly became evident [184-186]. In contrast, 
FLAP is dispensable for catalytic 5-LO activity in cell homogenates and in cells that are 
stimulated in presence of exogenous AA. It was found that FLAP can bind AA, but no 
enzymatic activity of FLAP is known up to now [187, 188]. There is some evidence that 
FLAP and 5-LO may functionally interact, as FLAP facilitates the usage of 12- or 15-HETE 
as substrate by 5-LO. Moreover, recent data suggest that FLAP can form a homodimer in 
neutrophils, and also a complex consisting of 2 FLAP and 2 5-LO molecules seems possible 
[189-191]. Up to now it is generally accepted that FLAP may assist in the provision of 
substrate to 5-LO at the nuclear membrane [16]. In addition to the mentioned proteins, further 
5-LO interacting proteins such as TGFβ receptor I associated protein 1 (TRAP-1) or Dicer 
may affect and modulate cellular 5-LO activity [12]. 
 
1.1.5  Summary of the concerted cellular LT biosynthesis 
Stimuli capable of inducing cellular LT formation by elevating the intracellular Ca
2+ 
concentration, inducing the release of DAGs and / or activating MAPKs, cause activation of 
both 5-LO and cPLA2α. In a generally accepted model, 5-LO and cPLA2α comigrate from a 
soluble compartment to the nuclear membrane, where AA is released by the catalysis of Introduction 
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cPLA2α from membrane phospholipids. Then AA is provided to 5-LO via the assistance of 
FLAP, and LTA4 is formed and further metabolized depending on the cell type [12, 16]. 
Human neutrophils, dendritic cells, B lymphocytes primarily produce LTB4, and human 
monocytes and macrophages synthesize more LTB4 than LTC4. Human mast cells, in 
contrast, release more LTC4 than LTB4, and human eosinophils, finally, are LTC4 secreting 
cells [192]. If 5-LO negative nonleukocyte cells do express LTA4 metabolizing enzymes they 
can take up LTA4 for the formation of bioactive LTs in a process termed “transcellular 
biosynthesis” [8, 9, 20]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Summary of the concerted cellular LT biosynthesis.  
 
 
1.1.6 Biological  activity of leukotrienes 
 
LT receptors 
LTs act on leukocytes, epithelial cells, smooth-muscle cells or also on endothelial cells by 
interaction with LT receptors, which are seven transmembrane-spanning rhodopsin-type G-
protein coupled receptors (GPCRs) expressed on the surface of the target cells. LT receptors 
can activate Gq proteins resulting in increased intracellular Ca
2+, and / or they activate Gi 
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proteins leading to decreased intracellular cyclic AMP (cAMP). These events trigger the 
activation of downstream kinase cascades, which influence several cellular and tissue 
responses. LTs thereby are analogous to hormones that act locally, as they can act on 
neighboring cells in a paracrine fashion or can, in an autocrine manner, even affect the source 
cell itself [8, 192]. 
LTB4 exerts its effects via the B leukotriene receptors BLT1 and BLT2. BLT1 is expressed 
primarily on leukocytes and binds LTB4 with high specifity, as competitive binding studies 
show displacement only with 20-hydroxy LTB4 and 12-epi LTB4. It is a high-affinity receptor 
for LTB4, responding optimally at concentrations of 1-100 nM. Interaction with LTB4 leads to 
activation of Gi proteins suppressing cAMP signaling or Gq proteins activating PLC [8, 192-
196]. BLT2 shows sequence similarities to BLT1, but is expressed more ubiquitously in 
various tissues. Human BLT2 is activated by a broader range of eicosanoids including 20-
hydroxy LTB4, 12-epi LTB4, 12-HETE, 15-HETE, 12-HpETE and 15-HpETE. Moreover, 
BLT1 has a lower affinity for LTB4 responding at concentrations greater than 10 nM with a 
maximal effect at 0.1-1 µM [8, 193, 194, 197]. Interestingly, besides its action on BLTs, 
LTB4 was also found to serve as a ligand for the peroxisome proliferator-activated receptor α 
(PPARα), which is a nuclear hormone receptor that plays a role in regulating lipid 
metabolism. LTB4 binds PPARα in vitro and activates it in cells [192, 198, 199]. 
The effects of the different cyteinyl LTs are mediated by the cysLT-binding G-protein 
coupled receptors CysLT1 and CysLT2. CysLT1 is expressed rather ubiquitously in human 
organ tissues. It preferentially binds LTD4 with high affinity (1-10 nM), whereas LTC4 and 
LTE4 binding occurs with approximately 200-fold less affinities. Also CysLT2 shows a rather 
broad distribution, but was found to bind LTC4 and LTD4 with equal affinity (Kd about 10 
nM) followed by LTE4. Activation of CysLT1 or CysLT2 initiates Ca
2+ influx through 
pertussis toxin (PTX)-resistant Gq proteins [8, 193, 200-204]. Recently, GPCR17 was 
discovered as a novel receptor that binds both uracil nucleotides and CysLTs, which increased 
Ca
2+ influx and inhibited adenylyl cyclase in cells overexpressing GPCR17 [205]. 
 
Biological activities of LTs 
LTs are potent biological mediators in inflammatory reactions and immune processes. 
LTB4 plays an important role in initiating inflammatory responses. As a brief outline, when 
LTB4 is produced by tissue leukocytes in response to infection or stress stimuli, it promotes 
adherence of leukocytes to the endothelium, chemotaxis, and additionally also activation of 
neutrophils or other leukocytes, which triggers important functions. Thus, LTB4 leads to Introduction 
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degranulation, release of superoxide and lysosomal enzymes or augments phagocytosis of 
neutrophils and macrophages. By this means, LTB4 drives the recruitment of leukocytes from 
the blood stream into tissues, with a concomitant activation of leukocytes, which results in a 
dramatic increase in tissue cellularity, a characteristic of inflammation [6, 192, 206-210]. 
CysLTs account for the biological activity that led to the previous term “slow-reacting 
substance of anaphylaxis”. They are best known for their bronchoconstricting effects as a 
result of the contraction of airway smooth muscle cells and the induction of mucus secretion 
by bronchial mucosa. CysLTs can also promote the constriction of arterial vascular smooth 
muscle and thus are involved in the regulation of vasoconstriction. Moreover, endothelial 
cells are affected by CysLTs to produce vascular leak of plasma into tissues resulting in 
edema. Finally, CysLTs are also involved in the attraction and activation of leukocytes, and 
by this way also contribute to inflammatory processes [8, 211-216]. 
 
Biological activities of other 5-LO products 
5-oxo-ETE, which is formed by the oxidation of 5-HETE by 5-HEDH, is a potent 
chemoattractant for granulocytes and elicits actin polymerization, Ca
2+ mobilization, integrin 
expression and degranulation in these cells. Also monocytes have been described to be 
attracted in response to 5-oxo-ETE. It acts via the Gi-coupled OXE-receptor and may play 
important roles in asthma and allergic diseases. Moreover, it has been found to promote the 
survival of tumor cells [18, 217-219]. 
Lipoxins, in contrast, act to reduce and resolve inflammation and promote wound healing. 
They were shown to control the entry of neutrophils to sites of inflammation, reduce vascular 
permeability and stimulate non-phlogistic uptake of apoptotic neutrophils by macrophages. 
Furthermore, lipoxins are chemoattractants for monocytes, cells that appear to be required for 
wound healing. Finally, lipoxins inhibit neutrophil adhesion, chemotaxis, degranulation and 
superoxide formation, but stimulate monocyte adherence and chemotaxis without causing 
degranulation or release of ROS [19, 220-227]. 
 
1.1.7  Pathophysiological role of leukotrienes 
Soon it became clear that LTs play an important role in inflammatory and allergic disorders. 
Particularly, bronchial asthma is presumed to be the major LT-associated disease. 
Accordingly, anti-LT therapies have been developed and are approved for the treatment of 
asthma including the CysLT1 antagonists montelukast, zafirlukast and pranlukast (approval in 
Japan only) or the 5-LO inhibitor zileuton (approval in the United States only). These drugs Introduction 
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are effective in reducing both the early and late phase of bronchospasm and decrease airway 
hyperreactivity [228, 229]. In the first instance, LTs have been identified to be involved in 
further disorders including rheumatoid arthritis, inflammatory bowel disease, psoriasis and 
allergic rhinitis, but ongoing research revealed that the influence of LTs in the 
pathophysiology of inflammatory bowel disease and rheumatoid arthritis seems of minor 
importance, and also in psoriasis, LTs appeared to have a negligible impact [12, 230]. Instead, 
the 5-LO pathway has recently been associated with the pathogenesis of cardiovascular 
diseases like atherosclerosis, aortic aneurysm, stroke or myocardial infarction (MI). In this 
regard, several studies revealed the considerable expression of LT producing enzymes and LT 
receptors in diseased tissues, and increased LT formation has been correlated with 
cardiovascular disorders in animal models as well as in patients [231-238]. Genetic studies 
with knockout mice support the link between cardiovascular disease and the 5-LO pathway, 
and even human population genetic studies correlated certain genotypes of LT forming 
proteins to cardiovascular disease [239-244]. Recently, clinical studies with the FLAP 
inhibitor DG-031 (veliflapon) have provided promising effects on the level of biomarkers 
associated with MI risk in MI patients carrying at-risk variants in the FLAP or LTA4 
hydrolase gene [245]. As another novel indication, the pathogenesis of osteoporosis has been 
linked to certain effects of 5-LO products, which appear to positively modulate bone-
resorbing osteoclasts, but exert a negative impact on the bone forming capacity of osteoblasts 
[12]. Finally, the 5-LO pathway appears to play a role in certain types of cancer including 
prostate, pancreas and breast cancer, as its enzymes and products were found to be present in 
transformed cells and tissues versus non-transformed cells, and 5-LO products seemingly can 
stimulate cancer cell proliferation and survival, whereas pharmacological or genetic inhibition 
of the 5-LO pathway results in cancer cell growth and inhibition of apoptosis. Very recently 
the 5-LO gene (Alox5) was identified as essential for leukemia stem cells to evolve into a 
chronic myeloid leukemia (CML), as Alox5 deficinecy caused a failure of CML development. 
This suggested 5-LO as a specific target gene for the inhibition of cancer stem cells and 
possibly a treatment of cancer [12, 230, 246].  
 
1.1.8  Leukotrienes and host defense 
Besides their role as promoters of inflammation and their disadvantageous role in the 
pathogenesis of several diseases, LTs yet are also noticed as highly relevant mediators of 
innate immunity against pathogens [192, 247]. Introduction 
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Thus, in vitro LT generation has been observed in response to bacteria, mycobacterial species, 
Toxoplasma gondii,  Pneumocystis carinii,  Histoplamsa capsulatum, influenza A virus or 
Epstein-Barr-Virus (EBV) [209, 248-254], and elevated levels of LTs have been reported in 
vivo in patients during bacterial and viral infections such as bacterial or syncytical virus 
pneumonia and infection with Vibrio cholerae, Helicobacter pylori or rhinovirus [255-259]. 
Moreover, studies using 5-LO deficient mice or pharmacological LT synthesis inhibitors 
support the involvement of LTs in host defense against infectious agents. In this regard, 5-LO 
deficient mice exhibited increased susceptibility to gram-negative pneumonia, and higher 
levels of bacteria were found in the peritoneal cavities of 5-LO
-/- mice compared to wild-type 
controls in a model of peritonitis and sepsis. Also, pharmacological inhibition of LT synthesis 
impaired peritoneal clearance of E. coli in a murine model of infectious peritonitis. As another 
example, intravenous injection of LTB4 reduced viral loads in mice infected with 
cytomegalovirus, whereas 5-LO
-/- mice or mice treated with a FLAP inhibitor had increased 
viral loads compared to wild-type or untreated mice [260-263]. LTs exert distinct effector 
functions that account for their important role in fighting bacterial, fungal or viral infections. 
First, LTs facilitate leukocyte recruitment through a number of mechanisms. LTB4, as a 
potent chemoattractant, recruits neutrophils and monocytes to the site of infection and up-
regulates expression of integrins on the surface of leukocytes, thus enhancing their adherence 
to endothelial cells in the vasculature of infected tissues. Also CysLTs may support leukocyte 
recruitment by enhancing microvascular permeability, which allows the movement of cells 
through the endothelium into tissues. LTs also contribute to effector T cell recruitment and 
dendritic cell (DC) trafficking following antigen stimulation and thus might play a role in 
directing the adaptive immune response [6, 264-271]. Secondly, LTs augment the ability of 
macrophages and neutrophils to phagocytose microoganisms as observed in numerous studies 
[209, 272-274]. Thirdly, LTs play a role in microbial killing by LTB4 mediated increase of 
lysosomal enzyme release and release of α-defensins or the induction of NO synthesis and 
ROS production, which can be triggered by LTB4 and CysLTs [275-279]. Finally, LTs can 
induce the release of preformed proinflammatory mediators or initiate gene expression of 
cytokines, chemokine receptors and transcription factors that in turn augment mechanisms of 
host defense and immunity [192]. 
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1.2  Toll-like receptors 
 
1.2.1  Function and classification of pattern recognition receptors (PRRs) 
Innate immunity acts as a sentinel for the immune system and is immediately activated after 
recognition of invading microbial pathogens. This is mediated via various pattern-recognition 
receptors (PRRs) expressed on immune and non-immune cells. They detect highly conserved 
structures of microbial pathogens, which are considered to be essential components for the 
survival of the pathogen and which are unique to microorganisms. They are termed as 
pathogen-associated molecular patterns (PAMPs). The detection of PAMPs by PRRs triggers 
the development of an appropriate immune response for host defense [280-282]. 
PRRs can be functionally classified into two classes, the non-signaling and the signaling 
PRRs [283]. Non-signaling PRRs include soluble factors such as acute-phase proteins (e.g. C-
reactive protein or lectins), or transmembrane proteins such as scavenger receptors. They can 
bind to microorganisms and thus facilitate phagocytosis or recognition by the complement 
system, but do not principally activate signaling cascades in innate immune cells. The 
signaling PRRs likewise comprise transmembrane and cytosolic proteins. The nucleotide-
binding oligomerization domain (NOD)-like receptors (NLRs) are cytosolic signaling PRRs 
[284], and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) as well belong to this 
category of PRRs [285]. Toll-like receptors (TLRs), finally, are representatives of 
transmembrane signaling PRRs. The detection of PAMPs by TLRs triggers signaling 
pathways that lead to the release of inflammatory cytokines and chemokines or type1 
interferons (IFNs). These responses are important not only to eliminate pathogens, but also to 
develop pathogen-specific B- and T cell mediated adaptive immunity by up-regulation of co-
stimulatory molecules on antigen-presenting cells, especially macrophages and dendritic cells 
(DCs) [282, 286, 287]. 
 
1.2.2  The family of toll-like receptors (TLRs) 
Initially, a so called Toll protein was identified in fruitflies (Drosophila) and was described to 
play an important role in the immune response against fungal infection with Aspergillus 
fumigatus in flies [288]. Ongoing studies led to the discovery of homologues of the Toll 
protein in humans and mice through data base searches, and were referred to as the TLRs 
[289-291]. To date, 13 members of the TLR family have been identified in mammals. Of 
these, TLR1-9 are conserved between humans and mice, whereas TLR10 is not functional in 
mice and TLR11-13 are lost in human genomes [281, 292]. Introduction 
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The structure of TLRs 
TLRs are type I integral membrane glycoproteins composed of three major domains. The 
extracellular N-terminal domain, which mediates the recognition of microorganisms, consists 
of approximately 16-28 tandem leucin-rich repeats (LRRs), and each LRR consists of 20-30 
amino acids with the conserved motif LXXLXLXXN. Some ligands induce homodimer or 
heterodimer complexes of TLRs, such as TLR3-TLR3, TLR4-TLR4 or TLR1-TLR2. 
Molecular detail on ligand recognition has recently emerged from the crystal structures of the 
TLR1-TLR2-ligand complex, the ectodomain mouse TLR4-MD-2 complex and of the 
complex of TLR3 ectodomain with its ligand. The heterodimer or homodimer of the 
respective LRR domains show a horseshoe-like structure and consists of both a concave and a 
convex surface. These surfaces are responsible for ligand binding and ligand-induced TLR 
dimerization [280, 281, 293-295]. The transmembrane domain connects the extracellular 
domain to the intracellular C-terminal domain, which is termed Toll/IL-1 receptor (TIR) 
domain due to its homology with that of the IL-1 receptor. This domain is required for the 
recruitment of various adapter molecules, which also contain a TIR domain for their 
interaction with the respective TLR leading to activation of downstream signaling pathways 
[296, 297]. 
 
Expression and localization of TLRs  
The TLR family members are expressed on various immune and non-immune cells including 
B lymphocytes, natural killer (NK) cells, DCs, macrophages, fibroblast cells, epithelial cells 
and endothelial cells [280]. Two subpopulations of TLR subtypes can be distinguished with 
regard to their subcellular localization. TLR1, 2, 4, 5, and TLR6 are expressed on the cell 
surface and recognize microbial membrane components such as lipids, lipoproteins and 
proteins, whereas TLR3, 7, 8 and TLR9 are localized in intracellular vesicles such as the ER 
and the endosome. Endolysosomes constitute the first site, where pathogen-derived nucleic 
acids are released after degradation of the microorganism in lysosomes. Thus, intracellular 
TLRs predominantely recognize various microbial nucleic acid species and particularly 
trigger anti-viral innate immune responses. Moreover, this intracellular localization of nucleic 
acid sensing TLRs is also important for the discrimination of non-self from self nucleic acids. 
In this regard, ectopic expression of TLR9 on the macrophage cell surface was shown to 
facilitate its response to DNA derived from self. Abnormal recognition of self-DNA, 
however, has been associated with the pathogenesis of autoimmune diseases [281, 286, 298]. Introduction 
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1.2.3  TLR subtypes and their ligands 
 
TLR2 
TLR2 is able to form a homodimer with another TLR2 molecule or heterodimers with TLR1, 
TLR6 or non-TLR molecules such as CD36, CD14 and dectin-1 to discriminate the molecular 
structures of a wide range of PAMPs derived from various pathogens ranging from bacteria, 
fungi, parasites and viruses. These ligands include triacyl lipopeptides from bacteria and 
mycobacteria, diacyl lipopeptides from mycoplasma, peptidoglycan (PGN) and lipoteichoic 
acid (LTA) from gram-positive bacteria, porin from Neisseria, lipoarabinomannan from 
mycobacteria, zymosan (consisting of β-glucan, mannans, chitin, lipid and protein) from 
fungi,  Trypanosoma glycosylphosphatidylinositol (GPI)-mucin and hemagglutinin protein 
from measles virus [281]. Regarding lipopeptide detection, the TLR2-TLR6 heterodimer was 
identified to generally recognize mycobacterial diacylated lipopeptides, but also LTA and 
zymosan, whereas TLR2-TLR1 appears to detect bacterial triacylated lipopeptides. However, 
there are still diacylated lipopeptides such as Pam2CSK4, which were shown to signal in a 
TLR6 independent manner, and it has been proposed that TLR2 forms a TLR2/TLR2 
homodimer when recognizing Pam2CSK4. CD36, a member of a class II scavenger receptor, 
is involved in sensing some of the TLR2 ligands, including TLR2-TLR6 activators. CD14, a 
GPI-linked protein containing LLRs, plays a role in the recognition of diacylated lipopeptide 
and lipoarabinomannan. Finally, Dectin-1, an immunoreceptor tyrosine-based activation motif 
(ITAM)-containing C-type lectin receptor, is required for TLR2 mediated inflammatory 
responses induced by β-glucan [281, 299-304]. 
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Figure 5: TLR2 ligands. LTA: TLR2/6 ligand; chemical structure of LTA from S.aureus; figure according to 
[305]. Pam3CSK4: synthetic triacylated lipopeptide recognized by TLR2/1 [306]. FSL-1: synthetic diacylated 
lipopeptide  recognized by TLR2/6 [307]. 
 
 
TLR4 
TLR4 is essential for responses to lipopolysaccharides (LPS), a major component of the outer 
membrane of gram-negative bacteria, which has long been known as a potent 
immunostimulatory molecule that can cause septic shock. TLR4 tightly associates with the 
cell surface protein MD-2, and this complex is required for a substantial induction of 
inflammatory cytokines. Additionally, the so called LPS-binding protein (LBP) and CD14 are 
involved in the detection of LPS. LBP is present as a soluble protein or a plasma membrane 
protein and binds LPS. CD14 in turn binds LBP and delivers LPS-LBP to the TLR4-MD-2 
complex [281, 292, 308]. 
 
Further TLR subtypes 
TLR5, also localized on the cell surface, recognizes a highly conserved central site of 
flagellin, a protein component of bacterial flagella [281, 309]. Moreover, various types of 
nucleic acids play a role in the activation of endosomal TLRs. TLR3 recognizes a synthetic 
analogue of dsRNA polyinosinic-polycytidylic acid [Poly (I:C)], genomic RNA purified from 
dsRNA viruses such as reovirus, and dsRNA produced during the replication process of 
ssRNA viruses such as RSV, encephalomyocarditis virus (EMCV) and West Nile virus 
(WNV) [281, 310, 311]. TLR7 was originally observed to respond to imidazoquinoline 
derivatives such as imiquimod and resiquimod (R-848) and guanine analogues such as 
loxoribine, all of which have anti-viral and anti-tumor properties. Subsequently, guanosine-
rich and uridine-rich ssRNA derived from HIV or influenza virus and synthetic polyuridine 
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ssRNA were identified to function as ligands for TLR7. TLR8 has a phylogenetically high 
similarity with TLR7. Thus, human TLR8 was found to preferentially recognize R-848, 
bacterial RNA as well as ssRNA derived from HIV, VSV and influenza A virus [281, 312-
314].  
 
TLR subtype  Adapters  PAMPs/Activators  Species 
      
TLR2-TLR1  MyD88 - TIRAP  Triacyl lipopeptides  Bacteria 
TLR2-TLR6  MyD88 - TIRAP 
Diacyl lipopeptides 
LTA 
Zymosan 
Mycoplasma 
Bacteria 
Fungus 
TLR2  MyD88 - TIRAP 
PGN 
Lipoarabinomannan 
Porins 
tGPI-mucin 
HA protein 
Bacteria 
Mycobacteria 
Bacteria (Neisseria) 
Parasites (Trypanosoma) 
Virus (Measles virus) 
TLR3 TRIF  dsRNA  Virus 
TLR4  MyD88 - TIRAP 
TRIF - TRAM 
LPS 
Envelope proteins 
Bacteria 
Virus (RSV, MMTV) 
TLR5 MyD88  Flagellin  Bacteria 
TLR7 MyD88  ssRNA  RNA  virus 
TLR8 MyD88  ssRNA  RNA  virus 
TLR9 MyD88 
CpG DNA 
DNA 
Malaria hemozoin 
Bacteria 
DNA virus 
Parasites 
 
Table 1: Overview of TLR subtypes, utilized adapters and respective TLR  ligands. According to [281]. 
 
 
TLR9 was initially identified to recognize unmethylated 2´-deoxyribo cytidine-phosphate-
guanosine (CpG) DNA motifs that are typically present in bacteria, but are rare in the host, 
where these sequences are highly methylated at the cytosine base and therefore exert poor 
stimulatory activity. Recent studies revealed that TLR9 recognition of natural DNAs occurs 
independently of the base sequence. The sugar backbone 2´-deoxyribose of DNA appeared to 
be sufficient to induce signaling, which was enhanced by DNA bases, even short CpG motifs. 
Three structurally distinct classes of synthetic oligodeoxynucleotides (ODNs) containing CpG Introduction 
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motifs are used experimentally for TLR9 activation. A-type (D-type) CpG ODNs show strong 
ability to induce type I IFN production from plasmacytoid DCs (pDCs), but weaker potency 
to activate B cells or macrophages. They contain a single CpG motif, and the activity requires 
a mixed backbone of phosphodiester-phosphorothioate. Especially the region around the CpG 
motif should be palindromic and phosphodiester-linked. In addition, a poly-G tail should be 
included at the 3´end. B-type (K-type) CpG ODNs has the potent ability to activate B cells 
and induce cytokine production from macrophages. This type has multiple CpG motifs, and 
the activity is stabilized by a phosphorothioate backbone. C-type CpG DNA, finally, exhibit 
type I IFN-inducing, as well as B cell-activating functions. It is comprised of a 
phosphorothioate backbone with multiple CpG motifs and a TCG dimer at the 5´end. In 
addition to DNA, hemozoin derived from Plasmodium falciparum activates TLR9 and 
triggers the production of inflammatory cytokines and chemokines [281, 283, 315-318]. 
 
1.2.4  TLR signaling pathways 
Signaling pathways via TLRs culminate in the activation of NF-κB and / or MAPKs including 
ERK1/2, p38 and c-jun N-terminal kinases (JNKs), which phosphorylate the activator protein 
1 (AP-1) family of transcription factors. Both variants, finally, regulate the expression of 
numerous immune and inflammatory genes. Several TLRs that recognize viral PAMPs 
additionally activate members of the IRF family of transcription factors, which induce the 
expression of type I IFNs and inflammatory genes [281, 285, 292]. 
 
MyD88-dependent TLR2 signaling pathway 
After ligand-induced homo- or heterodimer formation of TLR2, myeloid differentiation 
primary-response protein 88 (MyD88), which serves as an adapter protein, is recruited to the 
receptor complex through the assistance of a second sorting adapter, TIRAP (TIR domain-
containing adapter protein). MyD88 in turn recruits the IL-1R-associated kinase (IRAK) 
family protein kinases IRAK4, IRAK1 and IRAK2. The activation of IRAKs results in TNF 
receptor-associated factor (TRAF)6 activation. TRAF6 forms a complex with the E2 
ubiquitin-conjugating enzyme complex Ubc 13 and Uev1A to induce the synthesis of lysine 
63-linked polyubiquitin chains, which in turn activate TGFβ-activated kinase 1 (TAK1). 
TAK1, in combination with TAK1-binding proteins TAB1, TAB2 and TAB3, subsequently 
activates the two pathways involving the IκB kinase (IKK) complex or MAPK. The IKK 
complex, which comprises the catalytic subunit IKKα and IKKβ and a regulatory subunit NF-
κB essential modifier (NEMO, also known as IKKγ), catalyzes the phosphorylation of IκB Introduction 
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proteins that results in the degradation of IκBs and the subsequent nuclear translocation of 
NF-κB [281, 292, 319]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: MyD88-dependent TLR2 signaling pathway. Figure according to [281].  
 
 
Further TLR signaling pathways 
Although all TLRs, except TLR3, are known to utilize the MyD88-dependent pathway, 
individual TLRs additionally can trigger partially different signaling pathways leading to 
diverse responses depending on the PAMP present. These differences in signaling output 
were explained by the utilization of individual Toll/IL-1R (TIR) domain containing adapter 
proteins, which link activated receptors to the downstream kinases that define a given 
signaling pathway. Besides MyD88, which in most cases drives NF-κB and MAPK activation 
to induce a pro-inflammatory response, another three adapter proteins have been discovered. 
TIRAP, which functions as a sorting adapter to recruit MyD88, is utilized by TLR2 and 
TLR4, but not by the other TLRs for MyD88 recruitment. TRIF (TIR-domain-containing 
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adapter protein inducing IFN-β), is an adapter that initiates an alternative pathway leading to 
IRF3, as well as NF-κB and MAPK activation to induce type I IFN and inflammatory 
cytokines. TRIF is utilized by TLR3 and TLR4. TRAM (TRIF-related adapter molecule) in 
turn serves to link TRIF to TLR4, but not to TLR3. An even more complex picture arises, 
when considering the fact that MyD88 is also capable of inducing type I IFN production from 
some TLRs such as TLR7, 8 and TLR9. Because of the complexitiy of the pathways, TLR 
signaling is commonly categorized into MyD88-dependent and TRIF-dependent pathways 
[281, 286, 320-326].  
 
1.2.5  Functional role of TLRs in innate and adaptive immunity 
The main function of TLRs is the induction of inflammation and the establishment of adaptive 
immunity. On the one hand, TLR signaling can trigger substantial production of inflammatory 
cytokines such as IL-6 and TNFα, which in turn activate surrounding cells to express 
chemokines or adhesion molecules. Consequently, various inflammatory cells are recruited 
into the sites of infection. Recruited macrophages or neutrophils are activated and ingest 
invading pathogens through internalizing PRRs, which induces microbial killing by 
production of NO, ROS or defensins. Thus, inflammation is an important local response to 
resolve infection. However, inflammation needs guarded regulation, because excessive 
amounts of cytokines can be lethal for the host, as in the case of endotoxin shock. Aside from 
the direct innate immune response, TLR-activated antigen presenting cells (APCs) enhance 
the expression of surface molecules and, together with antigen-presentation, mediate T cell 
activation. CD4
+ T cells can differentiate into TH1 or TH2 cells. Whereas TH1 cells produce 
IFNγ and mediate antiviral or antibacterial immunity, TH2 cells secrete IL-4, IL-13 or both 
and play a role in allergic reactions or immunity against helminthes. TLR2 activation was 
found to provoke TH2 immune responses under certain conditions. Furthermore, LPS can 
induce TH2 responses at low dose or when inhaled. Most TLR ligands, however, stimulate 
APCs to release TH1-inducing cytokines such as IL-12 and IL-18 supporting TH1-driven 
immune responses. In particular, TLR9 signaling activated by CpG DNA has the strongest 
activity to induce TH1 cell differentiation [283, 327-330]. 
 
1.2.6  Pathophysiological role of TLR2 
Besides their crucial role in infectious diseases, much evidence also points to a role for TLRs 
in further immune and inflammatory disorders and increasingly in cancer. Not only PAMPS, 
but even also endogenous ligands, so called danger associated molecular patterns (DAMPs), Introduction 
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which may be expressed or accumulated at sites of tissue injury or tissue remodeling might be 
involved in TLR activation under such conditions. However, recently it was suggested that 
these molecules mediate their pro-inflammatory effects not by direct stimulation of TLRs, but 
rather by enhancing the sensitivity of local cells to PAMPs or other inflammatory mediators 
involved. The repetory of proposed endogenous agonists / assistants for TLR2 includes 
Hsp60, Hsp70, gp96, HMGB1, minimally modified LDL as well as biglycan [331-333]. 
 
TLR2 and noninfectious diseases 
TLR2 has been implicated in several inflammatory conditions, and its role in the pathogenesis 
of disorders like arthritis, inflammatory bowel disease or psoriasis has been supported by 
reports of elevated TLR2 expression in diseased tissue in patients and responsiveness of 
respective cell types to TLR2 activation, as well as by reports of TLR2 polymorphisms in 
humans linked to these diseases [332, 334-338]. Moreover, growing evidence points to a 
critical role for TLR2 in atherosclerosis. TLR2 expression in endothelial cells from 
atherosclerotic lesions was shown to be upregulated compared to endothelial cells of normal 
arteries. Also in atherosclerosis mouse models, atherosclerotic plaques and circulating 
monocytes exhibited increased expression of TLR2 compared to control mice, and 
administration of a TLR2/TLR1 ligand increased the disease burden, whereas TLR2 
dificiency led to a reduction in ligand induced atherosclerosis and plaque formation or 
reduced the levels of circulating monocyte chemoattractant protein-1 (MCP-1), which is 
suggested to play a critical role in the progression of atherosclerosis. Finally, a report suggests 
a TLR2 polymorphism to be associated with atherosclerosis, but results in this regard yet 
remain contradictory [339-344]. Furthermore, asthma and atopy have been linked to TLR2 
polymorphisms in some human population genetic studies [345, 346], also ischemia / 
reperfusion injury of the kidney and heart seems to importantly involve TLR2 [347-349], and 
a role of TLR2 in autoimmune diabetes is under discussion [350]. Finally, there is also some 
evidence that suggests a role of TLR2 for the development of certain types of cancer. 
However, it has also been shown that beneficial T cell-dependent immunity to some forms of 
tumor can depend on the stimulation of TLRs, particularly TLR2, expressed by macrophages 
and DCs [351-353].  
 
TLR2 as drug target 
The essential involvement of TLRs in a variety of diseases has opened the possibility to 
develop new approches using TLRs as therapeutical targets. TLR ligands are investigated as Introduction 
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adjuvants for the improvement of vaccines, are tested for cancer immunotherapy and seem to 
rebalance allergic immune responses. TLR antagonists instead could be beneficial for 
treatment of endotoxin shock as well as inflammatory and autoimmune diseases. Ongoing 
clinical trials include studies with several agents targeting TLR3, TLR4, TLR7 and TLR9 for 
various applications [354]. 
Some approaches targeting TLR2 as well are currently under preclinical and clinical 
investigation. A TLR2 neutralizing antibody has been developed which demonstrates 
therapeutic potential for the treatment of sepsis in a murine model [355]. In the field of cancer 
immunotherapy, a three-component vaccine composed of a TLR2 agonist, together with a 
peptide T-helper epitope and a tumor-associated glycopeptides was found to elicit high titers 
of IgG antibodies in mice [356]. In a phase I/II trial, the TLR2/6 agonist MALP-2 was 
successfully tested as an immunological adjuvant in patients with pancreas carcinomas [357]. 
Additionally, MALP-2 seems promising as a pharmaceutical agent in the field of allergy [358, 
359], as a vaccine adjuvant [360] as well as in the field of wound healing [361].  
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2   AIM OF THE PRESENT STUDY  
 
Leukotrienes (LTs) as pro-inflammtory mediators play a significant role in promoting 
inflammatory reactions and immune processes. They have been shown to be released from 
leukocytes in response to bacterial and viral infections and appear to substantially contribute 
to an effective immune reaction for host defense [247]. The mechanisms for innate immune 
pathogen recognition and signaling have been subject of intense research activity since the 
discovery of the TLR family of pattern recognition receptors approximately 10 years ago. By 
now it is well established that TLRs play a key role in the detection of invading pathogens 
and for subsequent initiation of the appropriate immune response [281]. Upon activation, they 
trigger the activation of signaling pathways such as especially the MAP kinase network, 
which as well is known to be involved in the regulation of cellular leukotriene biosynthesis. 
 
In this regard, it seemed conceivable that the release of LTs might be regulated in the course 
of TLR activation. Thus, the present studies were undertaken in order to verify and 
characterize a possible influence of TLR activation on the biosynthesis of LTs, and 
furthermore to identify the involved signaling pathways and underlying mechanisms.  
 
Few studies provided a first hint that TLR activation may be linked to LT formation. Thus, 
bacterial PGN and yeast zymosan, but not E. coli LPS or triacylated lipopeptide, had been 
found to directly induce LTC4 generation in human mast cells [362]. Furthermore, PGN had 
been noted to enhance anti-IgE antibody stimulated LTC4 release in human basophils [363]. 
The mechanisms, however, had not been studied, respectively. LPS, furthermore, had long 
been known to prime leukocytes for enhanced LT release upon stimulation [364-367]. It had 
not yet been asked, though, whether this effect was mediated via TLR4 activation and 
signaling. 
Monocytes / macrophages constitute key actors in host defense, which exert important 
effector functions like phagocytosis and microbial killing, as well as the modulation of innate 
immune responses [368]. The present investigations, accordingly, were carried out in various 
human monocytic cell systems. 
 
 Materials and Methods 
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3   MATERIALS AND METHODS  
 
3.1  Cells and cell culture 
 
3.1.1  Cell lines 
Mono-Mac-6 
Mono-Mac-6 is a human cell line which was established from the peripheral blood of a 64-
year-old man with acute monocytic leukemia. Mono-Mac-6 cells constitutively express 
phenotypic and functional features of mature monocytes [369]. Treatment of Mono-Mac-6 
cells with hTGFβ1 and 1α,25-dihydroxyvitamin D3 leads to expression of 5-LO protein with 
substantial enzymatic activity [132]. Cells were kindly provided by Prof. Dr. med. Dr. rer. 
nat. G. Geisslinger, Institute of Clinical Pharmacology, University Hospital Goethe-
University Frankfurt. 
THP-1 
THP-1 is a human cell line which was established from the blood of a 1-year-old boy with 
acute monocytic leukemia [370]. THP-1 cells are negative for several markers that are 
specific for mature monocytes [369]. After treatment with hTGFβ1  and 1α,25-
dihydroxyvitamin D3 substantial 5-LO activity can be measured. Cells were obtained from 
Prof. Dr. med. J. Pfeilschifter, Institute of General Pharmacology and Toxicology, University 
Hospital Goethe-University Frankfurt.  
 
3.1.2  Cell culture 
Mono-Mac-6 cells were maintained in RPMI 1640 medium supplemented with 2 mM L-
glutamine, 10% heat-inactivated fetal bovine serum, 100 µg/mL streptomycin, 100 U/mL 
penicillin, 1 mM oxaloacetic acid, 1 × MEM non-essential amino acids and 10 µg/mL human 
insulin (kindly provided by Sanofi-Aventis, Frankfurt a. M.) at 37°C, in an humified 
atmosphere and at 5% CO2. Mono Mac 6 cells were seeded at a density of 0.2 × 10
6 cells. For 
induction of  5-LO expression cells were differentiated with 1 ng/mL natural hTGFβ1 (R&D 
Systems GmbH, Wiesbaden, Germany) and 50 nM 1α,25-dihydroxyvitamin D3 (Sigma-
Aldrich, Schnelldorf, Germany) for 4 days, then harvested by centrifugation (200×g, 10 min, 
room temperature (RT)) and washed once in PBS pH 7.4. 
THP-1 cells were maintained in RPMI 1640 medium supplemented with 2 mM L-glutamine, 
10% heat-inactivated fetal bovine serum, 100 µg/mL streptomycin and 100 U/mL penicillin at Materials and Methods 
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37°C, in humified atmosphere, and at 5% CO2. THP-1 cells were also seeded at a density of 
0.2 × 10
6 cells. Also THP-1 cells were treated with 1 ng/mL natural hTGFβ1 and 50 nM 
1α,25-dihydroxyvitamin D3 for 4 days, then harvested by centrifugation (200×g, 10 min, RT) 
and washed once in PBS pH 7.4.  
 
3.1.3  Isolation of human PBMC from buffy coats 
Human peripheral blood mononuclear cells (hPBMC) were freshly isolated from buffy coats 
obtained from Municipal Hospital Frankfurt-Hoechst as follows. Buffy coats were diluted 
with PBS pH 7.4 and erythrocytes were depleted by dextran sedimentation (dextran 1% (w/v), 
30 min). The supernatant was subjected to density centrifugation (LSM 1077 Lymphocyte 
Separation Medium, PAA Laboratories GmbH, 800×g, 10 min, RT). The mononuclear cells 
including lymphocytes and monocytes appear as a layer on the separation medium after 
centrifugation. Human PBMC were washed twice with PBS pH 7.4 and the monocyte content 
was elevated by adherence in RPMI 1640 medium supplemented with 2 mM L-glutamine and 
25% human plasma for 3 hours (37°C, 5% CO2). Thus, lymphocytes in suspension were 
removed, and adhered monocytes were gently detached, resuspended in PBS pH 7.4 and 
harvested by centrifugation (200×g, 10 min, RT). Cell types were kindly determined by Dr. 
Ulrike Koehl, Pediatric Hematology and Oncology, University Hospital Goethe-University 
Frankfurt, by FACS analysis: CD14+ monocytes 30.2-52.9%, CD19+ B lymphocytes 3.6-
5.1%, CD3+CD56+ NK cells 7.5-9.0%, CD3+ T lymphocytes 25.2-43.8%.  
 
3.2   Determination of metabolites of the 5-LO pathway 
 
3.2.1  Cellular leukotriene biosynthesis 
Differentiated MM6 cells (3 × 10
6), differentiated THP-1 cells (3 × 10
6) or hPBMC (5 × 10
6) 
were resuspended in 1 mL endotoxin free PGC buffer (PBS containing 1 mg/mL glucose and 
1 mM CaCl2). In some experiments cells were pre-treated with inhibitors at 37°C for the 
indicated times. In the majority of cases cells were primed with TLR ligands (InvivoGen, 
Toulouse, France) or with PMA (Calbiochem, Merck, Darmstadt, Germany) as indicated. 
Then cellular leukotriene formation was induced by addition of ionophore A23187 or fMLP 
(both from Sigma-Aldrich, Schnelldorf, Germany) at the indicated concentrations. 
Alternatively, for determination of cellular 5-LO activity, leukotriene formation was induced 
by ionophore A 23187 in presence of exogenous AA (20-40 µM), in order to circumvent 
endogenous AA supply and to render biosynthesis of leukotrienes independent from PLA2 Materials and Methods 
_________________________________________________________________________________________________________________ 
  35
activity. For purified 5-LO enzyme in the presence of Ca
2+ it was described that maximum 
amounts of 5-LO products are formed within 6-8 min, remaining constant until ~13-15 min 
[127], implying that a 10 min incubation is suitable to assess cellular 5-LO activity. Thus, 
after 10 minutes at 37°C, the reaction was stopped with 1 mL methanol.  
 
3.2.2   Product formation of recombinant 5-LO (test of a potential 5-LO inhibitor) 
Recombinant 5-LO proteins, expressed in E. coli BL21 and purified using a ATP-agarose 
column as described previously [127], were kindly provided by Ann-Kathrin Haefner / Prof. 
Dr. D. Steinhilber, Institute for Pharmaceutical Chemistry, Goethe-University Frankfurt. 5-
LO enzyme (corresponding to an activity of 1 µg 5-LO products per amount of protein) was 
resuspended in 1 mL PBS containing 1mM EDTA and 1 mM ATP. After pre-incubation of 
the potential 5-LO inhibitor (test of different concentrations as indicated) for 15 minutes at 
4°C, the samples were pre-warmed for 30 s at 37°C and the 5-LO reaction was started by the 
addition of 20 µM AA in presence of 2 mM Ca2Cl. After 10 minutes at 37°C, the reaction was 
stopped with 1 mL methanol. 
 
3.2.3  Solid phase extraction and HPLC 
For further sample preparation, 30 µL 1N HCl, 500 µL PBS and 200 ng prostaglandin B1 as 
internal standard were added. After centrifugation (800×g, 10 min, RT) the samples were 
applied to C-18 solid-phase extraction columns (Clean-up
® Extraction Columns from UCT, 
Bristol, PA, USA), preconditioned with 1 mL methanol and 1 mL water. The columns were 
washed with 1 mL water and 1 mL methanol 75% (v/v). Subsequently, metabolites of the 5-
LO pathway were eluted with 300 µL methanol, diluted with 120 µL water and analyzed by 
HPLC as described [371] using a C-18 RP column (Novapak C-18 Radial-Pak column, 100 
mm 5 mm I.D., 4 µm, Waters). The mobile phase was composed of methanol 72% (v/v), 
water 28% (v/v) and TFA 0.007% (v/v). Metabolites were detected at 280 nm for the first 8 
min, then at 235 nm for the remaining 22 min. The flow was 1.2 mL/min. In samples derived 
from intact cells, product formation is expressed as ng 5-LO products per 10
6 cells, in samples 
derived from recombinant 5-LO, activity is measured as ng 5-LO products per amount of 
protein and inhibition of 5-LO activity is expressed as % of the control without inhibitor. 
Total 5-LO products include leukotriene B4 (LTB4; only in samples derived from intact cells), 
its all-trans isomers and 5(S)-hydroxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-HETE). 
Cysteinyl-LTs were not detected and oxidation products of LTB4 were not determined. 
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3.3  Determination of [
3H]AA release 
MM6 cells were resuspended at 2 × 10
6/mL in pre-warmed RPMI 1640 medium containing 
0.5 µCi/mL [
3H]AA (specific activity 7.4 MBq/µmol, from Biotrend, Cologne, Germany), 
and incubated for 3 hours at 37°C, 5% CO2. Thereafter, cells were collected by centrifugation 
(1000×g, 10 min, RT), washed with PBS containing 2 mg/mL low endotoxin fatty acid free 
bovine serum albumin (FAF-BSA, Sigma-Aldrich, Schnelldorf, Germany; ≤ 0.1 ng/mg 
endotoxin according to manufacturer´s specification) to remove unincorporated [
3H]AA, and 
resuspended in PGC buffer / FAF-BSA at 3 × 10
6/0.5 mL or 2 × 10
5/0.2 mL. After labeling, 
MM6 cells were in some experiments pre-treated with inhibitors and in the majority of cases 
primed with TLR ligands as indicated. [
3H]AA release was induced by the addition of 
ionophore A23187 2.5 µM for 10 min at 37°C unless otherwise noted. To stop the reaction, 
samples were placed on ice. After centrifugation (200×g, 5 min, 4°C), 100 µL of the 
supernatants were mixed with 3 mL of a liquid scintillation cocktail (Optiphase Hisafe 3, 
Perkin Elmer, Shelton, CT, USA), and analyzed with the Wallac 1409 liquid scintillation 
counter (Perkin Elmer). [
3H]AA release is expressed as decays per minute (dpm) per 10
6 cells. 
 
3.4   Calcium imaging 
MM6 cells (3 × 10
7/mL) were resuspended in PBS containing 1 mg/mL glucose and 
incubated with 2 µM Fura-2/AM for 30 min at 37°C. After washing, 5 × 10
6 cells/mL PBS 
(containing 1 mg/mL glucose) were pre-warmed in a thermally controlled (37°C) fluorometer 
cuvette in a spectrofluorometer (Aminco-Bowman series 2; Thermo Electron Corporation, 
Waltham, MA, USA) with continuous stirring. Then, 1 mM Ca
2+ was added and 2 min later 
measurement was started. After 30 s, cells were stimulated with TLR2 ligands, PMA or 
ionophore A23187 as indicated. The fluorescence emission at 510 nm was measured after 
excitation at 340 and 380 nm, respectively, and [Ca
2+]i  was calculated according to 
Grynkiewicz et al. [372]. Fmax (maximal fluorescence) was determined after lysing the cells 
with 1% Triton X-100 (w/v) and Fmin after chelating Ca
2+ with 10 mM EDTA. 
 
3.5  Determination of protein phosphorylation 
 
3.5.1  Incubation and sample preparation 
MM6 cells (3 × 10
6) were resuspended in 100 µl PGC buffer. For time course analyses, cells 
were stimulated with TLR ligands for different periods of time at 37°C as indicated. 
Alternatively, MM6 cells were stimulated with TLR ligands or ionophore A18237 for 15 Materials and Methods 
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minutes at 37°C. In some experiments, cells were pre-treated with inhibitors as indicated 
before stimulation. Incubations were stopped by addition of 100 µL of 2× SDS-PAGE sample 
loading buffer (20mM Tris / HCl pH 8.0, 2 mM EDTA, 5% SDS (w/v), 10% β-
mercaptoethanol) and placed on ice. Samples were heated at 95°C for 6 minutes and 
subsequently sonified (10 seconds).  
 
3.5.2  SDS PAGE and Western Blot 
Total cell lysates corresponding to 0.3 × 10
6 cells in 20 µL were mixed with 3 µL of glycerol / 
0.1% bromophenol blue (1:1, v/v) and analyzed by SDS-PAGE using a Mini Protean system 
(Bio-Rad, Munich, Germany) on a 10% gel. After electroblot on nitrocellulose membrane 
(Amersham Hybond C, GE Healthcare Europe GmbH, Freiburg, Germany) and blocking with 
Odyssey
® Blocking Buffer (LI-COR
® Biosciences, Bad Homburg, Germany) for 1 hour / RT, 
membranes were incubated with primary antibodies overnight at 4°C.  
 
Primary Antibodies 
Description      s o u r c e     dilution   producer 
phospho-p38 MAPK (Thr180/Tyr182)  rabbit pAby    1:1000    NEB, Frankfurt a.M. 
p38  MAPK  (C-20)      goat  pAby   1:1000   Santa  Cruz,  Heidelberg 
phospho-5-LO  (Ser271)      rabbit  pAby   1:1000   NEB,  Frankfurt  a.M. 
5-LO (catalytic domain)   mouse mAby, IgG1  1:100    Prof. Dr. D. Steinhilber,  
    (clone 6A12)        Inst. f. Pharm. Chem.,  
       Goethe-University,   
Frankfurt a.M. 
phospho-p44/p42 MAPK      mouse mAby; IgG1  1:1000     NEB, Frankfurt a.M. 
(Thr202/Tyr204)        (E10) 
p44/42  MAPK      rabbit  pAby   1:1000   NEB,  Frankfurt  a.M. 
phospho-Mnk-1  (Thr197/202)   rabbit  pAby   1:1000   NEB,  Frankfurt  a.M. 
Mnk-1  (C-20)      goat  pAby   1:200   Santa  Cruz,  Heidelberg 
phospho-cPLA2  (Ser505)    rabbit  pAby     1:1000   NEB,  Frankfurt  a.M. 
cPLA2  (C-20)      goat  pAby   1:200   Santa  Cruz,  Heidelberg 
IκB-α      rabbit  pAby   1:1000   NEB,  Frankfurt  a.M. 
  
The respective antibody solutions contained an antibody specific for the phosphorylated form 
of the investigated protein, together with a second antibody, detecting the unphosphorylated 
and the phosphorylated form of the protein (derived from different species). Membranes were 
washed with PBS pH 7.4 / Tween 0.1% (v/v) and incubated with infrared dye conjugated 
secondary antibodies (IRDye
®, LI-COR
® Biosciences) for 45min / RT under protection from 
light. Two differentially labeled secondary antibodies (emission wavelength 680 nm and 800 Materials and Methods 
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nm, respectively) were used for simultaneous detection of the phosphorylated form and the 
total amount of the investigated protein. 
  
Secondary Antibodies 
Description   source    dilution   producer 
IRDye
® 800CW    donkey anti-rabbit IgG  1:5000    LI-COR
®, Bad Homburg 
IRDye
® 680    donkey anti-goat IgG   1:5000    LI-COR
®, Bad Homburg 
IRDye
® 800CW    goat anti-rabbit IgG    1:5000    LI-COR
®, Bad Homburg 
IRDye
® 680    goat anti-mouse IgG   1:5000    LI-COR
®, Bad Homburg 
 
Membranes were washed with PBS pH 7.4 / Tween 0.1% (v/v), and finally with PBS pH 7.4. 
Visualization and quantitative analysis of protein bands was carried out with the Odyssey
® 
Infrared Imaging System (LI-COR
® Biosciences). For quantification, the intensities of bands 
representing the phosphorylated protein were corrected by band intensities of the total protein 
(loading control). Enhancement of phosphorylation was calculated by relating band intensities 
received after cell stimulation, to band intensities derived from unstimulated cell samples. 
 
3.6  5-LO translocation assay  
 
3.6.1  Preparation of nuclear and nonnuclear cellular fractions 
MM6 cells (5 – 10 × 10
6) were resuspended in 1mL PGC buffer and incubated as indicated at 
37°C. In several cases, cells were primed with TLR2 ligands or with PMA for 5-15 min 
before stimulation with ionophore A18237 for 5-10 min, in one of these experimental series 
the incubations were carried out in presence of p38 MAPK inhibitor SB203580. Otherwise, 
cells were separately treated with TLR2 ligands or ionophore A18237 at the indicated 
conditions. After incubation, the samples were chilled on ice for 5 min and centrifuged 
(200×g, 5 min, 4°C). Pellets were then suspended in 300 µL ice-cold NP-40-lysis buffer (10 
mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2, 1 mM EDTA, 0.1% NP-40, 1 mM PMSF, 
60 µg/mL STI and 10 µg/mL leupeptin), vortexed (3 × 5 s), kept on ice for 10 min and 
centrifuged (800×g, 10 min, 4°C). Resulting supernatants containing cytosol, plasma 
membrane, ER, Golgi apparatus and cytoskeletal proteins (nonnuclear fractions) were 
transferred to a new tube, and pellets containing intact nuclei (nuclear fractions) were 
resuspended in 300 µL ice-cold relaxation buffer (50 mM Tris-HCl pH 7.4, 250 mM sucrose, 
25 mM KCl, 5 mM MgCl2, 1 mM EDTA, 1 mM PMSF, 60 µg/mL STI and 10 µg/mL 
leupeptin). Both nuclear and nonnuclear fractions were centrifuged again (800×g, 10 min, Materials and Methods 
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4°C) for further purification. Nuclei in relaxation buffer were disrupted by sonication (3 × 5 
s). Aliquots of nuclear and nonnuclear fractions were mixed with the same volume of 2× 
SDS-PAGE sample loading buffer (20mM Tris / HCl pH 8.0, 2 mM EDTA, 5% SDS (w/v), 
10% β-mercaptoethanol) and heated at 95°C for 6 min. 
 
3.6.2  Preparation of membrane and cytosolic fractions 
MM6 cells (5 × 10
6) were resuspended in 1mL PGC buffer and primed with TLR2 ligands or 
with PMA for 15 min / 37°C at the indicated concentrations before stimulation with 2.5 µM 
ionophore A18237 for another 10 min at 37°C. Then the samples were chilled on ice for 5 
min and centrifuged (200×g, 5 min, 4°C). Pellets were suspended in 300 µL ice-cold NP-40-
lysis buffer, sonicated for 8 s, kept on ice for 10 min and 275 µL of this mixture were 
subjected to an ultracentrifugation step (100,000×g, 70 min, 4°C). Resulting supernatants 
containing cytosolic proteins (cytosolic fractions) were transferred to a new tube, and pellets 
containing cellular membranes (membrane fractions) were resuspended in 275 µL ice-cold 
relaxation buffer and resuspended by sonication (10 s). Aliquots of cytosolic and membrane 
fractions were mixed with the same volume of 2× SDS-PAGE sample loading buffer and 
heated at 95°C for 6 min. 
 
3.6.3  Analysis and assay control by SDS PAGE and Western Blot 
Aliquots (20 µL) of the subcellular fractions were mixed with 3 µL of glycerol / 0.1% 
bromophenol blue (1:1, v/v) and pair-wise samples (nonnuclear / nuclear or cytosolic / 
membrane) corresponding to identical cell numbers were processed separately by SDS PAGE 
on a 10% gel and subsequent electroblot on nitrocellulose membrane. For analyses with the 
Odyssey
® Infrared Imaging System, blocking was carried out with the Odyssey
® Blocking 
Buffer, in case of protein visualization by alkaline phosphatase reaction, blocking was done 
with 5% nonfat dry milk in TBS (50 mM Tris-HCl pH 7.4 and 100 mM NaCl) for 1 hour / 
RT. Then, membranes were washed with TBS and incubated with the 5-LO antibody 
overnight at 4°C.  
 
Primary Antibodies 
Description     source    dilution   producer 
5-LO (catalytic domain)   mouse mAby, IgG1  1:100    Inst. f. Pharm. Chem.,   
    (clone  6A12)     Frankfurt  a.M.     
GAPDH      rabbit mAby, IgG  1:2000    NEB, Frankfurt a.M. 
     (14C10)   
Lamin A/C      rabbit pAby    1:1000    NEB, Frankfurt a.M.  Materials and Methods 
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Primary antibody solutions contained two additional antibodies detecting the cytosolic marker 
protein GAPDH and also lamin A/C, which are ubiquitous proteins exclusively present in the 
nuclear membrane. By the analysis of both markers in each of the subcellular fractions, the 
samples were tested for correct fractionation. Furthermore, these marker proteins were used as 
loading controls in the respective subcellular fractions. In case of infrared imaging, 
membranes were washed with PBS pH 7.4 / Tween 0.1% (v/v) and incubated with infrared 
dye conjugated secondary antibodies for 45min / RT under protection from light. Membranes 
were washed with PBS pH 7.4 / Tween 0.1% (v/v), finally with PBS pH 7.4, and were 
analyzed with the Odyssey
® Infrared Imaging System. For quantification, band intensities of 
the 5-LO protein were corrected by band intensities of the loading control. Results are given 
as relative band intensities in the respective fraction after cell incubation, related to band 
intensities detected in the respective fraction of untreated cells. 
 
Secondary Antibodies 
Description source    dilution   producer 
IRDye
® 800CW  donkey anti-mouse IgG  1:5000    LI-COR
®, Bad Homburg  
IRDye
® 680  donkey anti-rabbit IgG  1:5000    LI-COR
®, Bad Homburg 
Anti-mouse  IgG  goat   1:1000   Sigma,  Schnelldorf 
(whole molecule) 
– alkaline phosphatase 
  
Otherwise, after incubation of the primary antibody, membranes were washed with TBS and 
incubated with alkaline phosphatase-conjugated anti-mouse IgG for 2 h / RT. After washing 
with TBS and TBS plus 0.1% NP40, 5-LO protein was visualized with the alkaline 
phosphatase substrates nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate in 
detection buffer (100 mM Tris-HCl pH 9.5, 100 mM NaCl, 5 mM MgCl2). 
 
3.7  Statistics 
Results are given as mean + S.D., n ≥ 3, except as noted otherwise. Statistical analysis was 
carried out by Student's unpaired t test (one-tailed), except as noted otherwise. Differences 
were considered as significant for p<0.05 (indicated as * p<0.05 or ** p<0.01). IC50 values 
were determined by non-linear regression  using  GraphPad  Prism  5.0  and  a  sigmoid          
concentration – response model.        Results 
_________________________________________________________________________________________________________________ 
  41
 
4 RESULTS 
 
4.1    The influence of TLR ligands on leukotriene biosynthesis in human monocytes 
 
4.1.1  Enhancement of leukotriene biosynthesis by TLR ligands in MM6 cells 
In order to evaluate the effects of TLR ligands on LT biosynthesis in human monocytes, 
several activators of different TLR subtypes were screened for their impact on 5-LO product 
formation in differentiated MM6 cells. Therefore, cells were pre-incubated with commonly 
used concentrations of the respective TLR ligands and subsequently stimulated for 
leukotriene formation with calcium ionophore A23187. The two different types of CpG ODN 
as TLR9 activators, TLR7 ligand Loxoribine and TLR3 ligand Poly (I:C) did not show any 
impact on the biosynthesis of 5-LO metabolites. As expected due to former publications, pre-
incubation with LPS, which is an activator of TLR4, enhanced the biosynthesis of 5-LO 
products. However, also the TLR2/6 ligands LTA and FSL-1, as well as TLR2/1 ligand 
Pam3CSK4 led to an approximate twofold increase of ionophore-induced 5-LO product 
formation.  
 
Figure 7: Enhancement of 5-LO product formation by TLR ligands in differentiated MM6 cells. Differentiated 
MM6 (3 × 10
6 cells) were primed with TLR ligand or solvent as indicated 20 min / 37°C (CpG 2216 1 µM and 
CpG 2006-G5 1 µM, TLR9; Loxoribine 100 µM, TLR 7; LPS 10 µg/mL, TLR4; Poly (I:C) 25 µg/mL, TLR3; LTA 
2 µg/mL, TLR2/6; FSL-1 1 µg/mL, TLR2/6; Pam3CSK4 1 µg/mL, TLR2/1) before stimulation with ionophore 
A23187 2.5 µM for another 10 min / 37°C. 5-LO products were determined by HPLC. Student´s t test; 
**p<0.01; 
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4.1.2  Characterization of TLR2 ligand mediated priming of MM6 cells 
The following studies focus on TLR2 ligand induced effects and provide a more detailed 
characterization of the observed enhancement of 5-LO product formation in MM6 cells. 
 
Determination of the optimal ionophore concentration 
In order to determine the optimal concentration of calcium ionophore within the experimental 
setting, 5-LO product formation was stimulated with 0.1 to 5 µM of A23187 after pre-
incubation with the three different TLR2 ligands, respectively. Relative 5-LO product 
formation was augmented with increasing concentrations of ionophore up to 2.5 µM, which 
was defined as optimal concentration for subsequent experiments. With a further increase of 
ionophore concentrations beyond 2.5 µM, the enhancement of 5-LO product formation by 
TLR2 ligands was diminished again.  
 
 
Figure 8: Determination of the optimal ionophore concentration. Differentiated MM6 (3 × 10
6 cells) were pre-
incubated with TLR ligands or solvent as indicated 20 min / 37°C before stimulation of 5-LO product formation 
with different concentrations of ionophore A23187 (Iono) for another 10 min / 37°C. 5-LO products were 
determined by HPLC. Relative increase of products was calculated in relation to product formation without TLR 
ligand pre-incubation, respectively. The data represent one out of two experiments. 
 
Determination of the optimal TLR2 ligand concentration 
Next, further dose response characteristics were determined. MM6 cells were pre-treated with 
increasing concentrations of LTA, FSL-1 or Pam3CSK4 before stimulation with ionophore. 
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Each of the ligands showed concentration-dependent effects. LTA and FSL-1 exhibited a 
maximum effect at 0.5 µg/mL, followed by a decreasing response beyond this concentration. 
Only at very high concentrations of LTA and FSL-1, a second enhancement of 5-LO 
metabolites could be detected. In contrast, Pam3CSK4  consistently enhanced cellular LT 
formation with increasing concentrations. 5 µg/mL Pam3CSK4 evoked a comparable increase 
of 5-LO products as the other two ligands at 0.5 µg/mL, suggesting a weaker potency of 
Pam3CSK4. LTA 0.5 µg/mL, FSL-1 0.5 µg/mL and Pam3CSK4 5 µg/mL were regarded as 
optimal concentrations for the following studies. 
 
 
Figure 9: Determination of the optimal TLR2 ligand concentration. Differentiated MM6 (3 × 10
6 cells) were pre-
incubated with solvent or TLR ligands at the indicated concentrations 20 min / 37°C before stimulation of 5-LO 
product formation with ionophore A23187 2.5 µM for another 10 min / 37°C. 5-LO products were determined by 
HPLC.   
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Time dependence of TLR2 ligand-induced effects 
For further characterization, time course experiments were performed. Therefore, cells were 
pre-incubated with TLR2 ligands for different periods of time before ionophore stimulation. 
All ligands showed comparable time-dependent characteristics. The maximum response was 
obtained with a pre-incubation time of 15 minutes. However, the effect disappeared when pre-
incubation was further extended up to 90 minutes. Pre-incubation of the ligands was essential, 
as no enhancement of LT formation was detectable when MM6 cells were treated with TLR2 
ligands and ionophore simultaneously. These observations indicated that TLR2 ligands 
seemed to act as priming agents on human MM6 cells for an enhanced response to ionophore 
stimulation, but did not seem to directly act as costimuli. 
 
 
 
Figure 10: Time dependence of TLR2 ligand-induced effects. Differentiated MM6 (3 × 10
6 cells) were pre-
incubated with solvent or TLR ligands at their optimal concentrations (LTA 0.5 µg/mL, FSL-1 0.5 µg/mL, 
Pam3CSK4 5 µg/mL) for different periods of time / 37°C before stimulation of 5-LO product formation with 
ionophore A23187 2.5 µM for another 10 min / 37°C. 5-LO products were determined by HPLC.   
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TLR2 ligand priming: a synergistic mechanism 
The aim of the following experiment was to further clarify, if TLR2 ligands are able to 
directly stimulate the formation of LTs. Within the optimal time frames of incubation, the 
effects of the three TLR2 ligands and of ionophore were investigated separately, and were 
then compared to the effects evoked by the optimal combination of the agents. Ionophore 
stimulation of MM6 cells for 10 minutes after 15 minutes of pre-incubation with solvent led 
to a distinct, but low 5-LO product formation (approximately 1.2 ng 5-LO products per 10
6 
cells). The response after incubation of MM6 cells with LTA and FSL-1 for 15 minutes with a 
subsequent incubation period of 10 minutes without ionophore was marginal, and Pam3CSK4 
only weakly induced a slight direct response. Thus, LT formation upon TLR2 ligand 
incubation is too low to characterize them as direct stimulators of the LT biosynthesis 
pathway. However, after combination of at least LTA or FSL-1 with ionophore, the extent of 
5-LO product formation was higher than the sum of the single effects of the ligands and of 
ionophore, respectively (up to 4.5 ng 5-LO products per 10
6 cells). From this it was concluded 
that these TLR2 ligands in a synergistic manner prime MM6 cells for enhanced biosynthesis 
of 5-LO metabolites.  
 
 
 
Figure 11: TLR2 ligand priming: a synergistic mechanism. Differentiated MM6 (3 × 10
6 cells) were incubated 
with solvent or TLR ligands as indicated (LTA 0.5 µg/mL, FSL-1 0.5 µg/mL, Pam3CSK4 5 µg/mL) at 37°C. After 
15 min, ionophore A23187 2.5 µM or solvent was added for another 10 min / 37°C. 5-LO product formation was 
determined by HPLC. 
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4.1.3  Confirmation of the priming effects of TLR2 ligands in hPBMC 
In order to confirm the observed effects of TLR2 ligands in MM6 cells and to exclude cell-
line specific effects, human primary cells were tested under analogous conditions. Human 
peripheral blood mononuclear cells (hPBMC) were primed with TLR2 ligands followed by 
stimulation with calcium ionophore. A significant increase of 5-LO products was detected 
when hPBMC were stimulated with 0.025 µM of ionophore after priming. Preliminary tests 
had revealed that the use of high concentrations of calcium ionophore (2.5µM) indeed led to 
substantial 5-LO product formation, which was not significantly enhanced by TLR2 ligands 
though. In a further experiment, N-formyl-leucyl-phenylalanine (fMLP) at 1µM was used as a 
physiological stimulus. In analogy, TLR2 activators led to a significant enhancement of 5-LO 
product release after fMLP stimulation. Taken together, TLR2 ligands showed a similar 
impact on hPBMC as on MM6 cells, particularly upon weak stimulation. 
 
 
 
Figure 12: Confirmation of the priming effects of TLR2 ligands in hPBMC. PBMC (5 × 10
6 cells) were primed 
with TLR2 ligands or solvent (LTA 0.5 µg/mL, FSL-1 0.5 µg/mL, Pam3CSK4 5 µg/mL) for 15 min/37°C. Then 5-
LO product formation was induced by ionophore A23187 (iono) 0.025 µM or fMLP 1 µM for another 10min / 
37°C. 5-LO products were determined by HPLC. Student´s t test; ** p<0.01; 
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The following tests complement initial screening experiments and test another two TLR 
ligands for their priming properties in MM6 cells. After pre-incubation with TLR5 ligand 
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phorbol-12-myristate-13-acetate (PMA) was used, which is known as a potent priming agent 
in MM6 cells that enhances 5-LO product formation upon ionophore stimulation [170, 373]. 
As it is shown in the figure below, also flagellin led to a significant increase of 5-LO 
metabolites in MM6 cells. In contrast, for TLR8 activator ssPolyU no clear priming effect 
was detected.  
 
 
 
Figure 13: Priming activities of further TLR ligands in MM6 cells. Differentiated MM6 (3 × 10
6 cells) were 
primed with solvent, PMA 100 nM or TLR ligand (flagellin 5 µg/mL, TLR5; ssPolyU/LyoVec 5µg/mL, TLR8) as 
indicated 15 min / 37°C before stimulation with ionophore A23187 2.5 µM for another 10 min / 37°C. 5-LO 
products were determined by HPLC. Student´s t test; ** p<0.01, * p<0.05; 
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4.2   The influence of TLR ligands on 5-lipoxygenase in human monocytes 
 
After description and characterization of TLR ligand induced priming of human monocytic 
cells for enhanced 5-LO product formation, the following studies concentrate on 
understanding the underlying mechanisms of the observed effects. 
At first, the influence of TLR ligands on 5-LO, the key enzyme in the biosynthesis of 
leukotrienes, was investigated in detail. 
 
4.2.1  The influence of TLR ligands on 5-lipoxygenase activity 
The aim of subsequent investigations was to elucidate if TLR ligands have an impact on 
cellular 5-LO activity, which may account for enhanced leukotriene formation after priming. 
For this purpose, cells were stimulated in presence of an overabundant amount of exogenous 
AA, respectively. Under such conditions, formation of 5-LO metabolites is no longer 
dependent on endogenous AA release and 5-LO activity can be measured irrespectively of 
PLA2 activity. 
 
Stimulation of 5-LO activity by TLR ligands in MM6 cells  
In order to find out if TLR ligands can stimulate 5-LO activity in MM6, cells were pre-
incubated with LTA as a representative of TLR2 ligands or with flagellin, before an excess of 
exogenous AA was added for another 10 minutes. Compared to the control, neither LTA nor 
flagellin further stimulated 5-LO activity in MM6 cells. In fact, LTA even showed an 
inhibitory effect in this experimental setting. 
 
Figure 14: Direct stimulation of 5-LO activity by TLR ligands in MM6 cells. Differentiated MM6 (3 × 10
6 cells) 
were pre-incubated with solvent, LTA 0.5 µg/mL or flagellin 5 µg/mL 15 min / 37°C. Then AA 40 µM was added 
for another 10 min / 37°C. 5-LO product formation was determined by HPLC. Student´s t test; * p<0.05; 
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Priming effect on 5-LO activity by TLR ligands in MM6 cells and THP-1 cells 
Next, TLR ligand priming for an increase of ionophore-stimulated 5-LO activity was 
analyzed in MM6 cells, and in THP-1 cells as a second monocytic cell line. MM6 or THP-1 
cells were primed with LTA, flagellin or ssPolyU, which had not been identified as a priming 
agent, and then stimulated with ionophore in presence of exogenous AA. Biosynthesis of 5-
HETE, which is independent from LTA4 hydrolase activity and also independent from 
subcellular localization of 5-LO, was used as a readout for 5-LO activity in these experiments. 
None of the TLR ligands led to an increase of 5-LO activity, neither in MM6 cells nor in 
THP-1 cells. Repeatedly, a slight trend to an inhibitory influence of TLR ligands was noticed 
in MM6 cells. 
 
 
 
Figure 15: Priming effect on 5-LO activity by TLR ligands in monocytic cell lines. Differentiated MM6 (3 × 10
6 
cells) or differentiated THP-1 cells (3 × 10
6 cells) were primed with solvent, LTA 0.5 µg/mL, flagellin 5 µg/mL 
or ssPolyU/LyoVec 5µg/mL as indicated 15 min / 37°C. Then ionophore A23187 2.5 µM plus AA 40 µM were 
added for another 10 min / 37°C. 5-HETE formation was determined by HPLC. Student´s t test; * p<0.05; 
 
Priming effect on 5-LO activity by TLR2 ligands and PMA in MM6 cells 
In addition to the antecedent data, all of the three TLR2 ligands were tested for a potential 
enhancement of 5-LO activity under analogous conditions. In a second experiment, priming 
properties of LTA were compared to PMA-mediated priming. LTA, FSL-1 and Pam3CSK4 
did not show an enhancing impact on 5-LO activity in MM6 cells. PMA, however, led to a 
significant increase of 5-LO product formation, as it was expected on the basis of 
corresponding publications, which report an increase of 5-LO activity after PMA priming 
[170, 373]. By comparison, LTA seemed to marginally inhibit 5-LO activity by trend. 
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Figure 16: Priming effect on 5-LO activity by TLR2 ligands in MM6 cells. Differentiated MM6 (3 × 10
6 cells) 
were primed with solvent, PMA 100 nM or TLR2 ligands (LTA 0.5 µg/mL, FSL-1 0.5 µg/mL, Pam3CSK4 5 
µg/mL) as indicated 15 min / 37°C. Then ionophore A23187 2.5 µM and AA 20 µM were added for another 10 
min / 37°C. 5-LO product formation was determined by HPLC. Student´s t test; * p<0.05;  
 
4.2.2   Influence of TLR2 ligands on 5-lipoxygenase translocation in MM6 cells 
The regulation of the subcellular distribution of 5-LO plays a crucial role in cellular LT 
formation from endogenous AA. Upon cell stimulation, 5-LO is activated and essentially 
translocates to the nuclear envelope, where a biosynthetic complex is assembled that 
facilitates AA release from membrane phospholipids by cPLA2 and subsequent transfer of AA 
to 5-LO via FLAP [16, 374].  
The influence of TLR2 ligands on subcellular 5-LO localization was investigated in MM6 
cells. The aim was to analyze if the increase of LT formation after priming can be traced back 
to enhanced 5-LO translocation to a membrane compartment, where the enzyme would have a 
greater access to free AA. 
 
Influence of LTA on 5-LO translocation 
The following translocation assays test TLR2 ligand LTA for its impact on subcellular 
distribution of 5-LO. Furthermore, the results compare the properties of LTA and PMA, 
which is known to enhance ionophore-induced 5-LO translocation in MM6 cells [373]. Cells 
were incubated with ionophore or with LTA, or they were primed with LTA or PMA before 
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cytoskeletal proteins were prepared from the cells. The subcellular fractions were then 
analyzed separately by 5-LO immunoblotting.  
 
 
 
Figure 17: Influence of LTA on 5-LO translocation. Differentiated MM6 (10 × 10
6 cells) were primed with 
solvent, PMA 100nM or LTA 0.5 µg/mL as indicated 15 min / 37°C. Then, solvent or ionophore A23187 2.5 µM 
was added for another 5 min / 37°C. After cell lysis, nonnuclear and nuclear fractions were separated by 
centrifugation and analyzed separately by SDS PAGE and immunoblotting (Odyssey
® Infrared Imaging System). 
For quantification, band intensities of 5-LO were corrected by band intensities of specific loading controls for 
the nonnuclear (GAPDH) and the nuclear fraction (Lamin A/C), respectively. The amount of 5-LO protein is 
related to the level of 5-LO protein in the negative control. Pair-wise samples (nonnuclear, nuclear) correspond 
to identical cell numbers. Student´s t test (paired; one-tailed); ** p<0.01, * p<0.05; 
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Quantification of 5-LO band intensities in the respective fractions revealed that in resting 
cells 5-LO was mainly located in the nonnuclear fraction, shown by a strong band in the 
nonnuclear and a weak band in the nuclear fraction. After stimulation with ionophore, 5-LO 
partially translocated from the nonnuclear fraction to the nucleus. The ionophore induced shift 
of 5-LO protein to the nuclear fraction was considerably enhanced by PMA priming, as it was 
shown in prior studies [373]. In contrast, after LTA priming no significant enhancement of 
ionophore induced 5-LO translocation was detected and subcellular distribution of 5-LO in 
primed and in unprimed cells was similar. The direct impact of LTA on 5-LO localization was 
investigated as well. Interestingly, a tendency towards an oppositional distribution of 5-LO 
was observed. After incubation of MM6 cells with LTA, an insignificant increase of 5-LO 
protein in the nonnuclear fraction was detected.  
 
 
Figure 18: Assay control: Unstimulated MM6 cells (10 × 10
6 cells) were lysed, nonnuclear and nuclear fractions 
were separated by centrifugation and analyzed separately by SDS PAGE and immunoblotting (Odyssey
® 
Infrared Imaging System). In each of the fractions both, the nonnuclear and the nuclear loading control proteins 
were measured, respectively.  
 
For each experiment, the cytosolic marker GAPDH and the nuclear marker protein lamin 
were measured simultaneously in each fraction, respectively. This was used as an assay 
control, in order to check an adequate separation of nonnuclear from nuclear compartments. 
The figure shows one representative example of these control experiments carried out with 
unstimulated MM6 cells. Besides the signal of the 5-LO protein, a strong band of GAPDH, 
but no lamin was found in the nonnuclear fraction. In the nuclear fraction, a weak band of 5-
LO and a distinct signal of lamin A/C could be detected. In comparison to the nonnuclear 
fraction, a low amount of GAPDH was found also in the nuclear fraction, which indicated a 
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slightly incomplete separation of the nonnuclear compartment from the nuclei. This was 
regarded as neglibigle, though, in terms of 5-LO translocation analyzes, and overall, the assay 
procedure appeared to provide a sufficient separation of fractions. 
In summary, subcellular distribution analyzes revealed that LTA priming did not result in an 
enhanced 5-LO translocation, which accordingly does not seem to account for enhanced LT 
biosynthesis after TLR2 ligand pre-incubation.  
 
Direct stimulation of 5-LO translocation by TLR2 ligands? 
In further translocation assays also the lipopeptides FSL-1 and Pam3CSK4 were tested 
regarding their impact on subcellular 5-LO localization in MM6 cells and their influence was 
checked against that of LTA. The following experiments were performed to exclude a direct 
stimulation of 5-LO translocation for each of the three TLR2 ligands.    
Therefore, MM6 cells were incubated with TLR2 ligands before analysis of nuclear and 
nonnuclear cell fractions by 5-LO immunoblotting. As a positive control experiment for 
strong 5-LO translocation, cells were stimulated with ionophore after priming with PMA. For 
resting MM6 cells, a predominant localization of 5-LO in nonnuclear compartments of the 
cell could be confirmed. PMA priming and subsequent ionophore stimulation again led to a 
clear shift of 5-LO protein to the nuclear fraction. Yet FSL-1 and Pam3CSK4 and again LTA 
did not directly induce 5-LO translocation to the nucleus in MM6 cells. However, from these 
analyzes it was not possible to detect reliably if 5-LO tends to redistribute into the nonnuclear 
compartment after TLR2 ligand incubation, as it was seen after LTA stimulation in previous 
translocation assays. 
 
 
Figure 19: Direct stimulation of 5-LO translocation by TLR2 ligands. Differentiated MM6 (5 × 10
6 cells) were 
incubated with solvent or TLR2 ligands (LTA 0.5 µg/mL, FSL-1 0.5 µg/mL, Pam3CSK4 5 µg/mL) as indicated 20 
min / 37°C. As positive control MM6 were primed with PMA 100 nM 10min / 37°C, before ionophore A23187 5 
µM was added for another 10 min / 37°C. After cell lysis, nonnuclear and nuclear fractions were separated by 
centrifugation and analyzed separately by SDS PAGE and immunoblotting (alkaline phosphatase reaction). 
Pair-wise samples (nonnuclear, nuclear) correspond to identical cell numbers. Similar results were obtained in 
2 additional experiments. 
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Enhancement of ionophore induced 5-LO translocation by TLR2 ligands? 
The influence of TLR2 ligand priming on ionophore induced 5-LO translocation was 
investigated, now including also the properties of FSL-1 and Pam3CSK4. After priming of 
MM6 cells and subsequent ionophore stimulation, nuclear and nonnuclear fractions were 
analyzed by 5-LO immunoblotting. Particularly the 5-LO bands of the nonnuclear fraction 
show that priming with none of the three TLR2 activators enhanced ionophore induced 5-LO 
translocation in comparison to unprimed cells. As a positive control, PMA priming again 
resulted in an augmented translocation of 5-LO. These results confirmed that besides LTA, 
also FSL-1 and Pam3CSK4 did not seem to enhance LT biosynthesis by increasing 
redistribution of 5-LO to the nucleus. 
 
 
 
Figure 20: Enhancement of ionophore induced 5-LO translocation to the nucleus by TLR2 ligands. 
Differentiated MM6 (5 × 10
6 cells) were primed with solvent, PMA 100 nM or TLR2 ligands (LTA 0.5 µg/mL, 
FSL-1 0.5 µg/mL, Pam3CSK4 5 µg/mL) as indicated. Solvent or ionophore A23187 2.5 µM was added for 
another 10 min / 37°C. Nonnuclear and nuclear fractions were separated by centrifugation and analyzed by SDS 
PAGE and immunoblotting (Odyssey
® Infrared Imaging System). Pair-wise samples correspond to identical cell 
numbers. Similar results were obtained in 3 additional experiments. 
 
 
 
 
Figure 21: Enhancement of ionophore induced 5-LO translocation to cellular membranes by TLR2 ligands. 
Differentiated MM6 (5 × 10
6 cells) were incubated as described above. After cell lysis, cytosolic and membrane 
fractions were separated by centrifugation and analyzed separately by SDS PAGE and immunoblotting 
(Odyssey
® Infrared Imaging System). Pair-wise samples correspond to identical cell numbers. Results reflect 
preliminary data.   
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Additionally it was excluded that 5-LO redistribution might occur to other cellular 
membranes than simply to the nuclear envelope. Thus, a cytosolic and a membrane fraction 
containing all the cellular membranes were prepared by ultracentrifugation of cell lysates, 
after priming and stimulation of MM6 cells. Separate analysis revealed that TLR2 ligand 
priming did not result in a definite increase of 5-LO translocation and again subcellular 
localization of 5-LO after stimulation was comparable in primed and in unprimed cells. 
Collectively, it was concluded that TLR2 ligand priming does not regulate cellular 
redistribution of 5-LO, neither to the nuclear envelope, nor to other cellular membranes. 
 
4.2.3  Excursus: Observation of the “5-HETE effect” after priming 
The following section contains a more detailed analysis of the product rates of 5-LO 
metabolites formed by primed and unprimed human monocytic cells after ionophore 
stimulation. 
 
Product rates after TLR ligand priming in MM6 cells 
At first, the data of the initial screening experiment, which was already discussed in an earlier 
section (4.1.1), were evaluated in more detail. For this purpose, various metabolites of the LT 
biosynthesis pathway were analyzed separately and their induction by TLR ligand priming 
was calculated.  
 
Figure 22: “5-HETE effect” after priming with TLR2 ligands. Differentiated MM6 (3 × 10
6 cells) were primed 
with TLR ligand or solvent as indicated 20 min / 37°C (CpG 2216 1 µM and CpG 2006-G5 1 µM, Loxoribine 
100 µM, LPS 10 µg/mL, Poly (I:C) 25 µg/mL, LTA 2 µg/mL, FSL-1 1 µg/mL, Pam3CSK4 1 µg/mL) before 
stimulation of 5-LO product formation with ionophore A23187 2.5 µM for another 10 min / 37°C. 5-LO products 
were determined by HPLC.    
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An approximate 2-fold induction by priming was observed for the entirety of the detected 
products including LTB4, its all-trans isomers and 5-HETE. However, separate analysis of 5-
HETE revealed an up to 5-fold enhancement after priming in comparison to unprimed cells. 
This “5-HETE effect” was observed after LPS priming, as well as after priming with TLR2 
ligands. The formation of LTB4 and its all-trans isomers after priming with LTA was further 
analyzed, but only a 1.5 – 2-fold enhancement of these metabolites was found.  
 
5-HETE formation in MM6 cells after priming with LTA or PMA 
Further studies were undertaken in order to clarify if the preferential increase of 5-HETE 
occurred as a result of poor 5-LO translocation in MM6 cells even upon priming with TLR2 
ligands and subsequent stimulation. The underlying idea was that in case of sufficient 
substrate supply, 5-HETE yet might be formed in the cytosol, even if the interplay of 5-LO 
with LTA4 metabolizing enzymes and the assembly of the biosynthetic complex at the nuclear 
envelope is not optimal.  Therefore, MM6 cells were primed either with TLR2 ligand LTA or 
with PMA for different periods of time before stimulation with ionophore, and 5-HETE 
formation was analyzed. Surprisingly, a “5-HETE effect” was not only observed after LTA 
priming, but also after priming with PMA, which had been shown to enhance 5-LO 
translocation potently. These results indicated that the “5-HETE effect” did not seem to 
reflect low 5-LO translocation under these conditions, and that a predominant induction of the 
5-HETE formation does not occur specifically after TLR2 ligand priming. 
 
 
 
Figure 23:  5-HETE formation in MM6 cells after priming with LTA or PMA. Differentiated MM6 (3 × 10
6 cells) 
were primed with LTA 0.5 µg/mL or PMA 100 nM  different periods of time / 37°C before stimulation with 
ionophore A23187 2.5 µM for another 10 min / 37°C. 5-LO products were determined by HPLC.   
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Interestingly, the curves showed different characteristics after LTA and PMA priming of 
MM6 cells, respectively. An up to 20-fold increase of 5-HETE was detected with LTA 
priming for 15 minutes, whereas PMA enhanced 5-HETE formation 30 to 40-fold already 
with shorter priming times of 5 to 10 minutes. Furthermore, PMA effects persisted on this 
high level, even if priming times were extended up to 90 minutes. In contrast, LTA effects 
decreased considerably, when priming times exceeded 15 minutes.  
 
5-HETE formation in THP-1 cells after priming with LTA or PMA 
In order to exclude that the observed “5-HETE effect” was specific only for MM6 cells, 
analogous time course experiments were repeated with THP-1 cells, another human 
monocytic cell line. Thus, THP-1 cells were primed with LTA or PMA for different periods 
of time and then stimulated with ionophore. Again for both agents, priming had a greater 
effect on the formation of 5-HETE than of the other metabolites, which confirmed the 
findings in MM6 cells.  
 
Figure 24: 5-HETE formation in THP-1 cells after priming with LTA or PMA. Differentiated THP-1 (3 × 10
6 
cells) were primed with LTA 0.5 µg/mL or PMA 100 nM different periods of time / 37°C before stimulation with 
ionophore A23187 2.5 µM for another 10 min / 37°C. 5-LO products were determined by HPLC.   
 
The kinetics of priming in THP-1 cells differed from that in MM6 cells, though. Two phases 
of enhanced 5-LO product formation became apparent after LTA and also PMA priming. 
LTA induced a first maximum with a priming time of 15 minutes and a second peak with a 
pre-incubation for 30 minutes. PMA enhanced 5-LO product formation by priming times up 
to 20 minutes. With further temporal extension of priming, the PMA effect disappeared, but 
appeared again with a priming time of 90 minutes. 5-HETE was enhanced approximate 9-fold 
by LTA, and up to 25-fold by PMA at its maximum, respectively. 
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5-HETE formation in hPBMC after priming with LTA or PMA 
Finally, time courses of LTA and PMA priming were once more analyzed also in hPBMC. 
After different times of priming, human primary cells were stimulated with a low 
concentration of ionophore (0.025 µM) as it was assessed as optimal in previous studies. A 
“5-HETE effect” was detected also in this cellular system, although it was not as pronounced 
after LTA priming as it was found in both monocytic cell lines. Pre-incubation with LTA for 
10 minutes resulted in an approximate 7-fold enhancement of 5-HETE and notably also a 5-
fold increase of total 5-LO products. Interestingly, PMA did not show a stronger priming 
effect than LTA in hPBMC. 
 
 
 
Figure 25: 5-HETE formation in hPBMC after priming with LTA or PMA. Human PBMC (5 × 10
6 cells) were 
primed with LTA 0.5 µg/mL or PMA 100 nM different periods of time / 37°C before stimulation with ionophore 
A23187 0.025 µM for another 10 min / 37°C. 5-LO products were determined by HPLC.   
 
In summary, again it was concluded that a particular increase of 5-HETE biosynthesis does 
not seem to be a specific event after TLR2 ligand priming, and apparently is observed 
generally after priming of human monocytes. 
 
4.2.4  Comparison of priming properties of LTA and PMA in MM6 cells  
So far, investigations concerning the underlying mechanisms of TLR2 ligand priming 
revealed that the ligands do not seem to enhance activity and translocation of 5-LO as 
opposed to PMA, a well-established priming agent [373]. The following studies were 
undertaken to analyze and understand the differing modes of action of LTA compared to 
PMA. 
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Influence of PKA inhibitors on priming effects 
In previous sections an insignificant decrease of 5-LO activity was found in MM6 cells after 
LTA priming and subsequent stimulation in presence of exogenous AA. Additionally, a 
redistribution of 5-LO into nonnuclear compartments was noticed after incubation with LTA. 
These observations led to the assumption that LTA might trigger cellular signals resulting in 
an inhibition of 5-LO and counteracting an increase of 5-LO activity after LTA priming. 
Therefore, the role of PKA as a negative regulator of 5-LO was determined under priming 
conditions, and LTA and PMA effects on 5-LO activity were analyzed in presence of the 
PKA inhibitors H-89 and 14-22 amide. First, the results confirmed once more that there was 
no enhancement of 5-LO activity after LTA priming in MM6 cells. Both PKA inhibitors 
caused a minor decrease of the leukotriene formation level, respectively. However, even in 
presence of H-89 as well as 14-22 amide, no LTA priming effect was detectable and also 
PMA priming was not affected in the control experiment. Thus it was reasoned that a possible 
PKA activation does not seem to play a role during priming with LTA. 
 
 
 
Figure 26: Influence of PKA inhibitors on priming effects.  Differentiated MM6 cells (3 x 10
6) were pre-
incubated without or with the PKA inhibitors 14-22 amide 100µM or H-89 10µM 30 min / 37°C. After priming 
with LTA 0.5 µg/mL or PMA 100 nM 15 min / 37°C, cells were stimulated with A23187 2.5 µM and AA 20 µM 
for another 10 min / 37°C. 5-LO products were determined by HPLC.  
 
In influence of LTA and PMA on the intracellular calcium concentration 
The intracellular Ca
2+ concentration is a key parameter for 5-LO activity and regulates the 
association of 5-LO with cellular membranes [11]. Therefore it was of interest to test and to 
compare the influence of LTA and PMA on the intracellular Ca
2+ level, in order to elucidate 
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possible differences in the mechanisms of priming. MM6 cells were incubated with LTA or 
PMA and intracellular Ca
2+ was measured, respectively. As a positive control, ionophore 0.25 
µM strongly induced a Ca
2+ influx and its concentration rose approximately to 250 nM. 
However, neither LTA nor PMA had an impact on intracellular Ca
2+, which remained on the 
basal level similar to the negative control. Thus, different priming properties of LTA and 
PMA are not predicated on differences concerning their influence on intracellular Ca
2+ levels. 
 
  
 
Figure 27: Influence of LTA and PMA on the intracellular calcium concentration. Differentiated MM6 (5 x 10
6 
cells) were loaded with Fura-2/AM 2 µM 30 min / 37°C and afterwards resuspended in 1 mL PBS containing 1 
mM Ca
2+. Then solvent, LTA 0.5 µg/mL, PMA 100 nM or ionophore A23187 0.25 µM were added as indicated. 
Fluorescence was measured and intracellular free Ca
2+ was calculated. The curve shows one typical experiment 
out of 3. 
 
Presence of arachidonic acid during priming 
The p38 MAPK and ERK pathways also play an important role in the regulation of 5-LO and 
may trigger a stimulation or an increase of 5-LO activity by phosphorylation [16]. MAP 
kinases are activated by various stress stimuli, phorbol esters or also as a result of TLR 
activation [16, 319]. It was demonstrated that efficient phosphorylation of 5-LO by ERK1/2 
required the presence of unsaturated fatty acids in vitro and that in MM6 cells PMA priming 
was essential for ERK1/2 activation and efficient phosphorylation of 5-LO [170]. In the 
following experiment, MM6 cells were primed with LTA in presence of various 
concentrations of AA, before ionophore and an excess of AA was added to stimulate LT 
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formation. The addition of 1-10 µM AA during the period of pre-incubation had no impact on 
the level of 5-LO product formation in comparison to the controls that were pre-treated 
without AA. Irrespective of the absence or presence of AA during pre-incubation, LTA 
priming again caused a slight decrease of 5-LO activity compared to unprimed cells. The 
addition of 30 µM AA at least resulted in a general reduction of the product formation level 
appearing to a comparable extent in primed as well as in unprimed cells. In summary, no 
enhancement of 5-LO activity became evident after priming of MM6 cells with LTA in 
presence of low AA concentrations. Accordingly, these conditions do not seem appropriate to 
imitate conditions of PMA priming and thus did not help to scent out different mode of 
actions of LTA and PMA.  
 
 
 
Figure 28: Presence of arachidonic acid during priming. Differentiated MM6 cells (3 x 10
6) were primed with or 
without LTA 0.5 µg/mL in presence or absence of different concentrations of AA as indicated 15 min / 37°C. 
Then cells were stimulated with A23187 2.5 µM and AA 20 µM for another 10 min / 37°C. 5-LO products were 
determined by HPLC.   
 
Comparative analysis of p38 MAPK activation 
In former publications it was demonstrated that inhibition of ERK signalling by U0126 
abolished the 5-LO upregulation effects of PMA in MM6 cells [170]. Hence, ERK pathways 
seem to play a decisive role in the mechanism of priming by PMA. Therefore it seemed 
promising to analyze LTA and PMA induced activation of the relevant MAP kinase pathways 
in more detail, to possibly get an idea about the differing modes of action of the two priming 
agents. At first, a comparative analysis of p38 activation was carried out. By immunoblotting, 
p38 phosphorylation was determined in MM6 cell lysates after treatment with LTA or PMA 
for different periods of time. Two clearly different p38 activation profiles were found. LTA 
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induced a substantial activation of p38 MAP kinase (up to 17-fold in comparison to untreated 
cells) already after 5 minutes. This activation level was detectable up to 15 minutes of 
incubation, but with further extension of incubation times p-p38 signals decreased again to the 
basic level after 90 minutes of incubation. PMA in comparison induced p38 phosphorylation 
only very weakly. After 5 minutes a maximal 2-fold activation became visible, but almost no 
activation of p38 was found for longer periods of incubation. In summary, LTA revealed to be 
a strong p38 activator as opposed to PMA. It was concluded that activation of p38 MAP 
kinase pathways may not be of major importance for a regulation of 5-LO by priming. 
 
  
Figure 29: Comparative analysis of p38 MAP kinase activation. Differentiated MM6 (3 × 10
6 cells) were 
incubated with LTA 0.5 µg/mL or PMA 100 nM for different periods of time / 37°C as indicated. As negative 
control, cells were treated with solvent for 15min / 37°C (solv 15). Total cell lysates were prepared and analyzed 
by SDS-PAGE and immunoblotting (Odyssey
® Infrared Imaging System). To detect p38 MAPK activation, an 
antibody specific for the dually phosphorylated form of the protein was used. As loading control, the total 
amount of the protein (phosphorylated and unphosphorylated form) was determined. For quantification, band 
intensities of the phosphorylated proteins were corrected by band intensities of both forms. Phosphorylation 
levels are related to the negative control (dotted lines).  
 
5-LO phosphorylation at Ser-271 
MK-2/3 lie downstream of p38 MAP kinase and were shown to phosphorylate 5-LO at Ser-
271
 resulting in a positive regulation of 5-LO activity [16]. In a preliminary immunoblotting 
experiment, phosphorylation of 5-LO at Ser-271 was investigated in MM6 cell lysates after 
incubation with LTA or PMA. As expected due to the antecedent results, after PMA treatment 
almost no 5-LO phosphorylation was measurable, only a slight band of p-5-LO may be sensed 
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after 5 minutes. After incubation with LTA, however, phosphorylated 5-LO was detected 
after 5 to 15 minutes of incubation. Nevertheless, these findings did not seem to have a 
relation to the lack of enhanced 5-LO activity observed after priming with LTA in contrast to 
PMA priming. Therefore studies were not further pursued.  
 
  
 
Figure 30: 5-LO phosphorylation at Ser-271: Differentiated MM6 (3 × 10
6 cells) were incubated with LTA 0.5 
µg/mL or PMA 100 nM for different periods of time / 37°C as indicated. As negative control, cells were treated 
with solvent for 15min / 37°C (solv 15). Total cell lysates were prepared and analyzed by SDS-PAGE and 
immunoblotting (Odyssey
® Infrared Imaging System). To detect 5-LO phosphorylation, an antibody specific for 
the phosphorylated form of the protein was used. As loading control, the total amount of the protein 
(phosphorylated and unphosphorylated form) was detected. The results reflect preliminary data.  
 
Comparative analysis of ERK1/2 activation 
It seemed of major relevance to investigate and to compare the activation of ERK1/2 
pathways after stimulation of MM6 cells with LTA or PMA. Phosphorylation of ERK1/2 was 
analyzed by immunoblotting. In comparison to the p38 MAP kinase activation profile, a 
converse picture emerged that might have a relation to different priming properties of LTA 
and PMA. As expected, PMA was identified as a strong activator of ERK1/2 pathways. 
Already after 5 minutes of incubation an up to 80-fold increase of p42 phosphorylation was 
measured in comparison to untreated cells. With extended periods of incubation p-p42 band 
intensities decreased again and were yet weak after 60 to 90 minutes of PMA treatment. LTA 
in contrast, turned out to be a rather weak ERK activator. The increase of phosphorylated p42 
was low and only very transient compared to PMA. LTA induced ERK1/2 activation was 
detectable after 5 minutes (approximately 10-fold), declined fast and was no more visible 
after a treatment for 20 minutes. 
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Figure 31: Comparative analysis of ERK1/2 activation. Differentiated MM6 (3 × 10
6 cells) were incubated with 
LTA 0.5 µg/mL or PMA 100 nM for different periods of time / 37°C as indicated. As negative control, cells were 
treated with solvent for 15min / 37°C (solv 15). Total cell lysates were prepared and analyzed by SDS-PAGE 
and immunoblotting (Odyssey
® Infrared Imaging System). To detect ERK1/2 activation, an antibody specific for 
the dually phosphorylated form of the protein was used. As loading control, the total amount of the protein 
(phosphorylated and unphosphorylated form) was determined. For quantification, band intensities of the 
phosphorylated proteins were corrected by band intensities of both forms. Phosphorylation levels are related to 
phosphorylation levels in the negative control. 
 
Kinetics of priming for enhanced 5-LO activity 
Considering the respective ERK activation profiles it was suspected that an appropriate 
intensity and persistence of ERK activation might be required for an upregulation of 5-LO by 
priming in MM6 cells. After incubation with LTA for 5 minutes, a distinct p42 
phosphorylation had been detectable. Hence the question came up, if a shorter period of 
priming (5 minutes instead of 15 minutes) would result in an upregulation of 5-LO activity by 
LTA. Therefore, another time course experiment was undertaken. MM6 cells were primed 
with LTA or PMA for different time periods, and 5-LO activity was measured after 
stimulation with ionophore in presence of AA. In fact, 5 minutes of LTA priming led to a 
distinct, yet not significant enhancement of 5-LO activity. With priming for 15 minutes, again 
a slight decrease of product formation was determined compared to unprimed cells. 5-LO 
upregulation after PMA priming was also maximal (about 2-fold) with a short incubation time 
for 5 minutes. When pre-incubation times were further extended, the enhancement of LT 
formation decreased again and was not yet measurable with 90 minutes of priming. This 
kinetics showed a strong analogy to the respective ERK activation profile. The time course 
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characteristics of LTA priming also showed a first induction of 5-LO activity, followed by a 
consistent decrease of activity values similar to the respective ERK activation profile. 
However, with longer periods of LTA priming, product formation dropped under the product 
level of unprimed cells. Yet with priming for 90 minutes, LT synthesis was similar in primed 
as well as in unprimed cells again. 
 
 
 
Figure 32: Kinetics of priming for enhanced 5-LO activity. Differentiated MM6 (3 × 10
6 cells) were primed with 
solvent, with LTA 0.5 µg/mL or PMA 100 nM different periods of time / 37°C as indicated, before stimulation of 
5-LO product formation with ionophore A23187 2.5 µM plus AA 20 µM for another 10 min / 37°C. 5-LO 
products were determined by HPLC. The increase of 5-LO products by LTA or PMA priming is related to the 
product formation level in cells that were analogously pre-incubated with solvent, respectively.  Student´s t test 
(paired; one-tailed); ** p<0.01, * p<0.05; 
 
Enhanced ERK activation during blockade of p38 MAP kinase pathways 
 In the following experiment MM6 cells were incubated with the TLR2 ligands LTA, FSL-1 
or Pam3CSK4 in absence or presence of p38 MAP kinase inhibitor SB203580, and ERK1/2 
activation was determined. In absence of the inhibitory agent, a weak p42 phosphorylation 
was detectable after treatment with LTA or FSL-1. After Pam3CSK4 incubation, ERK1/2 
activation was marginal. The presence of SB203580, however, considerably enhanced TLR2 
ligand induced activation of ERK1/2, and also after Pam3CSK4 incubation p42 
phosphorylation was substantial. These findings were harnessed in subsequent investigations.   
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Figure 33: Influence on ERK1/2 activation during blockade of the p38 MAPK pathway. Differentiated MM6 (3 × 
10
6 cells) were pre-incubated with or without SB203580 (10 µM) 15 min / 37°C and stimulated with or without 
TLR2 ligands (LTA 0.5 µg/mL, FSL-1 0.5 µg/mL, Pam3CSK4 5 µg/mL) as indicated for another 15 min / 37°C. 
Total cell lysates were analyzed by SDS PAGE and immunoblotting (Odyssey
® Infrared Imaging System).  
 
The influence of priming on 5-LO translocation during blockade of p38 MAPK  
The consequences of a shorter period of LTA priming for ionophore-induced 5-LO 
translocation in MM6 cells were assessed in the following studies. The preceding Western 
Blot results had shown a stronger activation of ERK pathways, when p38 MAPK signalling 
was blocked. Thus, translocation assays with 5 minutes of priming were additionally carried 
out in presence of SB203580, in order to provoke higher ERK activation levels after 
incubation with LTA and to render a potential ERK-mediated LTA effect detectable. Again, 
after incubation of MM6 cells nuclear and nonnuclear fractions were prepared and analyzed 
separately by 5-LO immunoblotting. Calculations of relative band intensities revealed that 
also after reduction of the period of pre-incubation from 15 to 5 minutes no significant 
enhancement of 5-LO translocation by LTA priming was detected, neither in the nonnuclear 
nor in the nuclear fraction. Even PMA mediated upregulation was not significant. The 
presence of SB203580 seemed to generally increase the degree of 5-LO translocation after 
stimulation of MM6 cells: in absence of SB203580, the decrease of 5-LO protein in the 
nonnuclear fraction after ionophore stimulation was approximately 25% in comparison to 
untreated cells, whereas in presence of the p38 inhibitor a reduction of 5-LO of about 50% 
was measured in the nonnuclear fraction compared to the untreated control. Complementary, 
a significant increase of 5-LO in the nuclear fraction was found after ionophore stimulation in 
presence of SB203580. Furthermore, PMA enhanced 5-LO translocation significantly in 
presence of the p38 inhibitor. Nevertheless, blockade of p38 MAPK pathways did not result 
in a significant increase of ionophore-induced 5-LO translocation after LTA priming for 5 
minutes.  
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Figure 34: Influence on 5-LO translocation during blockade of the p38 MAPK pathway. Differentiated MM6 (10 
× 10
6 cells) were pre-incubated with or without SB203580 (10 µM) 15 min / 37°C and were primed with solvent, 
PMA 100nM or LTA 0.5 µg/mL as indicated 5 min / 37°C. Solvent or ionophore A23187 2.5 µM was added for 
another 5 min / 37°C. After cell lysis, nonnuclear and nuclear fractions were separated by centrifugation and 
analyzed separately by SDS PAGE and immunoblotting as previously described (Odyssey
® Infrared Imaging 
System). For quantification, band intensities of 5-LO were corrected by band intensities of specific loading 
controls for the nonnuclear (GAPDH) and the nuclear fraction (Lamin A/C), respectively. The amount of 5-LO 
protein is related to the level of 5-LO protein in the negative controls, respectively (dotted line). Pair-wise 
samples (nonnuclear, nuclear) correspond to identical cell numbers. Student´s t test (paired; one-tailed); ** 
p<0.01, * p<0.05;  
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4.3  The influence of TLR2 ligands on arachidonic acid release in MM6 cells 
 
This chapter furthermore deals with the elucidation of the underlying mechanisms of TLR2 
mediated priming of MM6 cells for an increase of ionophore-induced 5-LO product 
formation. The results of the preceding sections (4.2) suggested that enhanced biosynthesis of 
5-LO products apparently does not result from an upregulation of 5-LO activity or 
translocation after TLR2 ligand priming. Hence, further investigations focussed on the impact 
of TLR2 ligands on the ionophore induced release of AA, which serves as substrate for LT 
biosynthesis via the 5-LO pathway. 
 
4.3.1  Time-dependent enhancement of AA release  
At first it was investigated, if enhanced TLR2 ligand mediated leukotriene formation is due to 
an increased availability of AA in MM6 cells. Thus, for time course analyses, MM6 cells 
were pre-treated with increasing concentrations of LTA, FSL-1 or Pam3CSK4 before 
stimulation with ionophore and AA release was determined in comparison to unprimed, but 
ionophore-stimulated cells. The results were similar to the time course experiments of 5-LO 
product formation after TLR2 ligand priming (4.1.2.3). Simultaneous addition of TLR2 
ligands with ionophore did not evoke an enhancement of ionophore induced AA release. 
Priming of the cells with TLR2 ligands, however, led to a time dependent increase in free AA, 
peaking after pre-incubation of 10 to 15 minutes. With further extension of pre-incubation 
times the response decreased again and almost completely disappeared with priming times of 
60 to 90 minutes. For all ligands, the kinetics of enhanced AA generation was comparable, 
even though the response upon Pam3CSK4 priming was slightly weaker.  
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Figure 35: Time-dependent enhancement of AA release. Differentiated MM6 cells (2 × 10
6 cells/mL) were pre-
labeled with 0.5µCi/mL [
3H]AA for 3 h / 37°C. Unincorporated [
3H]AA was removed and cells were 
resuspended in PGC buffer containing 2mg/mL fatty acid free BSA (3 × 10
6/0.5ml). [
3H]AA-labeled MM6 cells 
were primed with TLR2 ligands (LTA 0.5 µg/mL, FSL-1 0.5 µg/mL, Pam3CSK4 5 µg/mL) or solvent for different 
periods of time before induction of arachidonic acid release with ionophore A23187 2.5 µM for another 10min / 
37°C and free [
3H]AA was analyzed. Student´s t test; ** p<0.01; 
 
4.3.2  Direct stimulation of AA release 
Given that simultaneous addition of TLR2 ligands together with ionophore did not raise the 
levels of free AA compared to ionophore alone, it was expected that TLR2 ligands by 
themselves do not induce AA release.  
 
 
Figure 36: Direct stimulation of AA release. Differentiated MM6 cells (2 × 10
6 cells/mL) were pre-labeled with 
0.5µCi/mL [
3H]AA for 3 h / 37°C. Unincorporated [
3H]AA was removed and cells were resuspended in PGC 
buffer containing 2mg/mL fatty acid free BSA (3 × 10
6/0.5ml). [
3H]AA-labeled MM6 cells were incubated with 
either solvent, ionophore A23187 (iono) or TLR2 ligands (LTA 0.5 µg/mL, FSL-1 0.5 µg/mL, Pam3CSK4 5 
µg/mL) for 10 or 20 min / 37°C, and free [
3H]AA was analyzed. 
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In order to confirm this, MM6 cells were stimulated either with ionophore or with LTA, FSL-
1 or Pam3CSK4. Determination of free AA revealed that TLR2 ligands did not directly induce 
a significant release of AA after 10 or 20 minutes of incubation. Therefore, increased LT 
formation in MM6 cells by TLR2 ligand priming seemed to be due to an enhancement of AA 
release. 
 
4.3.3  The influence of TLR2 ligands on the intracellular calcium concentration 
Similar to the regulatory properties of 5-LO, AA releasing PLA2 enzymes are tightly 
regulated by Ca
2+, and a direct stimulation of cellular AA release requires an increase of the 
intracellular Ca
2+ level [16, 37]. Supplementary to the preceding experiment, the influence of 
the three TLR2 ligands on the intracellular Ca
2+ concentration in MM6 cells was investigated. 
Ionophore as a positive control expectedly stimulated a substantial increase of the intracellular 
Ca
2+ level. As it had been observed also in former analyzes (4.2.3), LTA incubation did not 
result in an alteration of the intracellular Ca
2+ concentration, which remained on a basal level 
comparable to the negative control. This could also be confirmed for FSL-1 and Pam3CSK4, 
which also did not evoke a cellular Ca
2+ influx. As expected, TLR2 ligands did not show an 
influence on intracellular Ca
2+ and accordingly did not directly stimulate AA release.  
 
 
 
Figure 37: Influence of TLR2 ligands on the intracellular calcium concentration. Differentiated MM6 (4 x 10
6 
cells) were loaded with Fura-2/AM 2 µM 30 min / 37°C and resuspended in 1 mL PBS containing 1 mM Ca
2+. 
Then solvent, LTA 0.5 µg/mL, FSL-1 0.5 µg/mL, Pam3CSK4 5 µg/mL or ionophore A23187 0.5 µM were added 
as indicated. Fluorescence was measured and intracellular free Ca
2+ was calculated. The curve shows one 
typical experiment out of 2. 
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4.3.4  Identification of the involved PLA2 enzymes  
AA release is catalyzed preferentially by group V secretory PLA2s (sPLA2) and by group IV 
cytosolic PLA2s (cPLA2) [37]. The following inhibitor studies were undertaken to identify the 
PLA2 enzymes that are involved in TLR2 ligand mediated enhancement of AA release.  
 
Effects of PLA2 inhibitors on enhanced AA release 
MM6 cells were treated either with iPLA2 inhibitor bromoenollactone (BEL), the sPLA2 
inhibitor dithiotreitol (DTT) or with the selective cPLA2 inhibitor pyrrolidine-1 (PYR) before 
priming and subsequent stimulation. As expected, BEL virtually did not repress AA release, 
neither in unprimed nor in primed MM6 cells, indicating an insignificant role of iPLA2 for 
AA release under these conditions. Inhibition of sPLA2 diminished AA release considerably, 
in primed as well as in unprimed cells. However, the magnitude of the TLR2 ligand mediated 
priming effect remained constant despite elimination of sPLA2 activity. Inhibition of cPLA2 
almost completely prevented AA release upon ionophore stimulation in MM6 cells, pointing 
to a crucial role of this enzyme for AA generation under these conditions. The residual PLA2 
activity was very low and TLR2 ligand mediated increase was not detectable any more. These 
data suggested that the effects of TLR2 ligands on AA are mediated by cPLA2. 
 
 
Figure 38: Effects of PLA2 inhibitors on enhanced AA release. Differentiated MM6 (2 × 10
6 cells) were pre-
labeled with 0.5 µCi/mL [
3H]AA for 3 h / 37°C. Unincorporated [
3H]AA was removed and cells were 
resuspended in PGC buffer containing 2 mg/mL fatty acid free BSA. [
3H]AA-labeled MM6 cells were pre-treated 
with or without PLA2 inhibitors (bromoenollactone (BEL) 10 µM, dithiotreitol (DTT) 1 mM, pyrrolidine-1 (PYR) 
10 µM) as indicated 15 min / 37°C. Subsequently cells were primed with TLR2 ligands (LTA 0.5µg/mL, FSL-1 
0.5µg/mL, Pam3CSK4 5µg/mL) or treated with solvent 15 min / 37°C, and thereupon stimulated for AA release 
with A23187 2.5 µM for another 10 min / 37°C. 
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Effects of PLA2 inhibitors on enhanced LT biosynthesis 
The aim of subsequent inhibitor studies was to verify a link between enhanced 5-LO product 
formation and the cPLA2  mediated increase of AA release by TLR2 ligand priming. 
Consequently, the effect of PLA2 inhibitors on the biosynthesis of 5-LO products was tested. 
The results were in line with the data for AA release. The sPLA2 inhibitor DTT clearly 
reduced 5-LO metabolites in primed and unprimed cells, but without affecting TLR2 ligand 
mediated increase of 5-LO product formation. The cPLA2 inhibitor completely abolished 
leukotriene biosynthesis. The data suggested that the effects of TLR2 ligands on leukotriene 
release were mediated by cPLA2. 
 
 
Figure 39: Effects of PLA2 inhibitors on enhanced LT biosynthesis. Differentiated MM6 cells (3 x 10
6) were pre-
incubated without or with PLA2 inhibitors (dithiotreitol (DTT) 1 mM, pyrrolidine-1 (PYR) 10 µM or both) as 
indicated 15 min / 37°C. After priming with TLR2 ligands (LTA 0.5µg/mL, FSL-1 0.5µg/mL, Pam3CSK4 5µg/mL) 
or solvent 15 min / 37°C, cells were stimulated with A23187 2.5 µM for another 10 min / 37°C. 5-LO products 
were determined by HPLC.  
 
Excursus: Effects of PLA2 inhibitors on 5-LO activity 
Extended investigations were carried out to confirm the antecedent data and to exclude other 
biological effects of the PLA2 inhibitors on the 5-LO pathway that would distort the preceding 
results. Once more MM6 cells were incubated with DTT or with pyrrolidine-1 before TLR2 
ligand priming. Subsequently, cells were stimulated in presence of exogenous AA, to keep the 
assay conditions independent from endogenous substrate supply. Thus, the influence of the 
inhibitors on 5-LO activity was determined. Surprisingly, a moderate increase of 5-LO 
activity by 1 mM DTT, and a remarkable inhibition of 5-LO activity by 10 µM of the cPLA2 
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inhibitor was observed, which called the selectivity of the inhibitors at least at the used 
concentrations into question. Moreover, it was concluded that the effects of these two PLA2 
inhibitors on LT biosynthesis were not only due to PLA2 inhibition, but were superposed by 
additional effects on 5-LO activity. 
 
 
Figure 40: Effects of PLA2 inhibitors on 5-LO activity. Differentiated MM6 cells (3 x 10
6) were pre-incubated 
without or with PLA2 inhibitors (dithiotreitol (DTT) 1 mM, pyrrolidine-1 (PYR) 10 µM or both) as indicated 15 
min / 37°C. After priming with TLR2 ligands (LTA 0.5µg/mL, FSL-1 0.5µg/mL, Pam3CSK4 5µg/mL) or solvent 
15 min / 37°C, cells were stimulated with A23187 2.5 µM plus AA 40 µM for another 10 min / 37°C. 5-LO 
products were determined by HPLC.  
 
Excursus: cPLA2 inhibitor pyrrolidine-1 as a direct 5-LO inhibitor 
Aside from the actual investigations on TLR2 ligand priming, the role of cPLA2 inhibitor 
pyrrolidine-1 as a direct 5-LO inhibitor was evaluated in more detail. 5-LO was expressed in 
E. coli and the purified enzyme was pre-incubated with the inhibitor, before 5-LO activity 
was stimulated by addition of AA in presence of calcium. Notably, pyrrolidine-1 directly 
inhibited the 5-LO enzyme in a concentration dependent manner with an IC50 value of 2.25 
µM. Hence, this unspecific side effect has to be taken into account, when pyrrolidine-1 is used 
as a cPLA2 inhibitor. 
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Figure 41: cPLA2 inhibitor pyrrolidine-1 as a direct 5-LO inhibitor. 5-LO was expressed in E. coli. Purified 
enzymes were diluted in PBS plus 1 mM EDTA, 1 mM ATP and pre-incubated with the indicated concentrations 
of pyrrolidine-1 (PYR) 15 min / 4°C. Then samples were pre-warmed, 2 mM CaCl2 and then 20 µM AA was 
added for 10 min / 37°C. 5-LO products were determined by HPLC.  
 
4.3.5     Activation of MAPK pathways by TLR2 ligands 
In successive studies the mechanisms of TLR2 ligand priming for enhanced cPLA2 activity 
were surveyed. The activity of cPLA2α has been shown to be regulated not only by Ca
2+, but 
also by phosphorylation leading to enhanced cPLA2α activity in vitro [22, 37]. The following 
experiments analyzed TLR2 ligand induced activation of MAP kinase pathways that play a 
role in cPLA2α phosphorylation. 
 
Time-dependent p38 MAPK activation by TLR2 ligands 
It has been demonstrated that activated p38 MAPK can phosphorylate cPLA2α at Ser-505
 
[22]. As it was already described in a former section (4.2.4), activation of p38 MAPK upon 
incubation with LTA was again analyzed in MM6 cell lysates by immunoblotting, but was 
now compared to p38 MAPK activation by FSL-1 and Pam3CSK4. An increase of 
phosphorylated p38 MAPK was detectable for each of the three TLR2 ligands. In this 
experiment, the ligand LTA significantly induced phospho-p38 MAPK 2-4 fold during 15 
minutes of incubation in comparison to unstimulated cells, whereas FSL-1 and Pam3CSK4 led 
to a 1.5 to 3.5 fold and to a 1.5 to 2.5 fold increase, respectively. Expectedly, activation of 
p38 MAPK was dependent on the incubation time. Time courses of p38 MAPK 
phosphorylation showed similar characteristics for each of the three TLR2 ligands with a 
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maximal activation between 5 minutes and 15 minutes, followed by a decline to the initial 
level.   
  
 
Figure 42: Time-dependent p38 MAPK activation by TLR2 ligands. Differentiated MM6 (3 × 10
6 cells) were 
incubated with LTA 0.5 µg/mL, FSL-1 0.5µg/mL or Pam3CSK4 5µg/mL for different periods of time / 37°C as 
indicated. As negative control, cells were treated with solvent for 15min / 37°C (solv 15). Total cell lysates were 
prepared and analyzed by SDS-PAGE and immunoblotting (Odyssey
® Infrared Imaging System). To detect p38 
MAPK activation, an antibody specific for the dually phosphorylated form of the protein was used. As loading 
control, the total amount of the protein (phosphorylated and unphosphorylated form) was determined. For 
quantification, band intensities of the phosphorylated proteins were corrected by band intensities of both forms. 
Phosphorylation levels are related to the negative control (dotted line). Student´s t test; ** p<0.01;  
 
Time-dependent ERK1/2 activation by TLR2 ligands 
ERK1/2 activation has also been reported to result in phosphorylation of cPLA2α at Ser-505
 
[22]. Analysis of the ERK1/2 activation profiles after TLR2 ligand incubation of MM6 cells 
revealed a rapid ERK1/2 phosphorylation, which peaked within 5 minutes. However, 
differences in the time course characteristics were observed between the TLR2 ligands, with 
respect to phospho-p42 (ERK2) induction. The profile of p42 phosphorylation by LTA was 
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slightly divergent from former analyzes (4.2.4), since in these experiments the effect was 
stable over 15 minutes. The initial state of phosphorylation was reached again after 30 
minutes of incubation. Phosphorylation of p42 was induced up to 13-fold by LTA in 
comparison to the control, which was similar to previous observations. Comparable peak 
inductions (12-fold) were obtained with FSL-1, but the induction was even less sustained. The 
ligand Pam3CSK4 evoked a very transient response, that peaked at an about 14-fold increase 
after 5 minutes and was almost completely abrogated after 10 minutes.  
 
 
 
Figure 43: Time-dependent ERK1/2 activation by TLR2 ligands. Differentiated MM6 (3 × 10
6 cells) were 
incubated as described above. Total cell lysates were prepared and analyzed by SDS-PAGE and immunoblotting 
(Odyssey
® Infrared Imaging System). To detect ERK1/2 activation, an antibody specific for the dually 
phosphorylated form of the protein was used. As loading control, the total amount of the protein (phosphorylated 
and unphosphorylated form) was determined. For quantification, band intensities of the phosphorylated proteins 
were corrected by band intensities of both forms. Phosphorylation levels are related to the negative control 
(dotted lines). Student´s t test; ** p<0.01;  
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Mnk-1 activation by TLR2 ligands 
Since p38 MAPK-activated protein kinase Mnk-1 is also known to influence cPLA2α activity 
by Ser-727 phosphorylation [37], Mnk-1 activation was investigated as well. It was observed 
that Mnk-1, which is a downstream target of MAP kinases, was also activated by the TLR2 
ligands. The ligands LTA and FSL-1 induced Mnk-1 phosphorylation to a comparable extent, 
whereas Pam3CSK4 again displayed weaker activity. 
 
 
 
Figure 44: Mnk-1 activation by TLR2 ligands. Differentiated MM6 cells (3 × 10
6 cells) were incubated with 
ionophore A23187 (iono) 5µM (positive control), solvent (negative control) or TLR2 ligands (LTA 0.5µg/mL, 
FSL-1 0.5µg/mL, Pam3CSK4 5µg/mL) for 15min / 37°C. Total cell lysates were prepared and then analyzed by 
SDS-PAGE and immunoblottin (Odyssey
® Infrared Imaging System). Mnk-1 activation was determined by using 
an antibody specific for the dually phosphorylated form of the protein. As loading control, the total amount of 
the protein (phosphorylated and unphosphorylated form) was determined.  
 
4.3.6  Time-dependent cPLA2 (Ser-505) phosphorylation by TLR2 ligands 
Next, the question was addressed, if TLR2 ligands induce cPLA2α phosphorylation at Ser-
505. MM6 cell lysates were analyzed for phospho-cPLA2α (Ser-505) after treatment with the 
TLR2 activators. Simultaneously, activation of the TLR2 signaling pathway was tested by 
analysis of IκBα degradation. Each ligand evoked time dependent phosphorylation of 
cPLA2α. Quantitative analysis of phospho-cPLA2α signals after LTA treatment revealed an up 
to 2-fold increase of cPLA2α phosphorylation. Extended incubation led to a decrease of 
phospho-cPLA2α after 60 to 90 minutes. Conversely, LTA and FSL-1 initially led to IκBα 
degradation over time with a recovery of IκBα protein after 60 to 90 minutes. In contrast, no 
definite IκBα degradation could be determined after Pam3CSK4 treatment, indicating a poor 
activation of the TLR2 signaling pathway in comparison to the other ligands. 
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Figure 45: Time-dependent cPLA2 phosphorylation (Ser-505) by TLR2 ligands. Differentiated MM6 (3 × 10
6 
cells) were incubated with TLR2 ligands (LTA 0.5µg/mL, FSL-1 0.5µg/mL, Pam3CSK4 5µg/mL) for different 
periods of time / 37°C as indicated, or cells were treated with solvent for 15 min / 37°C (solv 15). Total cell 
lysates were analyzed by SDS-PAGE and immunoblotting (Odyssey
® Infrared Imaging System). To detect cPLA2 
phosphorylation by p38 MAPK and ERK1/2, an antibody specific for phosphorylated cPLA2 (Ser-505) was used. 
As a control for the activation of TLR signaling pathways, IκB-α degradation was analyzed over time. 
Simultaneous detection of total cPLA2 served as loading control. For quantification, band intensities of 
phosphorylated cPLA2 were corrected by band intensities of the total cPLA2 protein. Phosphorylation levels are 
related to the negative control. 
 
4.3.7  Influence of kinase inhibitors on cPLA2 phosphorylation and AA release 
Furthermore, it was investigated if phosphorylation of cPLA2α (Ser-505) and the increase of 
AA release was linked to TLR2 ligand triggered activation of p38 MAPK and ERK1/2 in 
MM6 cells.  
 
The role of  MAP kinases in cPLA2 phosphorylation 
The following studies comprise the comparison of the increase of phospho-cPLA2α in 
stimulated and unstimulated cells, in presence or absence of p38 MAPK inhibitor SB203580, 
or of PD98059, which selectively inhibits ERK1/2 signaling. In line with the results of the 
preceding experiment, an up to 2-fold increase of cPLA2α phosphorylation upon TLR2 ligand 
stimulation of MM6 cells was found. In presence of SB203580 or PD98059, however, LTA 
and also FSL-1 mediated increase of phospho-cPLA2α was reduced, but neither of the two 
inhibitors abolished the increase completely. Obviously, the two MAPK pathways were 
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functionally redundant concerning cPLA2α phosphorylation. Only the presence of both 
inhibitors led to a total prevention of phospho-cPLA2α increase, which was significant for 
each of the three TLR2 ligands. Hence, both MAPK signaling pathways seem to play a role in 
TLR2 ligand induced cPLA2α phosphorylation at Ser-505. Control experiments analyzing 
IκBα protein confirmed the activation of TLR signaling pathways by LTA, FSL-1, and 
essentially to a weaker extent by Pam3CSK4. 
 
 
 
Figure 46: The role of MAP kinases in cPLA2 phosphorylation. Differentiated MM6 (3 × 10
6 cells) were treated 
with SB203580 (SB) 10 µM, PD98059 (PD) 50 µM, with both inhibitors or without inhibitor as indicated for 15 
min / 37°C. Then cells were stimulated with or without TLR2 ligands (LTA 0.5 µg/mL, FSL-1 0.5 µg/mL, 
Pam3CSK4 5 µg/mL) for another 15 min / 37°C. After termination of the incubation, total cell lysates were 
analyzed by SDS PAGE and immunoblotting (Odyssey
® Infrared Imaging System). The increase of cPLA2 
phosphorylation by TLR2 ligands is related to the cPLA2 phosphorylation level without TLR activation (dotted 
line), respectively. Student´s t test; * p<0.05;  
 
The role of MAP kinases in enhanced AA release 
By means of analogous inhibitor studies, it was determined if MAPK mediated 
phosphorylation of cPLA2α accounts for induced AA release after TLR2 ligand priming. 
Therefore, the inhibitory influence of SB203580 and of PD98059 on TLR2 ligand mediated 
increase of free AA was determined in MM6 cells. The results were in accordance with the 
antecedent data on cPLA2α phosphorylation. Only a combined use of both inhibitors 
completely blocked TLR2 ligand effects. Thus, activation of two MAPK pathways and 
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subsequent phosphorylation of cPLA2α seemed to account for the enhancement of ionophore 
stimulated AA release. 
 
  
Figure 47: The role of MAP kinases in enhanced AA release. Differentiated MM6 (2 × 10
6 cells) were pre-
labeled with 0.5 µCi/mL [
3H]AA for 3 h / 37°C. Unincorporated [
3H]AA was removed and cells were 
resuspended in PGC buffer containing 2mg/mL fatty acid free BSA. Cells were pre-treated with SB203580 (10 
µM), PD98059 (50 µM), with the combination of both, or without inhibitor as indicated 15 min / 37°. 
Thereupon, MM6 cells were primed with TLR2 ligands (LTA 0.5 µg/mL, FSL-1 0.5 µg/mL, Pam3CSK4 5 µg/mL) 
or treated with solvent 15 min / 37°C and subsequently stimulated for AA release with A23187 for another 10 
min / 37°C. The increase of AA release by TLR2 ligands is related to the AA release level without TLR2 ligand 
priming (dotted line), respectively. Student´s t test; * p<0.05;  
 
The role of  Mnk-1 and CamKII for enhanced AA release 
Apart from p38 MAPK and ERK1/2, two more protein kinases have been suggested to 
regulate cPLA2α activity by phosphorylation [37]. Mnk-1 accounts for cPLA2α 
phosphorylation at Ser-727, and Ca
2+/Calmodulin kinase II (CamKII) was found to 
phosphorylate cPLA2α on Ser-515
 [22]. Specific inhibitors for Mnk-1 and CamKII were used, 
respectively, to investigate the role of these two cPLA2 kinases in the enhancement of AA 
release in MM6 cells. However, neither of the two inhibitors showed a detectable impact on 
the effects of LTA, FSL-1 and Pam3CSK4, which indicated that these kinases do not seem to 
be involved in upregulation of  cPLA2α activity by TLR2 ligand priming. 
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Figure 48: The role of Mnk-1 and CamKII in enhanced AA release. Differentiated MM6 (2 × 10
6 cells) were pre-
labeled with 0.5 µCi/mL [
3H]AA for 3 h / 37°C. Unincorporated [
3H]AA was removed and cells were 
resuspended in PGC buffer containing 2mg/mL fatty acid free BSA. Cells were pre-treated with Mnk-1 inhibitor 
(Mnk1 Inh) 20 µM, with CaMKII inhibitor KN-62 (KN 62) 10 µM or without inhibitor as indicated 15 min / 37°. 
Then, MM6 cells were primed with TLR2 ligands (LTA 0.5 µg/mL, FSL-1 0.5 µg/mL, Pam3CSK4 5 µg/mL) or 
treated with solvent 15 min / 37°C and subsequently stimulated for AA release with A23187 for another 10 min / 
37°C. The increase of AA release by TLR2 ligands is related to the AA release level without TLR2 ligand 
priming (dotted line), respectively. 
 
4.3.8  TLR dependence of enhanced AA release and LT biosynthesis 
As a final study, it was tested whether the enhancing effect of LTA, FSL-1 and Pam3CSK4 on 
AA release is TLR2 dependent. Additionally, it was clarified if TLR4 was also involved in 
the initiation of the observed effects on AA release and LT formation in MM6 cells. 
 
The role of TLR 4 in TLR2 ligand induced priming effects 
The first experiments were undertaken to exclude that the augmentation of AA and LT 
formation was triggered by LPS contaminations activating TLR4. Therefore, MM6 cells were 
primed with TLR2 ligands or alternatively with LPS in presence or absence of LPS binding 
reagent polymyxin B. After subsequent ionophore stimulation, free AA or 5-LO product 
formation were measured. The addition of polymyxin B significantly blocked the LPS 
mediated increase of AA release and also of 5-LO product formation in MM6 cells. TLR2 
ligand induced increase, however, was not affected by the inhibitor of TLR4 signaling. From 
that it was concluded that TLR4 was not involved in TLR2 ligand priming. 
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Figure 49: The role of TLR4 in TLR2 ligand induced priming effects. TLR2 ligands: LTA 0.5 µg/mL, FSL-1 0.5 
µg/mL, Pam3CSK4 5 µg/mL; TLR4 ligand: LPS 10 µg/mL; stimulus: ionophore A23187 2.5 µM; the increase of 
AA release or 5-LO product formation by TLR ligands is related to the response level without TLR ligand 
priming (dotted line), respectively. To measure AA release, differentiated MM6 (2 × 10
6) were pre-labeled with 
0.5 µCi/mL [
3H]AA for 3 h / 37°C. Unincorporated [
3H]AA was removed and cells were resuspended in PGC 
buffer containing 2 mg/mL fatty acid free BSA. [
3H]AA-labeled MM6 cells were pre-treated with polymyxin B 
100 µg/mL or with solvent 15 min / 37°C. Subsequently cells were primed with TLR ligands or solvent as 
indicated 15 min / 37°C and then stimulated for AA release with A23187 for another 10 min / 37°C. To measure 
5-LO product formation, differentiated MM6 cells (3 x 10
6) were pre-incubated with or without polymyxin B 100 
µg/mL 15 min / 37°C. After priming with TLR ligands or treatment with solvent 15 min / 37°C, cells were 
stimulated with A23187 for another 10 min / 37°C. Student´s t test; ** p<0.01, * p<0.05;  
 
TLR 2 dependence of enhanced AA release 
Secondly, analyzes were undertaken to prove that the enhancement of AA release by LTA, 
FSL-1 and Pam3CSK4  was mediated by TLR2. In measurements of AA release, it was 
observed that a neutralizing anti-hTLR2 antibody significantly inhibited the TLR2 ligand 
induced priming effects in MM6 cells and almost completely blocked LTA, FSL-1 and 
Pam3CSK4 induced enhancement of ionophore induced AA release. Taken together, the 
investigations confirmed that priming of MM6 cells by LTA, FSL-1 and Pam3CSK4 for 
enhanced AA release is dependent on TLR2 activation. 
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Figure 50: TLR2 dependence of enhanced AA release. Differentiated MM6 (2 × 10
6) were pre-labeled with 0.5 
µCi/mL [
3H]AA for 3 h / 37°C. Unincorporated [
3H]AA was removed and cells were resuspended in PGC buffer 
containing 1 mg/mL fatty acid free BSA. [
3H]AA-labeled MM6 cells were pre-treated with anti-hTLR2 antibody 
(TLR2 Aby) 250 µg/mL or with solvent 15 min / 37°C. Subsequently cells were primed with TLR ligands (LTA 
0.5 µg/mL, FSL-1 0.5 µg/mL, Pam3CSK4 5 µg/mL) or solvent as indicated 15 min / 37°C and then stimulated for 
AA release with A23187 2.5 µM for another 10 min / 37°C. The increase of AA release by TLR ligands is related 
to the response level without TLR ligand priming (dotted line), respectively. Student´s t test; ** p<0.01; 
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5   DISCUSSION 
 
The results of the present project revealed an enhancement of the cellular LT biosynthesis by 
TLR ligand priming of human monocytes. Besides TLR4 ligand LPS and TLR5 ligand 
flagellin, the TLR2 ligands LTA, FSL-1 and Pam3CSK4 led to an increase of ionophore- or 
fMLP-induced 5-LO product formation in monocytic cell-lines and primary human 
monocytes. Investigations comprised a characterization of TLR2 ligand mediated effects and 
an analysis of the underlying mechanisms. The influence of TLR2 signaling on two key 
enzymes of the LT biosynthesis pathway, 5-LO and cPLA2α, was investigated. This section 
comments on the findings and provides a discussion of present results against the background 
of published knowledge in related research topics.   
 
5.1  Priming effect of TLR ligands on LT biosynthesis in human monocytes 
 
5.1.1  Overview: enhancement of LT biosynthesis by priming agents 
 
Enhanced LT biosynthesis in leukocytes after pre-treatment of these cells with so-called 
priming agents has been widely described. To provide an overview about numerous reports, a 
simplified classification of such priming substances into three groups is suggested in the 
following section: priming by various cytokines, by diacylglycerol-related compounds and 
furthermore by pathogen-derived molecules [11].  
Early reports refer enhanced biosynthesis of 5-LO metabolites in PMNL upon stimulation 
with fMLP or complement factor C5a, or also upon stimulation with a Ca
2+ ionophore, with 
PAF or alternatively also with LTB4 or IL-8, if cells had been pre-incubated with GM-CSF 30 
min – 2 h prior to stimulation [375-379]. Not only in isolated PMNL, but also in human blood 
[380], in human primary monocytes [381], and in peripheral blood eosinophils from allergic 
rhinitis patients [382], GM-CSF priming for enhanced 5-LO product formation has been 
reported. TNFα has been studied as a priming agent for PMNL and human blood to enhance 
fMLP-, PAF-, C5a-, zymosan- or Ca
2+ ionophore - induced biosynthesis of LTB4 and 5-HETE 
[380, 383, 384]. IL-3 and IL-5 enhanced Ca
2+ ionophore-stimulated LTB4 production in RBL-
1 cells [385], IL-3 primed human primary monocytes for enhanced 5-HETE and LTB4 
formation [381] and IL-5 increased fMLP induced LTC4 synthesis in human eosinophils 
[386]. Recent studies furthermore revealed priming activities of the C-C chemokines Discussion 
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RANTES and eotaxin, which enhanced ionophore-induced LTC4 biosynthesis in human 
eosinophils and basophils [387], and also IL-16 was shown to augment LTC4 release from 
human eosinophils [388]. 
Diacylglycerols and phorbol esters constitute another group of priming agents. Among the 
diacylglycerols, 1-oleoyl-2-acetylglycerol (OAG) and 1,2-dioctanoylglycerol (DiC8) have 
been characterized as priming agents for enhanced 5-LO product synthesis in PMNL upon 
stimulation with fMLP, Ca
2+ ionophore or zymosan [384, 389-391], and also in rat peritoneal 
macrophages, formation of 5-LO metabolites was augmented by OAG [392]. Among the 
phorbol esters, phorbol-12-myristate-13-acetate (PMA) is known to enhance ionophore- or 
fMLP-induced LTB4 release in PMNL [390, 391, 393] and 5-LO product formation in rat 
alveolar and peritoneal macrophages upon stimulation with Ca
2+ ionophore [392]. 
Furthermore, MM6 cells and PMNL were shown to be primed by PMA and its analogue 
mezerein for an increase of 5-LO metabolites [373]. PAF was also described to prime human 
PMNL for enhanced Ca
2+ ionophore - induced formation of LTB4 in one study [394]. 
Lipopolysaccharides (LPS), a component of the outer membrane of gram-negative bacteria, 
are potent activators of host defense mechanisms during infections and have early been 
recognized as priming agents for augmented LT formation. First studies described LPS 
priming of peritoneal mouse macrophages for 60 minutes, which resulted in enhanced 
formation of 5-LO metabolites upon stimulation with zymosan, immune complexes, PMA, 
Ca
2+ ionophore or latex particles [395]. Successive reports described an increase of zymosan-, 
PMA- or ionophore-induced, and furthermore fMLP-induced LTB4 synthesis from human 
PMNL after priming with LPS [364, 365, 367]. Also in human PBMC and in whole blood, 
LPS priming effects have been detected [365, 366]. Not only LPS as bacterial product, but 
also Epstein-Barr virus (EBV) was discovered to exert priming activity on human primary 
monocytes that were stimulated for LT formation with Ca
2+ ionophore, fMLP or zymosan 
[254]. In very recent investigations finally, priming for LT generation was linked to TLR 
activation for the first time [363, 396, 397]. PGN was found to enhance LTC4 release from 
human basophils stimulated with an anti-IgE antibody [363]. Buczynski et al. investigated 
TLR4 priming of RAW264.7 murine macrophages with Kdo2-lipid A, an LPS substructure 
with endotoxin activity, which resulted in enhanced 5-LO product formation after ionophore- 
or ATP-stimulation [397]. Furthermore, TLR7/8 ligand resiquimod was shown to act as a 
priming agent on human neutrophils via TLR8 activation, leading to enhanced LTB4 
formation upon stimulation with fMLP, PAF and ionophore [396].  
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 priming  agent  cell  type  agonist  reference 
 
C5a [377,  379] 
fMLP  [377-379, 
382] 
ionophore  [376, 378, 
379] 
PAF [375,  379] 
LTB4 [379] 
human PMNL 
IL-8 [379] 
human blood 
C5a, fMLP, 
ionophore, 
PAF, zymosan 
[380] 
human monocytes  ionophore  [381] 
GM-CSF 
 human eosinophils  fMLP  [382] 
fMLP [383]  human PMNL 
zymosan [384] 
TNFα 
human blood 
C5a, fMLP  
ionophore, 
PAF, zymosan 
[380] 
human monocytes  ionophore  [381]  IL-3 
RBL-1   ionophore  [385] 
RBL-1 ionophore    [385]  IL-5 
human eosinophils  fMLP  [386]  
RANTES, 
eotaxin  human eosinophils, basophils  ionophore  [387] 
 
IL-16  human eosinophils  ionophore  [388] 
 
fMLP [389,  390]  human PMNL 
ionophore [389,  391]  OAG 
rat peritoneal macrophages  ionophore  [392] 
fMLP [390] 
DiC8  human PMNL  
zymosan [384] 
fMLP [390] 
human PMNL 
ionophore  [373, 391, 
393] 
MM6   ionophore  [373] 
PMA 
rat peritoneal and alveolar 
macrophages  ionophore [392] 
human PMNL  ionophore  [373] 
mezerein 
MM6 ionophore  [373] 
 
PAF  human PMNL  ionophore  [394] 
 
mouse peritoneal macrophages  
zymosan, 
immune complexes, 
PMA, ionophore, 
latex particles 
[395] 
zymosan, PMA 
ionophore  [364]  human PMNL 
fMLP [365,  367] 
human PBMC  fMLP  [365, 366] 
LPS 
whole blood  fMLP, C5a, IL-8  [365] 
 
EBV  human monocytes  ionophore, fMLP, 
zymosan  [254] 
PGN  human basophils  anti-IgE antibody  [363] 
Kdo2-lipid A  RAW264.7 ATP,  ionophore  [397] 
 
 
resiquimod  human PMNL  fMLP, PAF, 
ionophore  [396] 
 
Table 2: Priming agents that increase 5-LO product formation upon subsequent agonist stimulation. Extended 
according to [11].
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The reported priming events showed some consistent characteristics, which have been 
described repeatedly throughout all studies. First, priming agents commonly do not have the 
ability to directly stimulate LT biosynthesis or only marginally induce the formation of 5-LO 
products [254, 364-367, 375, 377, 378, 383, 393, 395, 396], but pre-incubation of leukocytes 
with these agents synergistically augments the cellular response upon subsequent agonist 
stimulation. Thereby, priming has an extensive impact on LT biosynthesis, particularly if 
weak physiological agonists or suboptimal concentrations of the highly effective Ca
2+ 
ionophores are used for stimulation [254, 364, 373, 378, 379, 391, 393, 396]. Secondly, the 
extent of increased LT formation was dependent on the priming agent concentration as 
assessed in many cases [364, 365, 375, 377, 380, 387, 388, 391, 394, 396]. Furthermore, the 
priming effect is decisively dependent on the pre-incubation time. Several reports describe 
priming as a short-time effect that becomes visible after minutes, reaches its maximum with 
pre-incubation times for 15 – 120 minutes (depending on the assay conditions) and disappears 
with extended periods of pre-incubation [254, 364-367, 373, 375, 379, 380, 396]. 
 
5.1.2  Characterisation of TLR2 ligand priming in human monocytes 
 
In initial screening experiments of the present study it was shown that ligands for TLR2/6 
(LTA and FSL-1), for TLR2/1 (Pam3CSK4), and expectedly also TLR4 activator LPS 
displayed enhancing effects on 5-LO product formation in MM6 cells. Furthermore, TLR5 
ligand flagellin was found to increase 5-LO products in an additional experiment. In contrast, 
no influence on ionophore-induced LT levels was detected after pre-incubation with TLR3 
ligand Poly (I:C), TLR7 ligand Loxoribine, TLR8 ligand ssPolyU and type A or type B CpG 
ODNs, which are activators of TLR9. In analyses of TLR mRNA expression patterns in 
cellular subsets of hPBMC, it was shown that high expression of TLR2 was characteristic for 
monocytes [398]. These studies furthermore revealed considerable levels of TLR1 and TLR4, 
moderate levels of TLR5, TLR6 and TLR8, and weak, but detectable TLR9 expression in 
monocytes isolated from hPBMC [398]. TLR7 and TLR3, however, were absent in 
monocytes, and despite low expression of TLR9, monocytes did not respond to TLR9 
activators in the absence of plasmacytoid dendritic cells (pDC) [398, 399]. The TLR 
expression patterns described for monocytes are compatible with present observations that no 
response to TLR7 ligand Loxoribine, TLR3 ligand Poly(I:C) and to TLR9 activators CpG 
ODNs was detected in MM6 cells. It is not clear, though, why MM6 cells were not responsive 
to TLR8 ligand ssPolyU. In this regard it should be noted that MM6 cells only reacted on Discussion 
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ligands that activate TLRs localized on the cellular surface. TLR8, however, is located in the 
endosome. According to the manufacturer, ssPolyU/LyoVec
TM is a lyophilized preparation of 
single-stranded poly-uridine complexed with the cationic lipid LyoVec
TM, to protect it from 
degradation and facilitate its uptake, but nevertheless, TLR8 may possibly not be reached 
efficiently by its ligand within 15 minutes of pre-incubation. 
Toll-like receptor 2 ligand-mediated effects on leukotriene biosynthesis were characterized in 
terms of their concentration-dependence. As it was found in several reports mentioned in the 
previous section, the increase of LT formation was clearly dependent on the TLR ligand 
concentration. For LTA and FSL-1 an optimal concentration of about 0.5 µg/mL was defined 
resulting in a maximal enhancement of 5-LO products. A second maximum was observed at 
concentrations higher than 10 µg/mL, which may be due to additional, less specific effects or 
effects on low affinity receptors. Pam3CSK4, in contrast,  enhanced 5-LO products 
continuously with increasing concentrations without an intermediate maximum. For 
Pam3CSK4  it was reported in studies of lipopeptide-induced B-cell activation that a 
concentration of 80 µg/mL induced a moderate increase of intracellular calcium and it was 
speculated that this may be ascribed to ionophore-like membrane interactions [400]. 
Furthermore, Pam3CSK4, at concentrations greater than 25 µg/mL, was shown to activate 
superoxide formation and lysozyme release in human neutrophils and it was suggested that 
Pam3CSK4  acts through G-proteins in a similar way as fMLP [401]. Therefore, TLR2 
dependent effects of Pam3CSK4 on LT formation may be enhanced by additional mechanisms 
at concentrations greater than 10 µg/mL. Thus, the use of 5 µg/mL Pam3CSK4 was defined as 
optimal to enhance 5-LO products to a comparable extent as with LTA and FSL-1 at their 
optimal concentrations. Overall, Pam3CSK4 seemed to have a weaker potency, as a 10-fold 
higher concentration of Pam3CSK4 compared to FSL-1 was required to evoke similar 
response intensities. It can be suspected that this may be attributed to a lower affinity of 
Pam3CSK4  to its heterodimeric receptor, compared to possibly higher receptor-binding 
affinities of FSL-1 or LTA.      
A TLR2 ligand induced enhancement of 5-LO product formation was also found in human 
primary cells. The preparations of hPBMC in large parts consisted of monocytes (30.2 – 52.9 
%), which are known to highly express TLR2 [398]. Human PBMC also included proportions 
of T-lymphocytes (25.2 – 43.8%) and minor amounts of B-lymphocytes (3.6 – 5.1%) and NK 
cells (7.9 – 9.0%) as determined by FACS analysis. Whereas T cells are considered to lack 5-
lipoxygenase [16], B cells were shown to express 5-LO. It was demonstrated, however, that in 
B-lymphocytes calcium ionophore is not sufficient to activate 5-lipoxygenase [402]. Discussion 
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Moreover, lymphocytes are not responsive to fMLP [366, 403]. Preliminary experiments 
furthermore indicated, that human primary NK cell preparations do not seem to synthesize 
leukotrienes upon stimulation with calcium ionophore (data not shown in present studies). 
Thus, enhanced 5-LO product synthesis upon TLR2 ligand pre-treatment in PBMC was 
regarded as a monocytic response, even though it cannot be excluded, that other cell-types 
containing the LTA4 hydrolase enzyme may contribute to LTB4 synthesis through 
transcellular metabolism of LTA4 [366]. In summary it was concluded, that TLR2 ligands act 
on human primary monocytic cells in a similar manner as on MM6 cells, and that MM6 cells 
seem to be an appropriate model to investigate TLR2 mediated effects on 5-LO product 
formation in human monocytes.  
  TLR2 ligands enhanced LT formation in PBMC, particularly upon activation by low 
ionophore concentrations and the weak agonist fMLP, whereas strong stimulation by high 
concentrations of ionophore was not further enhanced. Also in MM6 cells it was observed 
that TLR2 ligand effects were strong upon stimulation with suboptimal concentrations of 
ionophore (1-2.5 µM), and were reduced again with high stimulatory concentrations of 
ionophore (>5 µM). Apparently, the influence of TLR2 ligands seems to be of importance, 
particularly if subsequent stimulation of 5-LO product formation is moderate. This is 
consistent with previous data that describe substantial LT formation or AA release upon 
stimulation with normally ineffective concentrations of weak stimuli like PAF or of 
ionomycin, when PMNL had been pre-treated with GM-CSF [375, 378]. Also PMA enhanced 
5-LO product formation in PMNL particularly upon low-dose ionophore stimulation [373], 
and PMNL priming with LPS or R-848 could not be demonstrated, when optimal stimulatory 
concentrations of ionophore were used [364, 396]. 
Time course experiments revealed that TLR2 ligand-mediated increase of 5-LO products is a 
transient short-time effect with a maximal enhancement with 15 minutes of pre-incubation. 
All of the three curve progressions showed that with pre-incubation times exceeding 15 
minutes the increase of 5-LO products was reduced. These findings very well correspond with 
previous reports that demonstrated similar kinetics of GM-CSF, LPS, EBV or R-848 priming 
[254, 365-367, 379, 396]. In analyses of 5-LO products of Kdo2-lipid A primed RAW264.7 
macrophages, a synergistic mode of action was determined for Kdo2-lipid A and the 
subsequently added Ca
2+ agonist, by calculation of a synergistic activation ratio [397]. In the 
present studies, pre-incubation of TLR2 ligands was essential for the enhancement of LT 
formation, and simultaneous addition of TLR2 ligands together with ionophore did not evoke 
augmented 5-LO product synthesis. These characteristics indicated that TLR2 ligands do not Discussion 
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directly stimulate LT biosynthesis in MM6 cells and that enhancement of leukotriene 
formation cannot be explained as a simple additive activation by two individual stimuli. This 
suggestion was confirmed by the observation that 5-LO product formation after TLR2 ligand 
pre-incubation and subsequent stimulation was higher than the sum of products formed by 
TLR2 ligand and ionophore stimulation separately. However, Pam3CSK4 showed a weak 
direct stimulatory potency on 5-LO product formation and the synergistic effect of Pam3CSK4 
priming with ionophore stimulation was not as pronounced as of the other ligands. It seems 
conceivable that Pam3CSK4 may additionally induce other weak cellular effects regardless 
from TLR activation, which may slightly interfere with the synergistic mechanism of priming. 
Essentially, it was concluded though that TLR2 ligands can synergistically prime human 
monocytes for an enhanced response upon stimulation and that they show typical priming 
characteristics, which are similar to the properties of previously known priming agents. 
 
5.2   Investigations on the underlying mechanisms of TLR2 ligand priming 
 
5.2.1  The influence of TLR ligands on the 5-lipoxygenase enzyme 
 
As 5-LO is the key enzyme for the biosynthesis of leukotrienes, the enhancement of LT 
formation by TLR ligand priming could be a result of a ligand-mediated augmentation of 
cellular 5-LO activity. If cellular LT biosynthesis is stimulated in presence of an 
overabundant amount of exogenous AA, the proportion of 5-LO products formed from 
cellular AA becomes insignificant [170]. Thus, 5-LO product formation – for the decisive part 
– occurs independent from endogenous substrate supply and can be investigated irrespective 
from PLA2 enzyme activity. Furthermore, it was assumed that exogenous substrate is also 
converted efficiently by 5-LO regardless of 5-LO redistribution to the nuclear envelope [373, 
404]. Therefore, measurement of 5-LO product formation in presence of exogenous AA 
should be independent from efficient 5-LO translocation and assembly of the LT biosynthetic 
complex at the nuclear membrane. Accordingly, a TLR ligand priming effect under such 
conditions would point to an enhancement of 5-LO enzymatic activity as a mechanism of 
priming. 5-HpETE is the first product formed from AA by the 5-lipoxygenase reaction. On 
the one hand it is further metabolized to LTA4 by 5-LO, but it can also be reduced to the 
corresponding hydroxyacid 5-HETE by cellular glutathione peroxidases [16]. As an early 
product of the 5-LO pathway, 5-HETE is formed independent from downstream enzymes of 
LT biosynthesis (e.g. LTA4 hydrolase). Thus, an increase of 5-HETE formation as a result of Discussion 
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priming may also indicate an enhancement of 5-LO activity. However, a priming effect of 
LTA, flagellin and expectedly ssPolyU on 5-HETE formation was not detectable in presence 
of AA, neither in differentiated MM6 cells, nor in differentiated THP-1 cells. Additionally, no 
enhancement of total 5-LO product formation became visible after priming of differentiated 
MM6 cells with the three different TLR2 ligands LTA, FSL-1 or Pam3CSK4 and subsequent 
stimulation with ionophore and AA. Surprisingly, TLR ligands rather exerted a slightly 
inhibitory influence on 5-HETE formation in MM6 cells under such conditions, which was 
only significant after LTA pre-treatment, though. Total 5-LO product formation also seemed 
weakly reduced after LTA priming. Therefore it was concluded that compared to PMA, which 
was used as a control priming agent [373], TLR ligands do not seem to prime human 
monocytes for enhanced LT formation by augmenting cellular 5-LO activity. By contrast, in 
former studies an influence on 5-LO activity indeed has been observed for several priming 
agents. Thus, GM-CSF or LPS pre-incubation of PMNL, and EBV pre-incubation of PBMC 
enhanced the conversion of the model substrate 15-HpETE into 5,15-diHETE upon 
stimulation of PMNL with PAF or fMLP, or of PBMC with ionophore [254, 367, 375]. 
Furthermore, PMA priming resulted in an increase of ionophore-induced 5-LO product 
formation in presence of exogenous AA in MM6 cells and PMNL [373]. 
In additional investigations, LTA and flagellin pre-incubation per se also did not result in a 
further stimulation of LT biosynthesis after addition of AA, which itself only marginally 
induces 5-LO product formation in MM6 cells compared to other cell-types [167]. Also 
simultaneous addition with AA had no effect (preliminary data not shown). Instead, LTA pre-
treatment again reduced 5-LO products in MM6 cells compared to the control. Therefore, a 
stimulatory influence on cellular 5-LO enzyme activity by TLR ligands was excluded. For 
some priming agents, in contrast, also direct stimulatory properties for 5-LO were shown. 
PAF on the one hand has been used as a priming agent in PMNL [394], but was also capable 
of weakly inducing 5-LO product formation as a stimulus in several studies [375, 379, 380, 
396]. Furthermore, OAG did not only prime for enhanced LT biosynthesis upon stimulation 
with ionophore or fMLP [389-392], but also by itself stimulated 5-LO activity, and a direct 
interaction of OAG with the 5-LO enzyme was demonstrated [127, 405].  
 
Not only enzymatic activity of 5-LO, but also its effective translocation to the nuclear 
envelope upon stimulation is a critical parameter for LT biosynthesis from endogenous 
substrate. In former studies, priming agents were demonstrated to upregulate 5-LO 
translocation, which may account for enhanced LT formation. It was reported that priming of Discussion 
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MM6 cells with the phorbol esters PMA or mezerein augmented ionophore-induced 
association of cellular 5-LO with the nuclear membrane and similar results were obtained for 
PMNL stimulated with low dose ionophore [373]. Furthermore, 5-LO translocation to the 
nuclear fraction was observed after fMLP stimulation of LPS-primed PMNL, but not of 
unprimed cells [367] and also TLR7/8 ligand resiquimod promoted 5-LO translocation in 
PMNL to cellular membranes, which was blocked by cPLA2α inhibitor pyrrophenone and 
FLAP inhibitor MK-0591 pointing to a FLAP-dependent mechanism [396]. In present 
investigations, however, no increase of 5-LO redistribution from the nonnuclear to the nuclear 
compartment was detected in TLR2 ligand primed MM6 cells compared to unprimed cells 
upon stimulation with ionophore. PMA mediated enhancement of 5-LO translocation, in 
contrast, could be confirmed as it was described for MM6 cells [373]. Similar to earlier 
observations, 5-LO was predominantly found in the nonnuclear fraction of resting cells, but 
divergent to the former report, ionophore stimulation per se in fact significantly induced a 
partial redistribution of 5-LO into the nuclear fraction of MM6 cells [373]. Dissimilar 
handling of the fractionation technique and different sensitivities of protein detection possibly 
might contribute to these divergent results, which are not contradictory in principle, though. 
Control experiments for adequate cellular fractionation revealed a weak signal of the cytosolic 
marker GAPDH in the nuclear fraction indicating that also a small proportion of nonnuclear 
5-LO was possibly detected in the nuclear fraction. However, this observation was neglected 
due to the minor extent of this inaccuracy. Moreover, this does not detract the findings that no 
enhancement of 5-LO translocation could be found in TLR2 ligand treated cells. TLR2 ligand 
incubation of MM6 cells without subsequent addition of ionophore also did not stimulate 5-
LO translocation, but LTA surprisingly seemed to exert opposite effects, as a slight increase 
of 5-LO in the nonnuclear fraction was detected. In an additional experiment, 5-LO 
translocation to cellular membranes in general was analyzed in MM6 cells, but TLR2 ligand 
priming did not result in enhanced translocation of 5-LO from the cytosol to the membrane 
fraction. Interestingly, also other sites of 5-LO product synthesis than the nuclear envelope 
have been discussed for primed leukocytes. PAF mediated enhancement of ionophore-
induced LTB4 release and also chemokine-enhanced LTC4 production was correlated with 
PAF- or chemokine-induced lipid body formation in PMNL or eosinophils and basophils 
[387, 388, 394]. Moreover, cytoplasmic lipid bodies were shown to be the site for enhanced 
LT synthesis in eosinophils [387, 406]. In very recent studies, leukocytes from Histoplasma 
capsulatum (Hc) infected mice were shown to produce lipid bodies, which correlated with 
enhanced generation of LTB4 upon stimulation with ionophore. Moreover, Hc-induced lipid Discussion 
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body formation in murine alveolar macrophages was dependent on TLR2 [407]. Also 
Mycobacterium leprae-induced lipid body formation was observed in human mononuclear 
phagocytes and mouse peritoneal macrophages, and an involvement of TLR2/6 activation was 
suggested. Furthermore, increased levels of PGE2 were detected temporally coinciding with 
lipid body formation [408]. Up to the present, there is no information available, if lipid body 
formation can also occur in MM6 cells, and present data do not provide any information, if 
TLR ligand enhanced LT formation might occur at such structures in MM6 cells. 
 
During analyses of TLR2 ligand mediated priming of MM6 cells, a more prominent 
enhancement of 5-HETE in comparison to total 5-LO products was noticed, which is referred 
to as “5-HETE effect” in this dissertation. Assuming sufficient substrate supply, it was 
speculated as a first hypothesis, if such a prominent 5-HETE formation might occur in the 
cytosol independent from effective interaction of LT forming enzymes within the biosynthetic 
complex, and thus might reflect poor 5-LO translocation to the nuclear envelope under TLR2 
ligand priming conditions. However, also the noticeable generation of the non-enzymatically 
formed all-trans isomers of LTB4 would have been expected under such conditions, which yet 
was not observed. Furthermore, if translocation of 5-LO in MM6 cells is relevant for effective 
co-localization with LTA4 hydrolase and their metabolic coupling in the conversion of LTA4 
to LTB4, is not clear. LTA4 hydrolase was described as a soluble enzyme, which was found in 
the cytosolic fraction of rat neutrophils [409, 410]. Moreover, different subcellular 
distribution of LTA4 hydrolase and co-localization with 5-LO was found depending on the 
cell type. Thus, in rat basophilic leukemia cells and rat primary alveolar macrophages, LTA4 
hydrolase together with 5-LO was detected in the soluble nuclear fraction of the cells. In 
human PMNL, in contrast, LTA4 hydrolase and 5-LO were located in the cytosol, but only 5-
LO subcellular redistribution into the nuclear fraction was observed in activated neutrophils 
[411]. Hence, if minor enhancement of LTB4 in TLR2 ligand primed MM6 cells is linked to 
ineffective 5-LO translocation, is not known. Nevertheless, in order to check the hypothesis, 
5-HETE formation in LTA primed cells was compared to PMA primed cells, which do show 
substantial 5-LO translocation upon stimulation with ionophore. However, the “5-HETE 
effect” was detectable in LTA primed and likewise in PMA primed MM6 cells, and these 
results were confirmed in THP-1 cells and to a lesser extent also in PBMC. Therefore it was 
concluded that the “5-HETE effect” does not seem to be characteristic particularly for TLR2 
ligand primed cells, and does not only occur in differentiated monocytic cell lines, but also in 
primary monocytes. In comparison, OAG priming of fMLP stimulated PMNL did not Discussion 
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increase 5-HETE to a greater extent than LTB4 [389, 390]. Kdo2-lipid A priming of 
RAW264.7 murine macrophages, in contrast, resulted in a stronger enhancement of 5-HETE 
than of LTC4 formation upon stimulation with ionomycin or ATP [397]. Monocytic cells, in 
contrast to neutrophils or B-lymphocytes, were shown to contain glutathione peroxidase-1, 
and MM6 cells were found to have high glutathione peroxidase activities [162], which 
possibly could also be true for monocytes / macrophages in general. Therefore, a considerable 
5-HETE formation might be characteristic for monocytic cells, which may have a greater 
capactity to reduce 5-HpETE to 5-HETE than other cell types. Nevertheless, the reason for a 
greater enhancement of 5-HETE compared to other 5-LO products in primed monocytes is 
not clear. It can only be speculated that priming may exert an enhancing effect on glutathione 
peroxidase activity or might possibly alter the velocity of single reaction steps catalyzed by 5-
LO. 
 
5.2.2  A comparison of priming properties of LTA and PMA in MM6 cells 
 
Present investigations revealed differences in the mechanism of priming of LTA compared to 
several other priming agents, which in contrast to LTA up-regulate 5-LO activity and 
translocation. As particularly PMA was shown to exert such effects in MM6 cells [373], the 
question came up, how differing modes of action of LTA and PMA would account for these 
differences regarding the mechanism of priming.  
The phorbol ester PMA is a PKC activator that directly binds PKC at its C1 domain within 
the regulatory domain, thus substituting for diacylglycerol, which is generated endogenously 
by PLC consequent to receptor-ligand interactions [392, 412]. Activation of PKC is regulated 
by DAG or phorbol ester binding in the presence of a phospholipid cofactor and also by Ca
2+, 
which binds at the C2 domain of PKC and mediates its association to membranes [412]. In 
early reports, PMA was shown to rescue ionophore-induced LTB4 synthesis and AA release 
that had been blocked by PKC inhibitors in PMNL [393], and it was demonstrated that PKC 
activation was accompanied with an up-regulation of the ionophore stimulated 5-LO pathway 
in resident rat alveolar and peritoneal macrophages [392]. Thus, a role of PKC for LT 
biosynthesis was ascertained. In MM6 cells, in contrast to PMNL, ionophore stimulation is 
not sufficient to induce pronounced LT biosynthesis, and previous PMA priming was required 
for substantial 5-LO translocation and 5-LO product formation from endogenous AA [373]. 
Both processes were blocked by PKC inhibitor Calphostin C, pointing to a role of PKC in 
PMA priming. Furthermore, in PMA primed MM6 cells, a Calphostin C sensitive up-Discussion 
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regulation of ionophore-induced MAPK-activated protein kinase 2 (MK2) activity was found. 
MK2 had been shown to phosphorylate 5-LO at Ser-271 in vitro, which is believed to 
positively regulate 5-LO catalysis [169, 171]. 5-LO was also found to be phosphorylated by 
ERK1/2 at Ser-663 in vitro, and in MM6 cells PMA priming was essential for ERK1/2 
activation and considerable 5-LO phosphorylation [170]. Moreover, enhancement of 
ionophore-induced 5-LO product formation in presence of exogenous AA was reversed by 
ERK activation inhibitor U0126 in PMA primed MM6 cells, but U0126 hardly affected 
product formation in unprimed cells [170]. Thus, 5-LO phosphorylation by MK2 and ERK1/2 
could contribute to increased 5-LO activity by PMA priming. Phosphorylation has been 
speculated to possibly lower the concentration of Ca
2+ needed to activate 5-LO in the cell 
[16]. A direct connection between 5-LO kinase activation and 5-LO translocation is still 
unclear. 5-LO phosphorylation may govern nuclear redistribution [16], but phosphorylation of 
other proteins important for 5-LO activity could also be involved [373]. 
TLR ligands are known to induce MAP kinase activation via the MyD88-dependent signalling 
pathway, which is common to all TLR subtypes except TLR3 [282, 286], and TLR2 
activation by LTA has been implicated in p38 MAPK and ERK1/2 activation in monocytic 
cells or macrophages in numerous studies [292, 413, 414]. Hence, LTA induced activation of 
the p38 MAPK and ERK1/2 pathways seemed likely also in MM6 cells, and consecutive 
phosphorylation of 5-LO seemed conceivable. Furthermore, LTA has also been described as a 
PKC activator, at rather high concentrations (1-50 µg/mL) though, in some studies. LTA was 
suggested to activate phosphatidylcholine-PLC (PC-PLC) and PC-PLD, but not PIP2-PLC, to 
induce PKC activation in a human pulmonary epithelial cell line (A549) [415]. In RAW 264.7 
macrophages and human tracheal smooth muscle cells, in contrast, LTA-induced PKC 
activation seemed to be mediated by PC-PLC and by PIP2-PLC [416, 417].  
 
As a positive regulation of 5-LO was not apparent after LTA priming, three possible causes 
were hypothesized. First, TLR2 signalling may additionally induce cellular processes that 
have an inhibitory impact on 5-LO, which counterbalance enhancing effects by a supposable 
MAP kinase activation. Second, besides MAP kinase activation, PMA may trigger further 
cellular processes, which essentially contribute to its priming effect, but which are not 
induced by LTA. Third, despite both priming agents do activate PKC and MAP kinase 
pathways, there might be a decisive difference regarding intensity and kinetics. 
 Discussion 
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Regarding the first hypothesis, LTA had displayed weak inhibitory effects on 5-LO activity in 
some experiments or seemed to have an opposed influence on 5-LO translocation, as 
mentioned previously. PKA mediated phosphorylation of 5-LO at Ser-523 was shown to 
inhibit its activity in vitro and in intact cells, but ionophore-induced 5-LO translocation was 
not affected by PKA activation [174]. Nevertheless, LTA-induced PKA activation was taken 
in account. However, neither H-89, nor the myristoylated protein kinase inhibitor peptide 
(PKA inhibitor 14-22 amide), both selective and cell permeable inhibitors of cAMP-
dependent PKA, did unmask LTA priming for enhanced 5-LO activity, and expectedly also 
PMA priming was not affected. LTA (10µg/mL) induced NO synthase expression in RAW 
264.7 macrophages, and this was shown to involve COX-2 induction, PGE2 release and 
subsequent PKA activation [418], but no reports were found regarding short-time PKA 
activation by LTA. That supports the present data, suggesting that PKA activation does not 
play a role in the transient process of LTA priming, which could have explained differences 
between LTA and PMA priming. PMA has scarcely been implicated in PKA activation. 
Similarly to LTA, PMA was reported to activate PKA indirectly by inducing the formation of 
PGE2, which then activates PKA via adenylyl cyclase linked cell surface receptors [419]. 
Such processes, however, might carry no weight in comparison to the rather strong up-
regulation of 5-LO. Another possibility for an inhibitory impact of LTA might be the 
enhancement of glutathione peroxidase activity. As it had already been considered in a 
previous section, such a process may on the one hand result in enhanced reduction of 5-
HpETE to 5-HETE, but may also further reduce cellular hydroperoxide levels and thus impair 
5-LO activation.  
 
As a second hypothesis it was speculated, if undefined PMA-induced cellular events besides 
5-LO kinase activation essentially contribute to the positive regulation of 5-LO, which in 
contrast may not be induced by LTA priming. In former publications it was reported that the 
presence of unsaturated fatty acids (UFAs) was required for effective in vitro phosphorylation 
of 5-LO at Ser-271 and Ser-663, and that 5-LO intrinsically turned out to be a rather poor 
substrate for MK2 and ERK1/2, respectively [170, 171]. It was assessed that UFAs like AA, 
oleic acid (C18:1) or linoleic acid (18:2) enhanced 5-LO phosphorylation, whereas saturated 
fatty acids, oxygenated metabolites of UFAs or esterified fatty acids were much less, or 
hardly ever effective. Conformational changes of 5-LO and the resulting exposure of 
phosphorylation sites due to fatty acid binding were presumed as an explanation of at least 
AA triggered upregulation of 5-LO phosphorylation. In connection with present Discussion 
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investigations it seemed conceivable that PMA priming, in contrast to LTA priming, may 
trigger cellular events, which result in the release of free UFAs also in the cellular context and 
therefore facilitate effective 5-LO phosphorylation. This could be mediated for instance by a 
slight elevation of the intracellular calcium level during the period of priming, which then 
may weakly activate cPLA2 and induce the release of an adequate amount of AA. Also oleic 
acid release was shown to be mediated by cPLA2 activity in macrophages in few reports [420, 
421], but this occurred during long-term cell stimulation and therefore may not be relevant 
during 15 minutes of priming. LTA was not able to significantly induce AA release in present 
studies, as it was investigated in a posterior experiment and will be discussed later-on. PMA 
on its own seems to liberate AA only in certain cell types such as macrophages and 
neutrophils [94], but interestingly, reports about a direct activation of AA release by PMA in 
such cells are contradictory [390, 391].  
Even slight elevations of the intracellular calcium are sufficient to induce the release of AA. 
At [Ca
2+]i greater than 210-280 nM, cPLA2α translocates to the endoplasmatic reticulum and 
the nuclear envelope, but already sustained [Ca
2+]i greater than 100-125 nM can induce the 
translocation of cPLA2α to the Golgi apparatus. Duration of [Ca
2+]i stabilizes the association 
with the membrane, leading to AA release [37]. Rather high Ca
2+ concentrations are necessary 
in MM6 cells to activate LT biosynthesis, as half-maximal 5-LO product formation in MM6 
cells was measured at about 325 nM intracellular calcium [422]. Thus, it seems possible that a 
slight release of AA could be activated by moderate calcium elevation without concomitant 
induction of 5-LO product formation during the period of priming. However, neither LTA nor 
PMA clearly affected the basal intracellular calcium level in MM6 cells, and [Ca
2+]i did not 
rise above 100 nM upon LTA or PMA treatment in present investigations. In fact, PMA 
seemed to rather lower the intracellular calcium concentration by trend. This is in accordance 
with publications reporting that PMA does not increase [Ca
2+]i in macrophages [94], or even 
diminishes stimulus-induced calcium mobilization in several cell types [423-428]. In contrast 
to present observations, some studies, however, revealed the TLR ligand induced elevation of 
[Ca
2+]i  as it will be described in a posterior section. As aforementioned, LTA has been 
identified as an activator of PLC pathways, which are known to result in Ca
2+ mobilization 
from intracellular stores. In human tracheal smooth muscle cells, high LTA concentrations 
(50-250 µg/mL) were found to transiently increase [Ca
2+]i, and an involvement of PC-PLC 
and PIP2-PLC in LTA-induced responses was suggested [417]. The lower LTA concentration 
(0.5 µg/mL) used during present priming studies, however, appears to be insufficient to 
induce an effective raise of [Ca
2+]i in MM6 cells.  Discussion 
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As PMA was described to induce arachidonic acid release without increasing [Ca
2+]i via an 
alternative mechanism  [94], a second experimental approach was used to survey the 
speculation, that PMA priming, but not LTA priming, may effect the presence of UFAs 
facilitating effectual 5-LO phosphorylation. LTA priming of MM6 cells was carried out in 
presence of various AA concentrations to compensate a possible lack of UFAs in the cell, but 
also under such conditions LTA priming was not able to enhance 5-LO activity.  
Therefore, besides 5-LO kinase activation, other additional cellular events than the release of 
UFAs might be activated by PMA priming, but not by LTA priming. It is conceivable, that 
PMA can activate also yet undefined signal transduction pathways, which contribute to 5-LO 
activation. Furthermore, it should be considered, that in addition to Ca
2+ and 5-LO 
phosphorylation, the endogenous generation of diacylglycerols (DAGs) was recently 
identified as a decisive determinant for cellular 5-LO activation in response to ionophore in 
presence of exogenous AA in PMNL. Besides elevation of [Ca
2+]i, ionophore induced DAG 
formation via the phospholipase D / phosphatidic acid phosphatase (PLD / PA-P) pathway 
was found to be required for 5-LO translocation and substantial 5-LO product formation 
[166]. In MM6 cells, in contrast, ionophore is not capable of substantially inducing 5-LO 
translocation, 5-LO product formation and also no substantial ERK1/2 activation could be 
detected [170, 373]. Thus, it was speculated that in MM6 cells ionophore cannot activate 
certain kinase cascades, as it is the case in PMNL, and that endogenous signal molecules such 
as DAGs, whose action can be mimicked by PMA, might not be adequately generated [373]. 
DAGs on the one hand are activators of PKC signalling pathways, but DAGs were also shown 
to influence the formation of 5-LO products apart from activating PKC / MAPK pathways 
[166]. 1-Oleoyl-2-acetylglycerol (OAG) functions as direct agonist of 5-LO product 
formation in PMNL [405], and was found to directly stimulate 5-LO catalysis in vitro by 
acting at the C2-like domain of 5-LO [127]. It was suggested that OAG renders 5-LO activity 
resistant against the inhibitory influence of glutathione peroxidases (GPx) by increasing the 
affinity towards hydroperoxides. Furthermore, OAG itself had no influence on cellular 
redistribution of 5-LO in PMNL [405], but was able to restore ionophore induced 5-LO 
translocation during blockade of endogenous DAG generation [166]. This indicates that 
DAGs could play a role for membrane association of 5-LO, as they do for PKC. PMA, in 
comparison, does not directly stimulate 5-LO activity and it seems daring to speculate that 
PMA, besides PKC activation, may in parts mimic also direct effects of DAGs. It is very 
interesting however, that there are some publications reporting PMA induced PLD activation 
via PKC activation, which indeed could result in DAG generation [429-431]. Interestingly, Discussion 
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for LTA (30 µg/mL) PLD activation was reported [415], but PLC / PLD / PKC pathways do 
not seem sufficiently activated by LTA in present investigations, which could be related to the 
lower LTA concentrations that were used for optimal MM6 priming in present studies. 
 
The third hypothesis is based on the assumption that ERK1/2 activation and subsequent 5-LO 
phosphorylation are the key events of PMA priming effects on 5-LO. This was suggested, as 
U0126, an inhibitor of ERK1/2 signalling pathways, abrogated this 5-LO up-regulation in 
MM6 cells [170]. Against this background it was assumed that intensity or duration of 
ERK1/2 activation might be decisive for 5-LO up-regulation, and differences herein may 
explain the lack of such effects after LTA priming compared to PMA priming.  
The comparison of p38 and ERK1/2 activation profiles by PMA and LTA, firstly revealed 
that LTA is a strong activator of p38 MAPK, and that PMA mediated p38 MAPK activation, 
in comparison, was rather moderate. Downstream 5-LO phosphorylation at Ser-271 was 
investigated as well, and according to the p38 MAPK activation profiles, a slight 
phosphorylation seemed apparent after LTA incubation, but was hardly visible after PMA 
treatment. These data, however, may be of minor importance regarding the underlying 
mechanism of PMA versus LTA priming. It seems that p38 MAPK pathways can be activated 
by priming, but may have no decisive relevance for a positive regulation of 5-LO in this case. 
Nevertheless, the detection of 5-LO phosphorylation by immunoblotting is worthy of 
particular attention. Earlier studies have reported technical difficulties in providing evidence 
for in vivo 5-LO phosphorylation [170]. In HL-60 cells 5-LO phosphorylation indeed was 
shown, but only a very small amount of 5-LO was phosphorylated [432], which might explain 
certain difficulties with reliable detection methods. Immunoblotting using phospho-specific 
antibodies, which are available for relevant 5-LO phosphorylation sites, may possibly help to 
resolve such problems. Admittedly, 5-LO phosphorylation at Ser-663 could yet not be 
detected successfully by immunoblotting in present studies.  
Of greater interest than the analysis of p38 MAPK profiles, was the observation that PMA 
induced ERK1/2 activation was strong and persistent up to 20 minutes, whereas only a 
moderate and very transient ERK1/2 activation was seen after 5 minutes of LTA treatment. It 
seemed consistent, that this difference may account for lacking 5-LO up-regulation effects 
after 15 minutes of LTA priming. Further experiments were undertaken to corroborate this 
assumption. Firstly, analysis of 5-LO activity after various periods of PMA and LTA priming 
revealed that the characteristics of enhanced 5-LO activity over time coincided with the 
respective ERK1/2 activation profiles. Whereas PMA clearly enhanced 5-LO activity after Discussion 
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priming for 5 up to 20 minutes, a weak LTA effect was detected only after 5 minutes of 
priming, which was yet not significant. Intriguingly, 5-LO activity dropped below the level of 
unprimed cells with increasing times of LTA treatment. In a second approach it was 
attempted to boost LTA mediated ERK1/2 activation by blockade of the p38 MAPK 
signalling pathway, which was found to shift MAPK activation towards a more pronounced 
ERK1/2 activation, to render 5-LO up-regulation detectable. However, 5 minutes of LTA 
priming in presence of SB203580, a selective inhibitor of p38 MAPK signalling that acts on 
MK2, did also not result in a significant enhancement of 5-LO activity, which could have 
been reversed by an ERK inhibitor in a subsequent approach (data not shown). Moreover, 
blockade of p38 MAPK signalling seemed to generally promote 5-LO nuclear translocation, 
but did not lead to a significant enhancement of ionophore-induced cellular resdistribution of 
5-LO by LTA priming for 5 minutes.     
 
In summary, LTA mediated ERK1/2 activation via the TLR2 pathway may be too weak and 
too transient to positively regulate 5-LO. Nevertheless it seems, that inadequate ERK1/2 
activation may not be the only decisive factor for missing LTA priming effects on 5-LO. 
Possibly, LTA concentrations that were determined as optimal for the TLR2-mediated 
enhancement of LT formation in these studies, might not be capable of effectively inducing 
PLC and PKC activation, which would on the one hand promote a more pronounced MAPK 
activation, but might possibly also trigger PKC mediated PLD activation and release of 
DAGs, which were shown to importantly determine 5-LO activity. Furthermore, some 
observations indicated that an undefined inhibitory influence on 5-LO may superpose and 
counteract LTA priming effects on 5-LO.     
 
5.2.3  The influence of TLR2 ligands on the release of AA 
 
Besides cellular 5-LO activity, the regulation of AA release is a crucial determinant for LT 
formation. The amount of free AA and its availability as a substrate for 5-LO thus is an 
important parameter for the extent of LT biosynthesis. In a set of experiments it was 
investigated, if an increased supply of AA accounts for TLR2 ligand mediated enhancement 
of LT formation in MM6 cells.  
 
Numerous reports indeed had described an increase of free AA after pre-treatment of agonist 
stimulated leukocytes with priming agents. Namely, the cytokines GM-CSF [376, 378] and Discussion 
_________________________________________________________________________________________________________________ 
  101
TNFα [376, 383], as well as OAG [389, 390, 392] and PMA [373, 390-392], EBV [254], and 
also LPS [365-367, 395, 433] have been reported to exert such effects. Moreover, TLR 
dependent priming for enhanced LT formation by resiquimod and Kdo2-lipid A has been 
linked to an augmentation of AA release [396, 397]. Also in present investigations, the TLR2 
ligands LTA, FSL-1 and Pam3CSK4 mediated an increase in ionophore induced supply of 
AA, and the respective time course characteristics of enhanced AA release and of increased 5-
LO product formation showed great coincidence. The maximal effect of TLR2 ligands on AA 
release occurred somewhat earlier (10 to 15 minutes of priming) than on 5-LO product 
formation (15 to 20 minutes of priming), probably reflecting the fact that the release of AA 
must occur prior LT synthesis. Some differences were observed regarding intensity. Whereas 
LT formation was enhanced up to twofold, the release of AA was at least three times higher in 
primed than in unprimed cells. This may be related to the fact that cells of the monocytic 
lineage contain high levels of GPx-1 [162], and 5-LO activation is therefore hampered in such 
cells. Moreover, AA is expected to be metabolized also by other lipoxygenases (12-, 15-LO), 
by cyclooxygenases and cytochrome P450 enzymes, or may be partially re-acylated into 
membrane phospholipids by lysophospholipid acyltransferase [1]. Finally, observations 
regarding intensity are in line with previous results, showing that TLR2 ligand priming did 
not promote, but rather seemed to inhibit 5-LO activity. As it had been detected for 5-LO 
product formation, enhanced AA levels were no longer apparent after extended priming for 60 
to 90 minutes. Furthermore, AA release was not increased, when TLR2 ligands were added 
simultaneously with ionophore without pre-incubation. These observations suggested that 
TLR2 ligands by themselves do not directly stimulate AA release, which could be confirmed 
in a respective experiment. Additionally, neither LTA, as already discussed previously, nor 
FSL-1 and Pam3CSK4 were capable of increasing the intracellular Ca
2+ level, which is an 
important factor for the stimulation of an immediate AA release. However, a couple of studies 
are known, which indeed report TLR ligand mediated Ca
2+ mobilization, and reports about 
TLR mediated AA release are partially conflicting. Not only LTA greater than 50 µg/mL 
directly evoked a peak of [Ca
2+]i in tracheal smooth muscle cells [417], but also other TLR2 
and TLR4 ligands have been implicated in Ca
2+ mobilization. Thus, TLR2 ligands Pam3CSK4 
at concentrations greater than 15 µg/mL [400, 434], and peptidoglycan (PGN) at 50 - 100 
µg/mL [435, 436] were shown to stimulate cellular Ca
2+ influx, and also LPS stimulation (1-
100 µg/mL) resulted in an increase of intracellular Ca
2+ levels [435, 437, 438]. In accordance 
with present results, Pam3CSK4 (1 µg/mL) failed to stimulate AA release within 20 minutes in 
murine mast cells and this was ascribed to the lack of a respective Ca
2+ signal [439]. Rather Discussion 
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high concentrations of ligands seem required to induce Ca
2+ mobilization by activation of cell 
surface TLRs, and such concentrations may possibly also be able to trigger direct stimulatory 
effects on rapid AA release and 5-LO product formation, whereas lower concentrations are 
sufficient for priming. On the other hand, LPS (10 µg/mL) failed to induce AA release in 
human PMNL, and this was also reported for LTA and Pam3CSK4 even at high concentrations 
[440]. Furthermore, TLR8 ligand resiquimod, which was identified as a priming agent, indeed 
triggered a direct release of AA in human PMNL, but the underlying mechanism was not 
investigated [396]. Besides concentration, also cell type specific differences may explain 
diverging effects of TLR ligands on the mobilization of Ca
2+ and AA. Interestingly, in murine 
macrophages and mast cells, a Ca
2+ independent direct AA release by TLR ligands, which 
was apparent after hours of stimulation, has been reported in several studies [397, 441-446]. 
As a mechanism, TLR mediated MAPK activation and cPLA2 phosphorylation [442-446] 
have been suggested, also PIP2 or C1P mediated redistribution of cPLA2 to cellular 
membranes have been discussed [397, 443] and a role for PA-P and PKC for cPLA2 
activation were found [441]. Additionally, enhanced expression of cPLA2 did not seem to 
play a role for the stimulation of AA release in these investigations [397, 443]. In summary, 
whereas TLR ligands may be capable of directly stimulating AA supply in certain cell-types 
and species, this was not detected in MM6 cells and does not play a role for the mechanism of 
priming.  
 
Nevertheless, present results suggested that the TLR2 ligand mediated enhancement of AA 
release is the critical step for the enhancement of LT formation, and further analyses were 
undertaken to identify the phospholipase A2 isoenzymes involved in this process. The sPLA2 
and cPLA2 family has been implicated in eicosanoid generation, whereas other PLA2s such as 
the iPLA2 are mainly involved in other phospholipid related processes [37]. Among the 
cPLA2 familiy, cPLA2α is considered as a key component of the initiation of AA metabolism. 
Present inhibitor studies revealed, that iPLA2 inhibitor bromoenollactone (BEL) [447, 448] 
expectedly did not affect AA release significantly, neither in primed nor in unprimed cells. 
Thus, it was concluded that iPLA2 does not contribute to the supply of AA under present 
conditions. The commonly used sPLA2 inhibitor DTT, however, which inactivates sPLA2, but 
not cPLA2 [449, 450], led to a considerable reduction of AA release in unprimed as well as in 
primed cells, indicating that sPLA2 is involved in AA release in ionophore stimulated MM6 
cells. However, the priming effect of at least LTA and FSL-1 was not affected considerably 
by DTT, which indicates that sPLA2 does not seem to play a decisive role for the mechanism Discussion 
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of priming. It was assumed, that it is not the sPLA2 activity, which is enhanced, and that 
sPLA2 does also not mediate enhanced AA release. Accordingly, the activity of cPLA2 must 
be augmented by TLR2 ligands. Moreover, the cPLA2α isoenzyme was found to be crucial 
under present experimental conditions, since its inhibition by the specific cPLA2α inhibitor 
pyrrolidine-1 [451] almost completely prevented AA release upon ionophore stimulation, and 
no appreciable sPLA2 activity remained detectable in presence of the cPLA2α inhibitor. Other 
publications support these findings, as cPLA2 was found to mediate AA release after fMLP 
stimulation of LPS-primed PMNL [367], as well as in EBV-primed mononuclear leukocytes 
after stimulation with ionophore [254], and a role of cPLA2α in TLR8 mediated priming of 
fMLP stimulated PMNL was demonstrated [396]. Furthermore, there is evidence of a 
functional coupling of sPLA2 and cPLA2 activation. Thus, it was demonstrated that activation 
of sPLA2 succeeds cPLA2 activation, as it is dependent on previous AA release by cPLA2 in 
LPS primed, PAF stimulated P388D1 macrophages [452, 453]. Such a sequential activation 
may serve as an explanation, why inhibition of cPLA2α activity completely blocked AA 
release in present investigations without sPLA2 being activated. Interestingly, LTA and also 
PMA priming of THP-1 cells, which has been discussed in a previous section, resulted in a 
biphasic enhancement of LT formation. It seems possible that this may arise from a 
successive activation of different PLA2 isoenzymes, which may occur in a retarded fashion 
and thus is discriminable in THP-1 cells, but not in MM6 cells. In this regard, it was reported 
that Pam3CSK4 stimulated biphasic eicosanoid generation was mediated by initial activation 
of cPLA2α within 5 minutes, which was further amplified by sPLA2 through its regulation of 
sequential phosphorylation of ERK1/2 and cPLA2α in a second phase of AA release after 
about 15 minutes [444]. However, sPLA2 dependent amplification of AA release does not 
seem to underlie the present priming effect by LTA and FSL-1, as an enhancement was still 
apparent during sPLA2 inactivation. Admittedly, Pam3CSK4 mediated priming was slightly 
reduced in presence of DTT. Therefore, a role of sPLA2 may not be definitely excluded in this 
case. Successive experiments revealed comparable effects of the PLA2 inhibitors on primed 
LT formation as on primed AA release suggesting that enhancement of LTs in fact is due to 
an increase of free AA. Surprisingly, control experiments yet revealed that cPLA2 inhibitor 
pyrrolidine-1 is not absolutely specific for the inhibition of cPLA2α, but also functions as a 
direct 5-LO inhibitor. This characteristic necessarily has to be taken in account in future 
investigations and may exclude its suitability in certain functional analyses of endogenous LT 
formation. Nevertheless, in the present case these findings actually do not challenge the Discussion 
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assumption that enhanced AA release triggers the increase of LTs in TLR2 ligand primed 
MM6 cells. 
 
The following analyses focused on the question of how TLR2 ligand priming can trigger an 
increase of cellular cPLA2α activity. Several studies have demonstrated that the activation of 
cPLA2α is not only regulated by Ca
2+ but also by phosphorylation [37, 46, 94, 454-456]. It has 
been shown, that cPLA2α is a target of MAP kinases. Phosphorylation at Ser-505 by p42 or 
p38 MAPK led to an increase in catalytic activity in vitro and mutation of this serine residue 
markedly reduced cPLA2α mediated AA release in cells stimulated with physiological stimuli 
[37, 86, 87, 89, 90, 457]. In general, phosphorylation at Ser-505 increases cPLA2α activation, 
but phosphorylation per se is considered as insufficient to induce cPLA2α mediated cellular 
AA release, and a concomitant increase in the intracellular calcium level seems required [37]. 
It was suggested that phosphorylation may influence calcium dependent membrane binding 
affinity, and may induce conformational changes optimizing interaction of cPLA2α catalytic 
domain with membrane substrates for catalytic activity [46]. Besides Ser-505
 
phosphorylation, cPLA2α activity was also positively regulated via phosphorylation of Ser-
727, which is a target of MAPK interacting kinase 1 (Mnk-1), a downstream kinase of p38 
MAPK and ERK1/2 [87, 95, 99, 458]. As a third serine residue playing a role for increased 
enzymatic activity, Ser-515 of cPLA2α was found to be phosphorylated by Ca
2+/calmodulin 
kinase II (CaMKII) in norepinephrine stimulated human vascular smooth muscle cells 
(VSMC) [88]. Besides, it was suggested that CaMKII activation leads to activation of 
ERK1/2 in rabbit or rat VSMC, which in turn can trigger Ser-505 phosphorylation of cPLA2α 
[96, 100, 459-461]. Toll-like receptor stimulation is known to result in activation of MAP 
kinases (ERK, JNK, p38) [282, 286]. Accordingly, in present studies it was demonstrated that 
phosphorylation of ERKs and p38 MAPK is detectable also in MM6 cells challenged with 
TLR2 ligands, moreover occurring within the time-frame of enhanced AA release and LT 
formation. Maximal activation of both MAPKs appeared fast within 5 minutes, and thus 
seems to precede AA generation and successive LT biosynthesis. In comparison to p38 
MAPK activation (maximal increase about 3-fold), p42 phosphorylation was induced to a 
greater extent (about 12-fold). Phosphorylation of p42 was more transient and displayed 
slightly different characteristics depending on the respective TLR2 ligand. In this respect, 
FSL-1 induced ERK1/2 activation was less sustained (5-15 min) than the response triggered 
by LTA (5-20 min), and Pam3CSK4 mediated ERK1/2 phosphorylation was even more 
transient occurring and disappearing within just about 5 minutes. It seems inconsistent that the Discussion 
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intensity of LTA induced p38 MAP kinase activation was clearly weaker than in precedent 
analyses (4.2.4). This may be attributed to a different responsiveness of cells or may depend 
on an unnoticed variation of assay or detection conditions between these two experimental 
series. Therefore, these data cannot be directly compared. Nevertheless, experiments within a 
narrow time-frame provided consistent data and thus seem to allow for valid comparative 
analyses.  
As shown in further investigations, time-dependent cPLA2α phosphorylation at Ser-505 was 
evoked by TLR2 ligands, which maximally occurred short after MAPK activation, but 
slightly preceded the intracellular release of AA. Interestingly, a high initial basal level of 
phosphorylated cPLA2α was found, as observed also by others [462], which could be possibly 
due to early stress-related MAPK activation by harvesting and handling the cells within the 
assay procedure. In following studies, the combined use of a p38 MAPK and a MAP kinase 
kinase (MEK) inhibitor led to complete prevention of TLR2 ligand induced increase of 
phospho-cPLA2α (Ser-505) as well as of TLR2 ligand mediated enhancement of AA release. 
This suggests, that cPLA2α phosphorylation via both, the p38 MAPK and ERK1/2 signaling 
pathway, is crucial for an increase in cPLA2α activity after TLR2 ligand priming. It cannot be 
excluded though that also other MAPK mediated cellular processes contribute to enhance AA 
release. Similar to present results, enhanced phospho-cPLA2α was detected in EBV primed 
human PBMC [254], and also TLR7/8 ligand resiquimod stimulated cPLA2α phosphorylation 
in PMNL [396]. LPS priming of PMNL as well resulted in a phosphorylation of cPLA2α, but 
this was considered as not sufficient for the enhancement of AA release and additionally a 
role of increased cPLA2α nuclear translocation was suggested [367]. In the present study, the 
involvement of other cPLA2α kinases in increasing AA release was tested. Although Mnk-1 
activation, presumably induced via p38 MAPK and ERK1/2 pathways, was detected in 
present studies upon TLR2 ligand treatment, a Mnk-1 inhibitor did not affect enhanced AA 
release under priming conditions. This suggests, that phosphorylation of Ser-727 does not 
substantially contribute to enhanced cPLA2α activity after priming with TLR2 ligands. 
Furthermore, also CamKII inhibitor KN-62 had no effect on primed AA release in MM6 cells, 
and it was concluded that neither CamKII triggered Ser-515 phosphorylation, nor a CamKII 
mediated ERK1/2 activation plays a role for the mechanism of priming. This was expected, as 
CamKII is activated by Ca
2+ influx as well as by Ca
2+ released from intracellular stores [463], 
which was not induced by TLR2 under present conditions. In summary, MAPK mediated 
cPLA2α phosphorylation at Ser-505 seems to account for enhanced AA release and successive 
LT formation in TLR2 ligand primed MM6 cells. Discussion 
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Following experiments confirmed that the observed priming effect is mediated by TLR2. As a 
first evidence, TLR2 ligand stimulated IκB-α degradation had been observed in previous WB 
analyses (4.3.6 and 4.3.7.1), indicating that TLR signaling pathways were active. A second 
approach demonstrated that neutralization of TLR2 by the use of an anti-hTLR2 antibody 
essentially abolished the priming effects of LTA and Pam3CSK4 on AA release, and also the 
response to FSL-1 was significantly reduced. This clearly indicated the involvement of TLR2, 
mediating the effects of the three ligands. Possibly TLR6 as part of the heterodimeric TLR2/6 
receptor complex is responsible for the remainig activity after FSL-1 priming in presence of 
the TLR2 antibody, as it may be still functional and capable of partly transducing an 
activation by FSL-1 under these conditions. In an additional experiment, the presence of 
polymyxin B, which functions as a LPS neutralizing polypeptide [464], did not alter the 
impact of TLR2 ligands on AA and LT release, assuring that LPS contaminations, possibly 
via TLR4 activation, do not contribute to the observed effects. In summary, these data clearly 
confirmed that the ligand effects are dependent on TLR2 activation. 
 
5.3 Concluding  remarks 
 
In the present study, short-term effects of TLR activation on the biosynthesis of LTs in 
mononuclear leukocytes were addressed. It was demonstrated that activation of TLR2 in 
human monocytes does not directly stimulate, but increase the formation of 5-LO products. 
This effect is due to an enhanced cellular AA supply, which arises from a MAPK mediated 
phosphorylation and up-regulation of cPLA2α activity. Thereby, TLR2 ligand priming before 
stimulus-induced activation of LT formation turned out to be essential. The anticipated 
phosphorylation of cPLA2α seems to prepare the enzyme for a boosted response upon 
subsequent Ca
2+ elevation. The 5-LO enzyme, however, was not positively regulated by LTA 
induced TLR activation under these conditions. In fact, LTA seemed to exert slight inhibitory 
effects on 5-LO activity. Present investigation revealed a priming mechanism that only in part 
corresponds with previous findings. Besides enhanced availability of AA, some studies also 
reported an up-regulation of 5-LO, and it was suggested that, in this case, priming increases 
the overlap of AA release and 5-LO activation, which leads to a greater capacity to synthesize 
5-LO products [367]. In Kdo2-lipid A primed mouse macrophages, however, a completely 
different mechanism was postulated. As priming, in this case, did not change cPLA2 activity 
and no cPLA2  phosphorylation was detectable, PIP2 or C1P mediated effects on cPLA2 
membrane localization and activity were proposed [397]. It seems likely that more complex Discussion 
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mechanisms underlie the effects of priming in general, affecting several cellular events 
depending on the priming agent, the cell type and the priming conditions.  
TLR dependent enhancement of LT biosynthesis represents an interesting link between 
activation of innate immune receptors and the rapid formation of proinflammatory lipid 
mediators. On the one hand, this seems to support the role of LTs in host defence and 
infectious deseases, but may also be relevant in pathophysiological processes, which involve 
TLRs as well as LTs, as it has been shown for the pathogenesis of atherosclerosis or allergic 
diseases. In this regard, Hsp70 was lately shown to stimulate LT synthesis through activation 
of TLR4 in mast cells, which are central effector cells in allergic responses [465]. Very recent 
studies, furthermore, demonstrate that TLR ligands can induce inflammatory cell functions 
such as PMN migration via the formation of LTB4 and PAF [466]. Thus, in the meanwhile 
more and more reports are emerging that support a role for TLR activation in the regulation of 
LT release in the context of infection as well as inflammatory diseases.      
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6   SUMMARY 
 
Leukotrienes (LTs) are pro-inflammatory lipid mediators that belong to the group of 
eicosanoids, which are oxygenated metabolites of one common precursor, the aracidonic acid 
(AA). This polyunsaturated fatty acid is esterified at the sn-2 position of cellular membrane 
phospholipids and can be released by phospholipase A2 (PLA2) enzymatic deacylation [1]. 
Among the PLA2 enzyme familiy, the group IVA PLA2 (cPLA2α) plays the key role for 
cellular release of AA, which then can be further converted into LTs by the catalytic reaction 
of 5-lipoxygenase (5-LO). Enzymatic catalysis of cPLA2α and of 5-LO are tightly regulated. 
Key determinants for the activation of both, cPLA2α as well as of 5-LO, are an increase of the 
intracellular Ca
2+ concentration and / or phosphorylation of serine residues by signal-activated 
protein kinases. For 5-LO activation, the presence of diacylglycerols (DAGs) appears to 
constitute another essential factor, as described in recent studies [166]. In response to cellular 
stimuli that elevate the intracellular Ca
2+ level, induce the release of DAGs and / or activate 
MAP kinase pathways, cPLA2α and 5-LO comigrate from a soluble cell compartment (mainly 
the cytosol) to the nuclear membrane, where AA is released und converted into LTs [16, 21]. 
LTs play a significant role in promoting inflammatory reactions and immune processes. They 
have been shown to be released from leukocytes in response to bacterial and viral infections 
and substantially contribute to an effective immune reaction for host defense [247].  
The mechanisms for innate immune pathogen recognition and signaling have been subject of 
intense research since the discovery of the Toll-like receptor (TLR) family of pattern 
recognition receptors. Within the last decade, 10 human TLR subtypes have been identified, 
all of which recognize distinct highly conserved microbial structures (pathogen-associated 
molecular patterns, PAMPs). As an example, TLR2-TLR6 heterodimers were identified to 
recognize lipoteichoic acid (LTA) from gram-positive bacteria or mycobacterial diacylated 
lipopeptides, whereas heterodimeric TLR2-TLR1 appears to be responsive to bacterial 
triacylated lipopetides. Receptor activation triggers the induction of signaling pathways that 
lead to the expression of numerous immune and inflammatory genes. Generally, TLR 
signaling culminates in the activation NF-κB and / or the MAP kinase network, which as well 
is known to be involved in the regulation of cellular leukotriene biosynthesis [281]. 
 
In this regard, it seemed conceivable that the release of LTs might be regulated in the course 
of TLR activation. Thus, present studies were undertaken in order to verify and characterize a Summary 
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possible influence of TLR activation on the biosynthesis of LTs, and furthermore to identify 
the involved signaling pathways and underlying mechanisms. Investigations were carried out 
in human monocytic cell lines and primary human monocytes, which constitute key effector 
cells in the first line of innate immune host defense. 
 
First screening experiments revealed that pre-incubation of differentiated Mono Mac 6 
(MM6) cells with TLR4 ligand LPS, TLR5 ligand flagellin, as well as TLR2/6 ligands LTA 
and FSL-1 (synthetic diacylated lipopeptide) and the TLR2/1 ligand Pam3CSK4 (synthetic 
triacylated lipopeptide) led to an about 2-fold enhancement of Ca
2+ ionophore-induced LT 
biosynthesis, whereas ligands of other TLR subtypes had no influence. This observation could 
also be confirmed in primary human monocytes stimulated with ionophore or fMLP. With 
focus on the TLR2 ligands, further studies were carried out to characterize the observed effect 
in MM6 cells. It was demonstrated that the enhancement of LT formation was more 
pronounced, when suboptimal concentrations of ionophore were used for stimulation, which 
is an experimental scenario that more closely imitates physiologically relevant conditions. 
Furthermore, the extent of LT formation was dependent on the ligand concentration used, as 
well as on the pre-incubation time. In this regard, 15 minutes of ligand pre-incubation turned 
out to be optimal, whereas prolonged incubation decreased LT formation again. Moreover, 
simultaneous addition of TLR2 ligands with ionophore did also not result in enhanced LT 
formation. These observations indicated that TLR2 ligands act as priming agents on human 
monocytes for an enhanced response upon ionophore stimulation, but do not directly act as 
costimuli. Further experiments confirmed that TLR2 ligands were not capable of directly 
stimulating the biosynthesis of LTs.  
To analyze the underlying mechanism, the influence of the TLR2 ligands on the two key 
enzymes of the LT biosynthesis pathway, cPLA2α and 5-LO, was investigated.  
In this regard, it could be shown that TLR2 ligands enhanced ionophore-induced release of 
AA in MM6 cells, which occurred in the same time frame and with a similar time-course as 
LT formation, but displaying a prior maximum at 10 minutes of pre-incubation. A direct 
stimulation of AA release, however, could not been detected, which was corroborated by the 
observation that TLR2 ligands had no influence on the intracellular Ca
2+ level. Inhibitor 
studies revealed cPLA2α to be essential for AA release in TLR2 ligand primed, ionophore-
stimulated MM6 cells, but also sPLA2 was found to be involved. However, the priming effect 
of TLR2 ligands appeared to be mediated exclusively by cPLA2α. Western Blot analyses 
indicated that p38 MAP kinase, as well as ERK1/2, become activated in MM6 cells in Summary 
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response to TLR2 ligands, and also Ser-505 phosphorylation of cPLA2α was detected. A 
cPLA2α phosphorylation at Ser-505 is known to be induced by MAP kinases and was shown 
to increase cPLA2α activity in vitro [37]. Interestingly, the time courses of these 
phosphorylations again coincided with LT biosynthesis in primed MM6 cells. Maximal 
phosphorylation occurred at 5-10 minutes of TLR2 ligand incubation, slightly preceding 
maximal AA release at 10 minutes and maximal LT formation at 15 minutes of priming. The 
combined use of a specific p38 MAPK inhibitor with an inhibitor of the ERK1/2 signaling 
pathway resulted in a complete prevention of cPLA2α phosphorylation, and also TLR2 ligand 
mediated enhancement of AA release was abolished. These results indicated that both MAPK 
pathways seem to play a role for TLR2 ligand mediated upregulation of AA release. An 
impact of other kinases such as Mnk-1 and CamKII, which can also regulate cPLA2α by 
phosphorylation, was excluded. Further studies were undertaken to exclude that LPS 
contaminations via TLR4 may trigger the observed effects. However, the LPS binding reagent 
polymyxin B did not affect the TLR2 ligand priming effects on AA or LT release. 
Furthermore, an anti-hTLR2 antibody significantly reduced enhanced AA release, confirming 
the priming effects to be dependent on TLR2 activation. 
5-LO, in contrast, could not been shown to be positively regulated by TLR ligand priming in 
5-LO activity assays. 5-LO activity was stimulated in presence of exogenous AA, in order to 
determine 5-LO activation independent from PLA2-mediated endogenous AA release. Neither 
a direct stimulation, nor an enhancement of 5-LO activity by TLR ligands was detectable in 
MM6, as well as in THP-1 cells. In fact, a slight inhibitory influence seemed to occur after 
LTA pre-incubation. Similarly, LTA did not enhance ionophore-induced 5-LO translocation 
to the nuclear membrane, but rather seemed to promote 5-LO redistribution into the cytosol. 
These results revealed differences in the mechanism of priming of LTA compared to 
established priming agents such as the phorbol ester PMA, which, in contrast, do upregulate 
5-LO activity and translocation presumably through the envolvement of MAPK pathways 
(particularly ERK1/2 pathways) and potentially by 5-LO phosphorylation [373]. Three 
possible hypotheses were tested, to analyze and understand the different modes of action 
between LTA and PMA. First, an involvement of protein kinase A (PKA), which can 
negatively regulate 5-LO by phosphorylation, was assumed to counteract an LTA priming 
effect on 5-LO, but PKA inhibitors did not unmask LTA priming. Secondly, it was 
hypothesized that PMA, but not LTA, might facilitate the release of polyunsaturated fatty 
acids, which are known to be required for efficient 5-LO phosphorylation by MAP kinases. 
However, supplementation of AA during LTA priming had no effect. Finally, comparison of Summary 
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the MAPK activation profiles of LTA and PMA suggested that ERK1/2 activation in response 
to LTA might be too weak and too transient to up-regulate 5-LO catalysis, compared to PMA. 
Nevertheless it seems that inadequate ERK1/2 activation may not be the only decisive factor 
for missing LTA priming effects on 5-LO. Possibly, PMA may trigger further cellular 
processes, which essentially contribute to its priming effect, but which are not induced by 
LTA. Furthermore, some observations indicated that an undefined inhibitory influence on 5-
LO may superpose and counteract LTA priming effects on 5-LO.     
 
In summary, it was concluded that the increase of LT biosynthesis by TLR2 ligand priming is 
considerably due to an enhanced cellular AA supply, which arises from a MAPK mediated 
phosphorylation and up-regulation of cPLA2α. 
TLR dependent enhancement of LT biosynthesis represents an interesting link between 
activation of innate immune receptors and the rapid formation of proinflammatory lipid 
mediators. On the one hand, this seems to support the role of LTs in host defence and 
infectious deseases, but may also be relevant in pathophysiological processes, which involve 
TLRs as well as LTs, as it has been shown for the pathogenesis of atherosclerosis or allergic 
diseases.  
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7   ZUSAMMENFASSUNG 
 
Leukotriene sind Entzündungsmediatoren aus der Gruppe der Eicosanoide, welche sich von 
der Arachidonsäure (AA) als ihre gemeinsame Vorstufe ableiten. Diese mehrfach ungesättigte 
Fettsäure ist in der Zelle an der sn-2 Position von Membranphospholipiden verestert, und 
kann enzymatisch durch Phospholipase A2 (PLA2)-Enzyme, insbesondere durch die 
cytosolische PLA2α (cPLA2α), freigesetzt werden [1]. In einem zweiten Schritt wird die AA 
enzymatisch durch die 5-Lipoxygenase (5-LO) zu Leukotrienen umgesetzt. Die 
Enzymaktivität der cPLA2α und der 5-LO sind sehr ähnlich reguliert. Eine Aktivierung beider 
Enzyme wird durch einen Anstieg des intrazellulären Ca
2+-Spiegels und / oder durch 
Phosphorylierungen der Enzyme durch Proteinkinasen ausgelöst, wobei für die Aktivierung 
der 5-LO nach neuesten Erkenntnissen zusätzlich auch die Freisetzung von Diacylglycerolen 
(DAGs) eine entscheidende Rolle zu spielen scheint [166]. Zelluläre Stimuli also, die zu 
einem zellulären Ca
2+-Einstrom, der Freisetzung von DAGs und / oder der Aktivierung von 
Mitogen-aktivierten Proteinkinasen (MAPKs) führen, lösen eine Aktivierung, und die 
konzertierte Translokation beider Enzyme aus dem Zytosol zur Kernmembran aus, wo die 
Freisetzung der AA und die Leukotrien-Biosynthese erfolgt [16, 21]. Leukotriene spielen eine 
wichtige Rolle in Entzündungsreaktionen und Immunprozessen. Sie werden von Leukozyten 
beispielsweise bei bakteriellen und viralen Infektionen gebildet, und tragen zur Aktivierung 
entsprechender Immunabwehrmechanismen bei [247]. 
Die Pathogenerkennung und Signalweiterleitung durch das angeborene Immunsystem ist seit 
der Enteckung der Toll-like Rezeptoren (TLRs), die eine Schlüsselrolle für die Detektion von 
Mikroorganismen im Organismus spielen, Gegenstand intensiver Forschung. Inzwischen sind 
10 verschiedene humane Subtypen der TLR-Familie bekannt, die jeweils definierte hoch 
konservierte pathogen-assoziierte molekulare Strukturen (PAMPs) erkennen, wodurch 
Signaltransduktionswege aktiviert werden, die zur Expression entzündungsrelevanter Proteine 
und somit zur Entwicklung einer Immunantwort führen. Beispielsweise erkennt das TLR2-
TLR6-Heterodimer Lipoteichonsäuren (LTA) aus gram-positiven Bakterien oder diacylierte 
Lipopeptide aus Mycobakterien, während TLR2-TLR1 bakterielle triacylierte Lipopeptide 
detektiert. Der dadurch aktivierte TLR-Signaltransduktionsweg führt im Allgemeinen zur 
Aktivierung des Transkriptionsfaktors NF-κB, aber auch zur Aktivierung von MAP-Kinasen, 
deren Rolle in der Regulation der Leukotrien-Biosynthese bereits erwähnt wurde [281]. 
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Vor diesem Hintergrund schien es denkbar, dass im Zuge einer TLR-Aktivierung auch eine 
Regulation der Leukotrienbildung erfolgen könnte. Ziel dieser Arbeit war es, diesen 
Zusammenhang zu verifizieren, den Einfluss von TLR-Liganden auf die Biosynthese von 
Leukotrienen zu charakterisieren und die zugrundeliegenden Mechanismen aufzuklären. 
 
Erste Versuche haben in der Tat gezeigt, dass die Vorbehandlung differenzierter Mono Mac 6 
(MM6) Zellen mit dem TLR4-Ligand LPS, dem TLR5-Ligand Flagellin, aber auch mit den 
TLR2/6-Liganden LTA und FSL-1 (diacyliertes Lipopeptid), und dem TLR2/1-Ligand 
Pam3CSK4 (triacyliertes Lipopeptid) etwa zu einer Verdopplung der Leukotrien-Biosynthese 
führte, die durch Ca
2+-Ionophor stimuliert worden war. Die Liganden anderer TLR-Subtypen 
zeigten dagegen keine Wirkung. Der verstärkende Effekt konnte in primären humanen 
Monozyten ebenfalls bestätigt werden. Die weitere Charakterisierung des beobachteten 
Effektes in MM6-Zellen erfolgte anhand der drei ausgewählten TLR2-Liganden. Die 
verstärkende Wirkung der Liganden war abhängig von der Liganden-Konzentration. 
Außerdem war sie besonders ausgeprägt, wenn die nachfolgende Stimulation durch Ionophor 
bei einer suboptimalen Konzentration erfolgte, was eine Stimulation unter physiologischen 
Bedingungen mit schwächeren Agentien gut imitieren dürfte. Weiterhin spielte die Dauer der 
Vorinkubationszeit eine entscheidende Rolle. Eine 15-minütige Vorbehandlung mit den 
Liganden erwies sich als optimal, während eine Verlängerung der Inkubationsdauer zu einer 
Abschwächung bis hin zum Verschwinden des Effektes führte. Wurden die TLR2-Liganden 
zusammen mit Ionophor inkubiert, war ebenfalls keine Verstärkung der Leukotrienbildung 
messbar. Diese Beobachtungen führten zu der Annahme, dass die TLR2-Liganden zwar als 
sogenannte Priming-Agenzien in der Lage sind, die Stimulation der Leukotrienbildung zu 
verstärken, selbst jedoch nicht direkt aktivieren können, was in Folgeexperimenten auch 
bestätigt werden konnte. 
Zur Aufdeckung des zugrundeliegenden zellulären Mechanismus wurde der Einfluss der 
TLR2-Liganden auf die cPLA2α, als auch auf die 5-LO untersucht. 
Zunächst konnte gezeigt werden, dass TLR2-Liganden in MM6 Zellen auch die Ionophor-
induzierte Freisetzung von AA verstärken. Hierbei war, wie für die Leukotrienbildung, eine 
analoge Zeitabhängigkeit des Effektes mit einer optimalen Vorinkubationszeit der Liganden 
von etwas 10 Minuten feststellbar. Auch in diesem Fall erfolgte keine direkte Stimulation der 
AA-Freisetzung durch die TLR2-Liganden, die dementsprechend auch keinen Einfluss auf die 
intrazelluläre Ca
2+-Konzentration zeigten. In Inhibitorstudien stellte sich heraus, dass sowohl 
die cPLA2α als auch sPLA2 an der AA-Freisetzung in vorbehandelten, und mit Ca
2+-Ionophor Zusammenfassung 
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stimulierten MM6-Zellen beteiligt sind. Der Verstärkungseffekt der Liganden schien jedoch 
allein durch die cPLA2α vermittelt zu sein. Weiterhin konnte in MM6-Zellen nach Inkubation 
mit TLR2-Liganden sowohl die Aktivierung der p38 und der p42/44 MAP-Kinase (ERK1/2), 
als auch die Phosphorylierung der cPLA2α an Ser-505 nachgewiesen werden. Aus der 
Literatur ist bekannt, dass die Phosphorylierung des Ser-505 durch MAP-Kinasen erfolgt, und 
in vitro zur Aktivitätssteigerung der cPLA2α führt [37]. Der zeitliche Verlauf der 
Phosphorylierungen deckte sich interessanterweise wiederum mit der Zeitkurve der 
Leukotrienbildung in geprimten, Ca
2+-Ionophor-stimulierten Zellen. Nach etwa 5-minütiger 
Behandlung riefen die Liganden maximale Phosphorylierung hervor, die somit einer 
maximalen AA-Freisetzung bei 10-minütigem Priming und einer maximalen 
Leukotrienbildung bei 15-minütigen Priming vorauszugehen schien. Die Kombination von 
Inhibitoren des p38 und des p42/44 MAP-Kinase Signalweges führte schließlich zur 
vollständigen Aufhebung sowohl der beobachteten cPLA2α-Phosphorylierung, als auch der 
Verstärkung der AA-Freisetzung. Beide MAP-Kinasewege scheinen somit eine Rolle für 
diesen Verstärkungseffekt der TLR2-Liganden zu spielen. Der Einfluss weiterer für die 
Regulation der cPLA2α relevanter Kinasen (Mnk-1 und CamKII) konnte mittels 
Inhibitorstudien ausgeschlossen werden. Weiterhin konnte abschließend gezeigt werden, dass 
die beobachtete Steigerung der AA-Freisetzung (und der Leukotriensynthese) nicht aufgrund 
von LPS-Kontaminationen durch eine TLR4-Aktivierung, sondern tatsächlich durch 
Aktivierung des TLR2 vermittelt wird. 
Im Gegensatz zur cPLA2α ließ sich für die 5-LO keine positive Regulation durch Priming von 
MM6-Zellen mit TLR2-Liganden nachweisen. Um die 5-LO-Aktivität unabhängig von der 
endogenen AA-Freisetzung messen zu können, wurde die Leukotrienbildung in Gegenwart 
exogen zugegebener AA stimuliert. Hierbei konnte weder in MM6-Zellen, noch in THP-1-
Zellen nach Inkubation mit TLR-Liganden eine direkte Stimulation, und auch keine 
Verstärkung der Ionophor-induzierten 5-LO-Aktivität detektiert werden. Der TLR2-Ligand 
LTA schien sogar eher einen inhibitorischen Einfluss auf die Aktivität der 5-LO auszuüben. 
Weiterhin zeigte LTA auch keine Verstärkung der Ionophor-induzierten 5-LO-Translokation 
zur nukleären Membran, sondern förderte eher die Akkumulation der 5-LO im Zytosol. Diese 
Ergebnisse standen im Widerspruch zu den Eigenschaften bekannter Priming-Agenzien wie 
z.B. des Phorbolesters PMA, der in MM6 Zellen tatsächlich in der Lage ist, sowohl die 5-LO-
Aktivität, als auch deren Translokation wahrscheinlich durch Aktivierung von MAP-Kinasen 
(vor allem der p42/44 MAP-Kinasen) und möglicherweise durch 5-LO-Phosphorylierung 
positiv zu regulieren [373]. Um die unterschiedliche Wirkungsweise von LTA und PMA zu Zusammenfassung 
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verstehen, wurden drei denkbare Hypothesen überprüft. Zum einen schien es möglich, dass 
eine LTA-vermittelte Aktivierung der PKA, welche die 5-LO durch Phosphorylierung negativ 
regulieren kann, einem Primingeffekt von LTA entgegenwirken bzw. diesen aufheben könnte. 
Jedoch führte die experimentelle Hemmung der PKA nicht zu einer Demaskierung eines 
möglicherweise vorhandenen LTA-Effekts. Zweitens schien es denkbar, dass PMA im 
Gegensatz zu LTA möglicherweise die zelluläre Freisetzung ungesättigter Fettsäuren 
stimulieren könnte. In der Literatur wurde berichtet, dass freie ungesättigte Fettsäuren die 5-
LO-Phosphorylierung durch MAP-Kinasen erheblich begünstigen und verstärken. Priming 
von MM6-Zellen mit LTA unter Zusatz exogener AA konnte jedoch eine Steigerung der 
Ionophor-induzierten 5-LO-Aktivität ebenfalls nicht provozieren. Schließlich führte ein 
direkter Vergleich der MAP-Kinase-Aktivierung (Ausmaß und Dauer) durch PMA bzw. LTA 
zu der Beobachtung, dass die Aktivierung der p42/44 MAP-Kinasen durch LTA wesentlich 
schwächer und transienter erfolgte als durch PMA, was für die fehlende LTA-Wirkung auf 
die 5-LO mitverantwortlich sein könnte. Dennoch ist es denkbar, dass PMA im Vergleich zu 
LTA zusätzlich zelluläre Prozesse aktiviert, die ebenfalls essentiell zur positiven Regulation 
der 5-LO erforderlich sind. Weiterhin scheinen auch unbekannte inhibitorische Effekte eine 
mögliche Verstärkung der 5-LO Aktivierung durch LTA zu überlagern oder zu verhindern. 
 
Zusammenfassend lässt sich feststellen, dass die TLR2-vermittelte Verstärkung der Ionophor-
induzierten Leukotrien-Biosynthese in MM6-Zellen hauptsächlich auf eine vermehrte 
Freisetzung von AA zurückzuführen ist. TLR2-Liganden induzieren die Aktivierung von 
MAP-Kinasen, die die Phosphorylierung und die verstärkte Aktivierung der cPLA2α, und 
damit die vermehrte AA-Bereitstellung vermitteln. 
Die TLR-abhängige Verstärkung der Leukotrienbildung stellt einen interessanten 
Zusammenhang zwischen der Aktivierung von Rezeptoren des angeborenen Immunsystems 
und der kurzfristigen Freisetzung pro-inflammatorischer Lipidmediatoren her, der die 
Bedeutung der Leukotriene für die Immunabwehr unterstreicht. Weiterhin spielen sowohl 
TLRs, als auch Leukotriene in der Pathogenese allergischer Erkrankungen oder 
beispielsweise der Atherosklerose eine wichtige Rolle. Auch hier könnte der beschriebene 
Zusammenhang von Bedeutung sein. References 
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